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Abstract 
 
Health-Related Quality of Life in Multiple Sclerosis: Measurement, Predictors and 
Utilization in Routine Clinical Practice 
 
Vivek S. Pawar 
 
There are a large number of patient-reported questionnaires to assess health-related 
quality of life (HRQoL) in patients with multiple sclerosis (MS).  In order to make a 
recommendation for use in clinical practice, a comparison of their psychometric properties is 
necessary.  In addition to accurate assessment, it is also necessary to identify factors that 
have a significant impact on HRQoL.  Further, lack of use of HRQoL information in clinical 
practice warrants examination of attitudes and behavior of neurologists about HRQoL 
assessment and their intention to consider incorporating HRQoL information in their decision 
making.  This study collected data from patients with MS as well as neurologists and 
consisted of two phases.  Phase I involved collection of primary data from non-
institutionalized patients with MS.  Data from Phase I was used to measure HRQoL, identify 
factors affecting HRQoL, and compare the measures on their psychometric properties.  A 
mail survey of neurologists was performed in Phase II.  This data facilitated investigation of 
factors that have a significant influence on neurologists’ intention to assess HRQoL 
information in clinical practice.  Possible predictors of intention such as: attitude, subjective 
norms, perceived behavior control and practice characteristics were included.  Based on 
analyses of Phase I, no measure emerged clearly or consistently better or worse than the 
others in terms of psychometric properties.  Hence, a recommendation of one particular 
measure for use in MS-related clinical practice cannot be substantiated.  The choice of a 
measure ultimately rests on the neurologist and may be related to their perception of its 
usefulness and their intention to use such information in the routine care.  With respect to 
predictors of HRQoL, visual function among other factors was found to have a significant 
and independent impact on HRQoL in patients with MS.  This suggests that visual screening 
should be performed periodically using patient-reported questionnaires in addition to 
conventional tests of visual acuity.  Over 90% of neurologists reported that they did not use 
standardized HRQoL questionnaires in clinical practice.  Organizations such as the American 
Academy of Neurology and fellow neurologists can exert significant influence on 
neurologists’ intention to assess HRQoL information in clinical practice.     
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Chapter 1: Introduction and Study Objectives 
 
Health-Related Quality of Life in Multiple Sclerosis 
Multiple sclerosis (MS) being a progressive neurological disease with no cure, lends 
itself as an important area for health-related quality of life (HRQoL) research.  The available 
treatments have only a modest effect on the course of the disease with MS patients reporting 
lower satisfaction with life, not only compared to people without any disease, but also those 
with chronic illnesses such as inflammatory bowel disease, rheumatoid arthritis, epilepsy, 
and diabetes (Hermann et al., 1996; Rudick, Miller, Clough, Gragg, & Farmer, 1992).  There 
are several ways in which MS can have an impact on patients’ HRQoL.  MS causes a 
disturbance in normal physiological functioning due to symptoms such as motor sensory 
impairments, ambulatory problems, bowel and bladder problems, cognitive disturbances, 
sexual dysfunction, and vision problems.  The progressive nature of the disease elicits a 
pervasive impact on patients' lives, with substantial negative consequences for family and 
working life, which can manifest during the most active and productive period of people's 
lives (Solari & Radice, 2001).   
Within 10 years of onset, half of all MS patients are unable to fulfill household and 
employment responsibilities; within 15 years, half of the patients are unable to walk unaided; 
and within 25 years half require a wheelchair (Confavreux, Vukusic, Grimaud, & Moreau, 
1999).  MS patients can be under immense social strain as the need for help, risk of divorce, 
loss of contact with relatives, difficulty leaving the house, need for structural changes in the 
house and need for pension can increase with worsening disability (Stenager, Stenager, 
Knudsen, & Jensen, 1994).  Since it usually occurs in young adults it can have an 
overwhelming influence on future productivity and personal development.  The 
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unpredictable course which the disease follows makes it very difficult for patients to 
anticipate and deal with the periods of relapses and remissions (Benito-Leon).   
Although no curative treatments exist for MS, a number of parenterally administered 
immunological drugs have been developed to curb the progression of the disease.  These 
treatments however, are not without their shortfalls.  Treatment with interferon beta which is 
administered via injections can produce side effects that may have a deleterious effect on a 
patient’s quality of life irrespective of whether it is given daily or once a week.  In addition, 
the side effects of this treatment seem to increase with time.  Adverse effects such as 
cutaneous ulceration and local pain at the injection site as well as flu like symptoms have 
been reported in MS patients on interferon therapy (Logan-Club & Stacy, 1995; Inafuku, 
Kasem Khan, Nagata, & Nonaka, 2004; Gottberg, Gardulf, & Fredrikson, 2000).   
Skin reactions in response to disease modifying therapy have the potential to evolve 
into serious lesions culminating in infection, necrosis, and in some circumstances requiring 
surgical repair (Frohman et al., 2004).  In addition to local skin reactions, therapy with 
glatiramer acetate and mitoxantrone has also been associated with several adverse events.  
Systemic adverse events such as flushing, chest-tightness, sweating, palpitations and anxiety 
have been observed in patients on glatiramer acetate therapy (Munari, Lovati, & Boiko, 
2004).  Adverse events such as nausea, alopecia, infections, menstrual disorders, risk of 
cardiotoxicity and malignancy may occur following administration of mitoxantrone (Edan, 
Morrissey, & Le Page, 2004).  Side-effects are rarely incorporated in the overall results of a 
trial or intervention.  They are either listed separately or often ignored.  
Physicians generally lean towards assessing physical disability in MS patients, but are 
skeptical about the additional benefits of measuring HRQoL (Barbotte, Guillemin, & Chau, 
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2001).  HRQoL in MS has been known to correlate with measures of impairment and 
disability such as the Expanded Disability Status Scale (EDSS).  However, this correlation 
has been found to vary from 2% to 29% (on the correlation coefficient) depending upon the 
presence of other influencing factors such as fatigue, cognition, mood disorders etc. 
(Benedict et al., 2005; Patti et al., 2003; Fruehwald, Loeffler-Stastka, Eher, Saletu, & 
Baumhackl, 2001).  The EDSS has to be administered by the physician and as a result certain 
patient-centered domains of health which may contribute to HRQoL may be overlooked.  
This can be a problem because it has been noted that patients with multiple sclerosis and 
possibly those with other chronic diseases are less concerned than their clinicians about 
physical disability in their illness (Rothwell, McDowell, Wong, & Dorman, 1997).   
MS patients identify role limitations, cognition and emotional problems as having a 
significant influence on their HRQoL in addition to just the physical manifestations of the 
disease.  Murphy and colleagues have shown that these domains are substantially lower in 
patients with MS compared with controls, and that these changes correlate poorly with 
neurological impairment and disability as measured by the EDSS (Murphy et al., 1998).  
Thus, assessment of quality of life during routine care of MS patients might alert health 
professionals to less obvious burdens of the disease.  These may include factors that are 
affected by the disease process, are more closely related to overall HRQoL, and may also be 
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Factors Affecting Health-Related Quality of Life in MS 
Neuro-ophthalmologic manifestations are common and disabling in patients with MS.  
Any area of the visual system can be affected, including the optic nerves, chiasm, tracts and 
even optic radiations, leading to a variety of symptoms from blurring to distortion of vision 
(Nordmann, Saraux, & Roullet, 1987; Warner & Lessell, 1994).  Although visual symptoms 
in MS may precede, occur at onset, or develop during the course of the disease, they may 
represent the most prominent symptoms of MS from the patient’s point of view.  Visual 
symptoms may cause difficulties with activities used in day-to-day life such as dressing, 
eating, writing, simple communications or interactions with others, and daily travel 
(Stelmack, 2001; Keeffe, Lam, Cheung, Dinh, & McCarty, 1998).  In addition to daily 
activities and functional status, mood level and social relationships can particularly be 
affected by visual impairment (Carabellese et al., 1993).  Given the wide-spread impact, it is 
not surprising that visual impairment has been found to be associated with overall HRQoL in 
MS patients.  This was noted in studies which used visual subscales of the general or 
functional status measures to correlate with the overall quality of life scores (Rudick et al., 
1992; Fischer et al., 1999).   
Objective measurements of vision impairments, particularly measures of visual acuity 
and visual fields have also been commonly used to represent a patient’s functional 
capabilities during treatment.  The term objective is usually used when the variable is 
manifest, that is, a publicly observable and quantifiable attribute or behavior.  Since many 
clinical treatment trials depend on such objective measures as primary study variables, there 
is a growing demand to include subjective patient-based visual function assessments, which 
can be accomplished with several questionnaires that have been developed exclusively for 
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this purpose (Massof & Rubin, 2001; 1993; USDHHS, 1993).  These instruments include the 
Visual Function Index (VFI) (Bernth-Petersen, 1981), Activities of Daily Vision Scale 
(ADVS) (Mangione et al., 1992), 14-Item Visual Functioning Index (VF-14) (Steinberg et 
al., 1994), and the National Eye Institute’s Visual Functioning Questionnaire (VFQ) 
(Mangione et al., 2001), among others.     
 Depression is one of the strongest predictors of HRQoL in patients with MS 
(Lobentanz et al., 2004; Fruehwald et al., 2001).  This can be due to several reasons 
(Mitchell, Benito-Leon, Gonzalez, & Rivera-Navarro, 2005).  It can impair motivation, 
interest and concordance, thus retarding physical progress.  It can also manifest itself at the 
point where the patients have exhausted their resources to cope with the disease.  Presence of 
depression can distort an individual’s view of their surroundings as well as their health, 
leading to a more negative assessment of quality of life.  The association may also be due to 
the fact that HRQoL and depression are both typically associated with similar facets of 
experience such as distress and suffering.  A strong inverse correlation of depression with 
generic and MS-specific quality of life measures has been shown (Amato et al., 2001; Bakshi 
et al., 2000).   
In the study by Bakshi et.al., the association of depression with lower quality of life 
scores remained significant after adjusting for other factors like severity of neurological 
disability and fatigue.  Depressed patients with MS have also scored worse on various scales 
such as energy, mental health, cognitive function, overall quality of life, sexual and 
emotional function compared with non-depressed MS patients (Wang, Reimer, Metz, & 
Patten, 2000).  Additionally, studies have tried to correlate neurological disability with 
impaired HRQoL in MS patients.  Results from these studies have shown that neurological 
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disability has a significant influence on HRQoL (Brunet, Hopman, Singer, Edgar, & 
MacKenzie, 1996; Modrego, Pina, Simon, & Azuara, 2001).  
 
Problem Statement 
In order to determine the relative advantages and disadvantages of various HRQoL 
instruments, a comparison of their psychometric properties in the same population is 
necessary.  Although researchers have examined the psychometric properties of each of these 
three health status measures to be compared, some limitations can be noted.  Only three 
studies have compared the properties of HRQoL measures on the same cohort of patients.  
The Multiple Sclerosis Quality of Life – 54 items (MSQoL-54) was used in two of the three 
studies which provided conflicting evidence regarding its superiority over its comparators 
(Vickrey, Hays, Genovese, Myers, & Ellison, 1997; Nicholl, Lincoln, Francis, & Stephan, 
2001).  Moreover, neither of these studies evaluated the full spectrum of psychometric 
properties, particularly ignoring responsiveness, for the included HRQoL measures.   
One study performed a comparison of all psychometric properties among three 
patient reported outcome (PRO) measures and found that the Multiple Sclerosis Impact Scale 
(MSIS-29) performed better than Functional Assessment in Multiple Sclerosis (FAMS) 
(Riazi, Hobart, Lamping, Fitzpatrick, & Thompson, 2003).  The authors however, 
acknowledged the need for further evaluation of their work owing to the small sample size of 
the study.  A number of instruments have been designed to measure HRQoL in MS patients 
with many being published in recent years (Nortvedt & Riise, 2003; Solari, 2005).  As a 
result, physicians have a greater range of choices but limited information on which to base 
the selection of health status measures.  Hence, it is necessary to perform a rigorous and all-
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inclusive concurrent comparison of currently relevant MS-related HRQoL instruments for 
use in routine clinical care.  MSIS-29 is one such currently relevant measure which has been 
validated in a number of settings and has been shown to have better psychometric properties 
compared to other commonly used HRQoL measures.  MSIS-29 however, measures only 
physical and psychological impact of the disease and not HRQoL per se.  Other relevant 
measures include: the Hamburg Quality of Life Questionnaire in MS (HAQUAMS) which 
was recently developed and is the only measure that addresses all domains relevant to 
patients with MS; and the ubiquitous Medical Outcomes Survey – Short Form 36 Items (SF-
36) which has been extensively used in MS research.             
In addition to accurate and efficient assessment of quality of life, it is also necessary 
to identify and focus on factors that affect the quality of life of MS patients.  A number of 
studies have reported association of overall quality of life with impairment and disability as 
measured by neurological symptoms or measures of disability (Miller, Rudick, Cutter, Baier, 
& Fischer, 2000; Ozakbas, Cagiran, Ormeci, & Idiman, 2004; Janardhan & Bakshi, 2000; 
Modrego et al., 2001).  Others have demonstrated that variables such as fatigue, depression 
and anxiety and disease course (Pfennings et al., 1999a) can also have an impact on quality 
of life while some conflict exists regarding the impact of cognitive impairment (Benito-Leon, 
Morales, & Rivera-Navarro, 2002; Kenealy, Beaumont, Lintern, & Murrell, 2002).  Of these 
variables, only neurologic disability, fatigue and depression have been shown to contribute 
independently to overall HRQoL (Henriksson, Fredrikson, Masterman, & Jonsson, 2001; 
Merkelbach, Sittinger, & Koenig, 2002a; Janardhan & Bakshi, 2002).  However, no evidence 
is available on whether visual impairment affects MS-related quality of life, irrespective of 
disability, depression and other important clinical features of the disease.  Since visual 
    
8 
impairment is a common manifestation among MS patients and can have a significant impact 
on HRQoL such information may be relevant in the routine care of patients.   
The past decade has seen an increase in the number of MS-related clinical trials with 
quality of life as one of the outcomes of interest (Leuschen, Filipi, & Healey, 2004; Panitch, 
Miller, Paty, & Weinshenker, 2004; Patti et al., 2004a).  A number of disease-specific quality 
of life measures have also been developed for use in MS research (Solari, 2005; Nortvedt et 
al., 2003).  One of the major issues in HRQoL assessment is the transfer of newly developed 
measures from medical research to clinical practice (Belli, Tamburini, & Paci, 1994).  No 
studies of the perspectives of neurologists on quality of life assessment in clinical practice 
have been reported in the literature.  Thus, in addition to developing HRQoL measures 
appropriate for use in routine practice, more information is needed about the attitudes and 
behavior of neurologists about HRQoL assessment and their intention to consider 















Objective 1: To compare the HAQUAMS with the SF-36 and the MSIS-29 in terms of their 
psychometric properties (scaling assumptions, acceptability, reliability, validity and 
responsiveness) as well as the preference of MS patients for each of  these instruments. 
Objective 2: To investigate the impact of visual impairment, in addition to other possible 
predictors such as disability and depression, on overall HRQoL in patients with MS.  
Objective 3: To determine predictors (visual impairment, disability, depression, demographic 
factors, duration of disease and comorbid conditions) of various MS-specific HRQoL 
domains including fatigue, mobility, mood and social function, in patients with MS. 
 
PHASE II 
Objective 1: To compare neurologists’ preferences regarding the usefulness and practicality 
of various MS-specific HRQoL measures in clinical practice. 
Objective 2: To report neurologists’ knowledge of and current practices regarding MS-
specific HRQoL measures. 
Objective 3: To identify barriers and facilitators to the use of HRQoL information in the 
routine care of patients with MS. 
Objective 4: To investigate whether neurologists’ intention to use HRQoL information in the 
routine care of patients with MS is associated with social cognitive factors (attitudes, 
subjective norms and perceived behavior control). 
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This study pertains to all aspects of health-related quality of life and its assessment in 
patients with MS.  First, in order to make a recommendation for clinical practice, Objective 1 
for both Phase I and II compared two MS-specific HRQoL measures in terms of: (1) their 
psychometric properties; and (2) patient and physician preferences regarding their usefulness 
and practicality.  Objective 2 for Phase I focused on correlates of HRQoL and its specific 
domains and helps elucidate the relative contribution of visual impairment to overall 
HRQoL.  Finally, Objectives 2, 3 and 4 from Phase II investigated neurologists’ attitude and 
practices regarding HRQoL information in MS and examine behavioral factors that have an 
impact on the neurologists’ intention to use HRQoL questionnaires in the routine care of 
patients with MS. 
 
Study Significance 
The current study yields important results that can be used by health care 
professionals to decide which instrument to use when evaluating HRQoL in patients with MS 
in routine clinical practice.  Head-to-head comparisons in the same population can help 
provide an evidence-based framework to guide researchers in selecting measures for variety 
of purposes (Hobart, Riazi, Lamping, Fitzpatrick, & Thompson, 2004).  Since the 
psychometric properties of the MSIS-29, HAQUAMS, and SF-36 will be assessed using the 
same cohort of patients receiving care at an outpatient clinic, the comparison will be easier to 
interpret.  Another important aspect of this study is the comparison of responsiveness of the 
three measures, which is their ability to measure clinically important change over time.  The 
responsiveness of MS-related quality of life measures in general has been examined in 
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context of clinical trials, after patients initiate specific treatments and are expected to 
improve (Riazi et al., 2003).  Most instruments perform reasonably well in such situations.   
Due to the focus on use of HRQoL measures in clinical trials, it becomes difficult to 
assess whether these instruments can be useful for patients who may show comparatively 
smaller changes in their health status during routine care or follow-up.  This study will 
compare the properties of the measures in a clinical setting.  As such; its conclusions may 
help researchers to determine if they exhibit stability in patients showing no change and with 
ongoing disease, in addition to having discriminative properties.  Comparison of ease of use, 
time to completion, accuracy and preference of individual patients regarding each measure, 
along with the complete psychometric properties will help neurologists choose the right 
measure for their setting, per their requirements. 
If visual function is found to be a significant independent predictor of HRQoL in MS 
patients, the study findings may have important implications for patient care.  It will allow 
policy makers and treating physicians to determine whether visual impairment should be 
screened for periodically in MS patients using HRQoL measures, regardless of neurological 
disability and other clinical characteristics of the disease.  Mild visual impairment may be 
overlooked during routine visits, but if accurately monitored and treated successfully, it may 
have a significant impact on the HRQoL of patients. 
The physician’s perception of HRQoL is important, especially because they are 
primary decision makers regarding the treatment that is administered (Bezjak, Ng, Taylor, 
MacDonald, & Depetrillo, 1997).  Due to a multitude of chronic conditions that exist in the 
society today and presence of limited healthcare resources, data from HRQoL questionnaires 
can be useful in decisions whether to continue or withhold treatment or even approve new 
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medications and technology (Drummond, 1987).  In addition to determining the 
appropriateness of MS-specific PRO measures, phase II of this project will help to determine 
key factors that affect the neurologists’ intention to use HRQoL information in their clinical 
setting.  Since the data will be obtained from a nationwide survey of neurologists, it may also 
be useful as the basis for developing large-scale evidence-based HRQoL related intervention 
strategies to increase neurologists’ utilization of MS-related HRQoL information in their 
clinical practice.   
 
    
13 
Chapter 2: Background 
 
About Multiple Sclerosis 
Multiple sclerosis (MS) is one of the most common chronic neurological diseases in 
adults, affecting about one in 1000 people.  There are an estimated 1.1 million MS patients 
worldwide (Mitchell et al., 2005).  It is an acquired primary demyelinating disease of the 
central nervous system (CNS) in which myelin is the target of an autoimmune inflammatory 
process (Whitaker JN & Mitchell GW, 1997).  Myelin is a fatty material that insulates nerves 
and allows them to transmit impulses rapidly.  The speed and efficiency with which these 
impulses are conducted permits smooth, rapid and coordinated movements to be performed 
with little conscious effort.   
The sites of the nerves where the demyelination occurs appear as hardened, sclerosed, 
or scarred areas in the CNS and spinal cord.  It is the presence of these sclerosed areas or 
lesions at multiple sites within the CNS that gives the disease its name.  These lesions have a 
predilection for the optic nerves, periventricular white matter, brain stem, cerebellum and 
spinal cord.  The lesions track along small and medium vessels, with an influx of 
inflammatory cells occurring perivascularly.  The inflammation involves lymphocytes, 
macrophages, and reactive astrocytes.  Inflammation and demyelination leads to a disruption 
in the ability of the nerves to conduct electrical impulses thus causing the many symptoms of 
the disease (Jacobs & Galetta, 2004).   
Clinical hallmarks of MS include: 1) a temporal profile of symptoms and neurological 
deficits occurring in multiple episodes, designated as a relapse or an exacerbation, followed 
by disappearance of the symptoms and restoration of normal function, called remission; and 
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2) the dissemination of lesions anatomically within the CNS.  In other words, lesions must be 
clearly disseminated in time and space within the CNS for clinically definite diagnosis of 
MS.  By definition, a relapse should last for at least twenty-four hours and can not be 
attributed to another cause.  The severity of the relapse mainly depends on the area and the 
volume of the damage caused by the demyelination (Whitaker JN et al., 1997). 
 
Clinical Symptomatology  
MS affects different people in different ways, and symptoms can vary in the same 
person from day to day.  The majority of patients with MS develop an increasing range of 
symptoms, many of which worsen slowly, resulting in progressive and complex disability.  
Symptoms of MS can be categorized into three different categories; 1) primary symptoms 
that stem from actual demyelination of the CNS including spasticity, weakness, tremor, 
ataxia, numbness, cognitive disabilities, bladder and bowel dysfunction, blurred and double 
vision, and occasionally apraxia (total or partial loss of the ability to perform coordinated 
movements or manipulate objects in the absence of motor or sensory impairment); 2) 
secondary symptoms which originate because of the presence of primary demyelination such 
as contractures, urinary tract infections, and obesity, and 3) tertiary symptoms which emanate 
from the psychological, vocational or marital stress of a chronic disease (Schapiro RT, 
Baumhefner RW, & Tourtellotte WW, 1997). 
Primary neurological symptoms reflect the location of the lesion in the CNS; for 
example, visual loss reflects lesions of the optic nerve; hemi-, para-, or quadri-paresis; with 
or without bladder dysfunction, reflects a lesion of the spinal cord; vertigo or diplopia 
(double vision), corresponds to a lesion of the brain stem; and ataxia, a lesion of the 
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cerebellum (Weinshenker & Lucchinetti, 1998).  As many as 50% of MS patients experience 
vision loss as an initial presenting symptom, while 80% eventually end up with some degree 
of visual impairment (McDonald & Barnes, 1992; Leibowitz & Alter, 1968; Sorensen, 
Frederiksen, Bronnum-Hansen, & Petersen, 1999).  Neuro-ophthalmologic manifestations of 
MS can occur due to the impact of the disease in the afferent or the efferent visual system.  
Afferent Visual System  
The most common cause of vision loss in MS patients is optic neuritis (sometimes 
called retrobulbar neuritis) which is an episode of demyelination in the optic nerve behind the 
eyeball.  Optic neuritis is frequently the initial manifestation of MS.  Symptoms associated 
with optic neuritis include: loss of central vision acuity, pain associated with eye movement, 
abnormal color vision, visual field defects, altitudinal defects, and visual loss associated with 
increased body temperature (Uthhoff’s phenomenon) (Jacobs et al., 2004).  Ocular 
inflammation including anterior uveitis, posterior uveitis, and periphlebitis (sheathing or 
cuffing of the retinal veins) can also occur in MS patients (Jacobs et al., 2004).   
Efferent Visual System 
Visual symptoms as a result of the impact of MS on the efferent visual system include 
diplopia (double vision), internuclear ophthalmoplegia, nuclear palsies, one-and-a-half 
syndrome (caused by lesions in the pons), skew deviation and nystagmus (rapid, involuntary, 
oscillatory motion of the eyeball).   
 
Epidemiology and Prevalence  
MS is approximately two times more common in females than in males and recent 
data suggest that the prevalence among women is increasing (Noonan, Kathman, & White, 
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2002).  The disease is unusual before adolescence, rises steadily in incidence from teens to 
age thirty five, and declines gradually thereafter (Sadovnick, Dyment, & Ebers, 1997; Hauser 
S, 1994).  Onset of the disease is slightly later in males than in females.  Marked differences 
in the prevalence of MS exist between different populations and ethnic groups, with it being 
more common among Caucasians (particularly those of northern European ancestry) 
compared to other ethnic groups (Hogancamp, Rodriguez, & Weinshenker, 1997).   
MS is a disease associated with temperate climates.  In both hemispheres, it occurs 
with much greater frequency in higher latitudes (above 40° latitude) away from the equator 
(Kurtzke JF, 1977).  Migration may also be one of the risk factors for MS.  This is backed by 
evidence that individuals who move from a region with one risk level to a region with a 
higher or lower risk, in general, adopt the risk level of their new home.  This is especially 
true for people moving from a low-risk to a high-risk area (Gale and Martyn, 1995; Elian 
et.al, 2003; Kurtzke JF, 1977).      
Conflicting data exists as to whether MS is caused or triggered by an infectious agent 
(viral or bacterial) (Granieri et.al, 2001; Munger et.al, 2004; Gilden 2005; Goldacre et.al, 
2004).  Others have explored whether environmental factors contribute to the onset of MS, or 
the probability of MS attacks (Marrie RA, 2004; Casetta and Granieri, 2000).  Some studies 
suggest that relapses of MS are more likely in the warmer months and less likely in the 
colder months (Abella-Corral et.al, 2005; Jin et.al, 2000).  Pregnancy is associated with a 
decrease in the risk for MS attacks, particularly during the third trimester, while the 
postpartum period sees a significant increase in the risk (Salemi et.al, 2004).  In certain 
populations, a genetic marker, or trait, has been found to occur more frequently in people 
with MS than in those who do not have the disease (Hogancamp et.al, 1997).  No specific 
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gene however, has been identified that definitively confers susceptibility to MS (Dyment 
et.al, 2004; Giordano et.al, 2002).  It is thought that aggregation of MS in certain 
geographical areas, ethnic populations, or families can be explained by common 
environmental exposure, shared genetic background, or a combination of susceptibility to 
both (Sotgiu et.al, 2004).   
 
Clinical Course & Prognosis 
 People with MS can expect one of four clinical courses of disease, each of which can 
be mild, moderate, or severe.  The first, Relapsing-Remitting Multiple Sclerosis (RRMS), is 
characterized by discrete clinical “attacks” or “relapses” followed by subsequent 
improvement.  These attacks generally evolve over days to weeks and may be followed by 
complete, partial, or no recovery.  Recovery may occur within weeks, months, or sometimes 
may not occur for two or more years.  This is the most common form of MS at the time of 
initial diagnosis (NICE, 2003).  The second possible course of the disease, Chronic 
Progressive MS, results in gradually progressive worsening without periods of stabilization 
or remission.  Chronic progressive MS however, is largely an outdated term that describes 
any of the following forms of MS: 1) Secondary Progressive MS; 2) Primary Progressive MS 
or 3) Progressive Relapsing MS (PRMS).   
Many years after onset, a majority of relapsing remitting MS patients will develop a 
slow, insidiously progressive neurological deterioration (usually progressive gait 
impairment) over many years, with or without clinical attacks superimposed.  This is termed 
as Secondary Progressive and after 10 years, about 50% of people with relapsing remitting 
MS will have developed Secondary Progressive (National Institute for Clinical Excellence, 
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2003b).  By contrast, Progressive Relapsing MS follows a progressive course right from the 
onset, punctuated by relapses.  There is significant recovery immediately following relapses 
similar to Relapsing Remitting MS, but the disease gradually worsens between the 
occurrences of relapses.  Finally, a minority of patients have Primary Progressive MS; which 
is characterized by a gradual worsening right from the onset, with the complete absence of 
distinct relapses or remissions.  It is relatively rare and patients may show variation in rates 
of progression over time, occasional plateaus, and temporary minor improvements (National 
Institute for Clinical Excellence, 2003a).  
 The prognosis of MS is widely variable.  Natural history studies prior to the use of 
current immunomodulatory treatment showed that, on average, patients achieved a disability 
score of six on the Expanded Disability Status Scale (EDSS) at a median of 15 years 
following diagnosis (Weinshenker, 1995).  This score implies the requirement of unilateral 
assistance with ambulation.  At the same point in time, about 10-15 % required the use of a 
wheel-chair, while 20-25 % remained unrestricted in their ambulation, a condition termed 
benign MS (Weinshenker BG, 1995).  Other studies report that trends toward favorable 
outcomes have been found in patients with optic neuritis, sensory symptoms, and younger 
age at onset, which are all factors associated with Relapsing Remitting MS.  On the other 
hand, factors associated with Primary Progressive MS, namely motor symptoms and older 
age have indicated unfavorable outcomes for the patients (Myhr et.al, 2001).  Other clinical 
indicators of relatively good prognosis are female gender, complete recovery from attacks, 
few attacks, and long inter-attack intervals.  Relatively poor prognostic factors also include 
male gender, predominant cerebellar and motor involvement, incomplete resolution of 
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attacks, progressive course of onset, frequent early attacks, and short inter-attack intervals 
(Weinshenker et.al, 2001). 
 
Diagnostic Criteria for Multiple Sclerosis 
 There is no MS-specific diagnostic test, and the intermittent nature of the disease and 
high variability in presenting symptoms makes diagnosis difficult.  Prior diagnostic criteria 
for MS have included a combination of both clinical and para-clinical studies.  The 
Schumacher criteria were the first set of diagnostic criteria that were developed in 1965 to 
make a clinical diagnosis of MS (Thompson et al., 2000).  These criteria require two or more 
episodes of neurological dysfunction at least one month apart or slow stepwise progression 
for more than six months, plus objective signs of neurological dysfunction on examination 
displaying dissemination in space (distinctly separate lesions).  The diagnosis of MS was not 
backed by any definitive laboratory tests and was essentially a clinical one.   
This was followed by a revision in 1983 by Poser  and colleagues (Poser et al., 1983) 
in order to reflect the advances of para-clinical detection techniques such as Magnetic 
Resonance Imaging (MRI) which was still in its infancy.  Poser and colleagues concluded 
that clinically definite MS requires two attacks and clinical evidence of two separate lesions, 
or two attacks with clinical evidence of one lesion and para-clinical evidence of another 
separate lesion.  The revised criteria also included degrees of diagnostic certainty that were 
identified by categories ranging from clinically definite diagnosis to laboratory-supported 
definite MS, clinically probable MS, and laboratory-supported probable MS.  None of these 
criteria was appropriate for the diagnosis of Primary Progressive MS, since the basic 
requirement of episodes of neurological dysfunction cannot be fulfilled.   
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These criteria were used for about two decades during which the science of imaging 
technology flourished.  Neurologists were hampered by out-dated diagnostic paradigms due 
to the lack of use of advanced technologic tools (such as MRI).  Since MRI shows many 
clinically silent lesions, it seemed logical to integrate MRI evidence into the diagnostic 
criteria to achieve an earlier diagnosis of MS.  In July 2000, the International Panel on 
Diagnosis of MS was convened in London, United Kingdom to reassess the Poser criteria 
and to develop new criteria (McDonald et al., 2001).  The panel emphasized that para-clinical 
evidence like MRI, along with analysis of cerebrospinal fluid (CSF), and visual evoked 
potentials (VEP), add to clinical diagnosis and may be essential in making a definite 
diagnosis when clinical presentation alone is not sufficient.   
One objective of the panel was to create diagnostic criteria suitable for use by 
practicing physicians and also for clinical trials.  As such, the new McDonald criteria also 
include a scheme for the diagnosis of the Primary Progressive type of MS.  In a prospective 
study of patients suffering from a clinically isolated syndrome, Dalton and colleagues 
addressed the added value of the McDonald diagnostic criteria as compared to the Poser 
criteria (Dalton et al., 2002).  The authors supported the clinical relevance of the newer 




 Management of MS may be divided into categories consisting of 1) treatments that 
affect the long-term course; 2) treating exacerbations; and 3) symptomatic management and 
rehabilitation.   
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Treatments that affect the long-term course of the disease 
The goal of therapy in patients with MS is to prevent relapses and progressive 
worsening of the disease (Thompson AJ, Murray TJ, McDonald WI, & Polman C, 2001).  
Drug treatments can reduce future disease activity for many individuals with relapsing forms 
of MS, including those with secondary progressive disease who continue to have relapses.  
These agents decrease the frequency of clinical exacerbations and delay the accumulation of 
physical disability.  Disease progression can be treated by administering immunomodulatory 
drugs namely interferon beta-1a [Avonex & Rebif], interferon beta-1b [Betaseron], and 
glatiramer acetate [Copaxone] (Thompson AJ et al., 2001).   
Copaxone represents an alternative to interferon beta therapy for patients with 
relapsing remitting MS.  Mitoxantrone is an anti-neoplastic agent that exerts potent 
immunomodulatory effects, and it has been suggested that it may provide a safe treatment 
alternative for patients with Relapsing Remitting MS, who experience rapid and severe 
worsening of their disease despite interferon therapy (Correale, Rush, Amengual, & 
Goicochea, 2005).  The risk of cardio-toxicity at higher cumulative doses however, limits the 
duration of treatment with this drug (Avasarala et al., 2003).  All these treatments have been 
approved by the United States Food & Drug Administration (USFDA) for treating patients 
with MS (Galetta & Markowitz, 2005).  
  
Treatment for exacerbations 
At least 80 to 85% of people with MS have an exacerbation at some time during the 
course of the disease (Polman).  Exacerbations are usually treated with corticosteroids, which 
may be used as "rescue" therapy, given as monthly boosters in patients who respond poorly 
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to the immunomodulators (Stangel & Gold, 2005).  Corticosteroids are widely used for 
treatment of acute relapses because of their potent immunosuppressive and anti-inflammatory 
properties (Pozzilli, Marinelli, Romano, & Bagnato, 2004).   
Adrenocorticotropic hormone (ACTH) was the first agent to be helpful in recovery 
from acute exacerbations.  However, intravenous methylprednisolone has become the 
intervention of choice in recent years, especially because it can be given as a short course 
(typically 3-5 days), has a rapid onset of action, and is associated with relatively fewer side-
effects.  Possible mechanisms of action of IV methylprednisolone include restoring the 
integrity of the blood-brain barrier (Miller et al., 1992), eliciting an inhibitory effect on 
demyelination (Richert et al., 2001) and possibly, remyelination promotion (Zivadinov, 2005; 
Stangel et al., 2005).  According to the Multiple Sclerosis International Federation (MSIF) 
Medical Management Committee, plasmapheresis should be considered for those rare cases 
that present with acute, fulminant symptomatology and do not respond to intravenous 
steroids.  
Symptomatic Management & Rehabilitation 
Treating optic neuritis with intravenous (IV) methylprednisolone provides short-term 
benefits for MS patients with visual problems.  In one clinical trial, visual function returned 
faster in the IV methylprednisolone group compared to oral corticosteroids and placebo, 
resulting in slightly better vision in visual field testing, contrast sensitivity, and color vision 
at six months.  This difference however, did not last at the end of one year (Beck et al., 
1992).  The use of corticosteroids and immunomodulatory agents in patients with optic 
neuritis may also reduce the frequency and severity of developing clinically definite MS 
(CDMS) (Arnold, 2005).  Diplopia in its acute phase can be treated with an eye-patch or with 
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occlusion of an eyeglass lens.  Patients who experience severe diplopia accompanied by 
symptoms such as vertigo or weakness can also be treated with a course of IV corticosteroids 
(Jacobs et al., 2004).  Medications such as gabapentin, baclofen, memantine, and clonazepam 
may alleviate symptoms associated with severe nystagmus (Averbuch-Heller et al., 1997).     
 Identification and treatment of other symptoms besides visual dysfunction is also 
considered throughout the disease course.  Drugs used to relieve common MS symptoms 
include: (1) muscle relaxants (baclofen, dantrolene) and benzodiazepines (diazepam, 
clonazepam) to relieve spasms and stiffness; (2) anti-cholinergics, urinary tract anti-
spasmodics (oxybutynin), and anti-diuretic hormones (vasopressin, desmopressin) for 
treating urinary problems; (3) Selective Serotonin Reuptake Inhibitors (SSRIs) (citalopram, 
fluoxetine, paroxetine, sertraline) and tricyclic antidepressants (imipramine, amitriptyline) 
for treating MS associated depression and anxiety; (4) CNS stimulants (pemoline, modafinil) 
for fatigue; (5) anti-convulsants (carbamazepine, phenytoin, acetazolamide) and tricyclic 
antidepressants for neuropathic pain; and (6) laxatives (bisacodyl) for bowel irregularities 
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Quality of Life (QoL) Research 
 Historically, the term quality of life has been used in areas of politics, sociology, 
anthropology and psychology (Bullinger, 2002).  Pigou first mentioned it in 1920 with 
regards to government support for the lower class and its impact on their lives as well as on 
the national finances (Wood-Dauphinee, 1999).  Social science literature also provides many 
meanings of quality of life ranging from individual fulfillment and satisfaction with life – the 
satisfaction of basic human needs, the ability to lead a ‘normal life’ to the quality of the 
external environment (Bowling, 2001).  Social indicators research which developed during 
the 1960s onwards focused on the importance of measuring subjective well-being as well as 
external, or objective circumstances of life such as housing, leisure activities, work, the 
environment and so on.  The concerns with subjective indicators led to the first large surveys 
of life satisfaction, happiness, quality of life and the ‘good life’ among adults and older 
people.   
The development of quality of life research is characterized by three phases.  The first 
phase in the mid-1970s saw the rise of philosophical work regarding what quality of life is 
and how to measure it (Bullinger, 2002).  In 1977, ‘quality of life’ became a keyword in the 
Medical Subjects Headings of the US National Library of Medicine MEDLINE Computer 
Search System (Wood-Dauphinee, 1999).  The second phase corresponds with a more 
explicit assessment of quality of life and the corresponding development of measurement 
instruments.  Finally in the 1990s, the third phase evolved and was distinguished from the 
other phases by the inclusion of quality of life instruments/measures in several types of 
clinical studies.   
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Health-Related Quality of Life (HRQoL) 
Research on valued states of existence has reported that health is among the most 
valued states, and among the most important areas of life and of quality of life nominated by 
people (Bowling A & Windsor J, 2001).  In a national opinion survey on quality of life 
related to choice of where to live, Rogerson (Rogerson RJ, Findlay AM, Coombes MG, & 
Morris A, 1989) found that healthcare provision ranked third in importance among the 
respondents.  In order to narrow its operationalization in clinical research studies, quality of 
life in this regard is referred to as health-related quality of life (HRQoL).   
Health-related quality of life is considered to be a multi-dimensional concept which 
represents a subjective perception reported by the patients.  Mirroring the World Health 
Organization (WHO) definition of health, Greer (1984) has defined HRQoL as the social, 
emotional and physical well-being of the patients following treatment.  Kaplan on the other 
hand noted that quality of life as it relates to health, was concerned with the impact of the 
disease and treatment on disability and daily functioning.  Bullinger et.al. (2002) found that 
HRQoL focused on the impact of perceived health on the individual’s ability to live a 
fulfilling life.  Bowling (2001) defined HRQoL as optimum levels of mental, physical, role 
(e.g. work, parent, career etc.) and social functioning, including relationships and perceptions 
of health, fitness, life satisfaction and well-being.  It should also include some assessment of 
the patient’s level of satisfaction with the treatment, outcome, health status and with future 
prospects.   
The term HRQoL allows us to distinguish widely valued aspects of life which do not 
fall under the health domain.  Although low income, lack of freedom or a good quality 
environment can adversely affect health, these problems are often distant from health or 
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medical concerns (Guyatt, Feeny, & Patrick, 1993).  Hence, people (clinicians) who assess 
the impact of disease and treatment on lives of the patients use the term HRQoL.  The focus 
stays on HRQoL, although when ill or diseased, almost all aspects of life can become health-
related for the patient (Guyatt et.al, 1993).   
 
Advantages of Assessing HRQoL in Routine Clinical Practice 
Measurement of HRQoL in routine practice can have a number of potential benefits 
to both the clinician and the patient.  Clinicians may often stay unaware of significant 
changes in patient functioning (Nelson et al., 1987), social and even more so, psychological 
problems (el Mallakh, Wright, Breen, & Lippmann, 1996; Paykel & Priest, 1992; Maguire, 
Walsh, Jeacock, & Kingston, 1999).  While patients may want physicians to ask them about 
their problems with functioning and well being, such inquiry rarely occurs (Schor, Lerner, & 
Malspeis, 1995).  Quality of life instruments can aid in evaluating quality of care, assessing 
acceptability of treatment, and in determining the need for physiotherapy or psychological 
support (Moore, Wolfson, Alexandrov, & Lapierre, 2004).  Patients and physicians may have 
different priorities regarding a certain treatment course or the effect of illness on their lives 
(Rothwell et al., 1997; Gulick, Cook, & Troiano, 1993), and patients are likely to assign 
varying importance to different outcomes.   
Evidence has shown that patients may not comply with prescribed treatments unless 
they are actively included in the therapeutic process, understand their condition and its 
treatment and are motivated to do so (Stanton, 1987; Morrow et al., 2004).  Patient-based 
measures of health present patients with clear information on a range of problems allowing 
them to learn more about their condition as well as its symptoms and treatment.  Such 
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measures can also provide a standardized method by which physicians can gain information 
on patients’ assessment of their own health, and thus may be useful as a starting point in 
patient assessment and diagnosis.  In these respects, HRQoL information can promote shared 
decision making and may positively influence doctor-patient communication (Greenhalgh & 
Meadows, 1999).  Using patient-based measures of health to incorporate patients’ views in 
treatment decisions will not only empower them, but can also improve satisfaction with care 
and adherence to treatment (Stimson, 1974).  Health-related quality of life information can 
also be used to identify aspects of the disease which may otherwise go unattended as they 
lack clinical relevance, but may be important in explaining disease severity or coping 
problems (Higginson & Carr, 2001).  Health-related quality of life measures can thus 
complement, rather than replace, clinical evaluation by demonstrating the importance of 
signs or symptoms to the individual patient (Moore et al., 2004).  
 
HRQoL Assessment 
 Patrick and Bergner (1990) have noted that the health of the nation cannot be 
determined specifically with reference to the structure and process of the health care system 
and require assessment of health and quality of life outcomes.  In light of the effect of social 
inequities and restrictions to health care, they emphasized the use of appropriate and 
inclusive measures of HRQoL.  The second phase in the evolution of quality of life research 
during the 1980s involved the construction and testing of instruments designed to measure 
health and HRQoL.  
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Generic Measures 
Measures which are implicitly or explicitly geared to assess HRQoL are usually 
referred to as generic measures or broader measures of health status.  Generic measures are 
broadly applicable across different medical treatments (Prasad, Rentz, & Revicki, 2003) or 
health interventions (Pickard, Johnson, & Farris, 1999; Kauppinen, Sintonen, & Tukiainen, 
1998), and across demographic (Izquierdo-Porrera et al., 2005; De Oliveira, Barbiere, Santos, 
Faresin, & Fernandes, 2005) and cultural subgroups (Baker, Jacoby, Gorry, Doughty, & 
Ellina, 2005).  Generic measures have been used in a large number of different populations 
especially subjects with chronic conditions such as rheumatoid arthritis (Kosinski, Keller, 
Hatoum, Kong, & Ware, Jr., 1999), multiple sclerosis (Miller et al., 2003), and chronic 
obstructive pulmonary disease (COPD) (Domingo-Salvany et al., 2002).  An example of a 
generic measure is the Sickness Impact Profile (SIP) which assesses the sickness-related 
dysfunction in twelve different categories, producing a score for each category.  Categories 
may be aggregated under umbrella terms such as the physical dimension score, the 
psychosocial dimension score, and an overall score (Miller et al., 2003).   
Other commonly used generic health status measures are the Nottingham Health 
Profile (NHP) (Teixeira-Salmela et al., 2005) and the Medical Outcomes Survey Short Form 
– 12 & 36 items (SF-12 & SF-36) (Domingo-Salvany et al., 2002; Kosinski et al., 1999).   
Such wide utilization makes generic quality of life instruments invaluable methods of 
measurement. Since these measures permit the comparison of different populations and 
different programs, they are ideal in policy analysis and decision making situations.  
Continued use of generic measures allows policy makers to compare benefits of different 
health interventions and facilitate resource allocation decisions.  Cummulative knowledge of 
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HRQoL outcomes will establish the relative burden of diseases which impact our society and 
the relative success of interventions targeted towards such illnesses.  An important constraint 
of generic measures however, is that they are unable to identify disease-specific aspects that 
are essential for the measurement of certain outcomes. 
Disease-Specific Measures 
 Disease-specific measurement scales have the goals of being more clinically and 
socially significant in relation to specific conditions and of being able to discriminate more 
finely between patients’ levels of severity of a particular condition.  Since a universal 
questionnaire for eliciting relevant health status information for a number of conditions 
would be enormous, use of disease-specific quality of life measures allow brevity.  Although 
it seems intuitive that these measures would be automatically more sensitive to change than 
the more wide-ranging generic instruments, studies in various disease areas have found 
conflicting evidence regarding such an assumption (Bessette et al., 1998; Fitzpatrick, 
Ziebland, Jenkinson, Mowat, & Mowat, 1993a; Hagen, Smedstad, Uhlig, & Kvien, 1999; 
Harper et al., 1997).  Additionally, their narrow focus may mean that they could miss 
unexpected problems, such as adverse drug reactions.  It has therefore been suggested that 
generic measures, such as SF-36 should act as the core of the outcome measurement, that is 
to have disease-specific measures be used together with a generic measure.  Several disease-
specific measures have been developed for a number of conditions including cancer, arthritis 
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Quality Standards for HRQoL Measures 
The choice of a quality of life measure is determined by the research question and the 
application of measurement in clinical research, practice or policy analysis.  HRQoL 
measures may be used to discriminate among respondents at a point in time, to predict future 
outcomes and/or events, and to measure changes over time (Kirshner & Guyatt, 1985).  The 
quality standards that a HRQoL measure should meet vary according to the objective of 
measurement and the specific environment of application.  Over the years, the rigors to 
which quality of life measures should be developed and continually evaluated have been 
investigated.  Tully and Cantrill (1999) stress the importance of continuously evaluating 
HRQoL instruments, even if they have been in long use in order to provide ongoing evidence 
of their validity and to ensure that their language and content remains relevant to ever-
changing cultures.  The following sections will review the measurement properties against 
which HRQoL measures are judged. 
Scaling Assumptions 
Scaling assumptions are used to test whether the items are correctly grouped into 
scales measuring a unique underlying dimension for example, physical function, and if they 
can be summed without weighting or standardizing to produce a score.  Scaling assumptions 
are examined by determining whether items in each scale have roughly similar distributions 
of item responses; display equivalence of item means and standard deviations; and possess 
item internal consistency.   
Acceptability 
Acceptability of HRQoL measures is determined by the range and distribution of its 
scores.  A measure is considered acceptable if the observed scores are well distributed, and if 
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mean scores are near the mid-point for each scale.  Acceptability of HRQoL questionnaires is 
also determined by floor and ceiling effects.  Floor and ceiling effects represent the 
percentages of the sample scoring the lowest and highest possible scores respectively, and 
reflect the extent to which scores cluster at the bottom or the top of the score range.  The 
presence of floor and ceiling effects indicates that the measure may not be able to 
discriminate between subjects (Mao, Hsueh, Tang, Sheu, & Hsieh, 2002).  Floor and ceiling 
effects over 20% are generally considered unacceptable (McHorney, Ware, Jr., Lu, & 
Sherbourne, 1994).   
Validity 
Validity is a statement of confidence that the measure reflects the underlying concept 
it is supposed to measure rather than something else.  It is not a statement about the 
measurement operations, but a statement about the interpretation about the instrument’s 
score.  Validation evidence can be divided into three types namely construct-related, content-
related, and criterion-related (Aaronson N, 2002).   
Construct validity refers to the degree to which the measure provides results the way 
it should.  It includes face validity which refers to what an item appears to measure based on 
its manifest content.  One of the simpler forms of construct validity is known-groups or 
concurrent validity.  This is based on the principle that certain groups of patients may be 
anticipated to score in a different manner than others.  An instrument is said to be valid if it is 
sensitive to such differences.  Investigators usually select patients in whom differences may 
be anticipated within groups and as a result even small-sized studies can provide sufficient 
evidence to confirm that the observed differences are unlikely to be due to chance.  It is not 
the p-value but the magnitude of the differences that is relevant in these situations (Fayers 
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PM & Machin D, 2000).  Inter-correlations are used to measure the other two types of 
construct validity.  When a measure correlates well with other measures of the same 
construct it is said to have convergent validity, and when it correlates poorly with other 
measures of some other construct it is said to have divergent validity.  Advance specification 
of expected differences based on specific logical relationships among relevant concepts or 
constructs is necessary to establish this type of validity.     
Criterion validity involves assessing an instrument against the true value, or against 
some standard that is accepted as providing an indication of the true values for the 
measurement and is divided into concurrent validity and predictive validity (Fayers PM et al., 
2000).  Concurrent validity means agreement with the true value or “gold standard”.  
Predictive validity, a type of criterion validity is the degree to which a test can predict how 
well an individual will do in a future situation for e.g. future health status.  It is determined 
by the degree of correspondence between the assessment instrument and the specific criteria 
used for future performance. 
Reliability 
Reliability refers to the extent to which a measure yields the same score each time it 
is administered, all other things being equal.  Conceptually, a test score contains a “true-
score” component and an “error” component.  To the extent that random error is large, a test 
score will be unstable and hence unreliable.  There are two basic ways to evaluate test 
reliability; internal consistency reliability and reproducibility (e.g. test-retest reliability, inter-
observer and intra-rater reliability).  Internal consistency reliability is the most frequently 
used estimate of a measure’s reliability.  The measure of internal consistency is the average 
degree of association among the items on a test.  Cronbach’s alpha, which is an index of 
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internal consistency of the items, is a popular statistical test of reliability of an instrument.  
Commonly accepted minimal standards for reliability coefficients are 0.70 for group 
comparisons and 0.90-0.95 for individual comparisons (Aaronson N, 2002).  The 
interpretation of alpha is that a higher value implies that the responses are more consistent, 
and the sum of the item responses yields a score for the underlying dimensions that the items 
represent.  A low alpha coefficient usually indicates the item does not come from the same 
conceptual domain (Williams JI, 1989). 
Responsiveness 
 Responsiveness is also referred to as sensitivity to change and is an important part of 
the longitudinal validation of a HRQoL instrument.  Responsiveness is the instrument’s 
ability to detect change, that is, whether the measure can detect differences in outcomes, even 
if those differences are small.  Analyzing and interpreting changes in health status measures 
can be a problem for all longitudinal observational case studies, cohort studies, clinical trials, 
or health services evaluation.  Changes in physiologic measures such as blood pressure can 
be interpreted in terms of prognostic implications and well-established or pre-determined cut-
off point.  Changes in generic HRQoL measures are more difficult to interpret, although 
small changes in portions of the measure for example the physical or mental scale can be 
quite useful.  Single score or aggregated measures can make it difficult to identify which 
items or components are responsible for change.  Even if changes in the scores are found to 
be sensitive, the relative magnitude of the change can be difficult to ascertain for example, 
how much more meaningful is a five-point difference from a three point difference (Patrick 
& Deyo, 1989).   
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Responsiveness of disease-specific measures may be easier to interpret, because the 
items on such a measure are closely associated with the clinical measures of the disease 
activity such as time to walk 8 feet and visual acuity testing in MS patients.   
Self-assessed improvements by patients which are a common measure of change may be 
more closely associated with a disease-specific measure compared to a generic HRQoL 
measure (MacKenzie, Charlson, DiGioia, & Kelley, 1986).  In situations where a battery of 
HRQoL instruments is used, interpreting changes can be cumbersome due to different results 
presented by the constituent measures of the battery.  This is especially difficult when 
multiple comparisons or statistical tests are necessary (Guyatt, Veldhuyzen Van Zanten, 
Feeny, & Patrick, 1989).  Responsiveness of health status measures in clinical research has 
been assessed using various sensitivity-to-change coefficients including effect size (ES) 
(Kazis, Anderson, & Meenan, 1989), standardized response mean (SRM), paired t value 
(Liang, Fossel, & Larson, 1990; Guyatt, Walter, & Norman, 1987), Guyatt’s Responsiveness 
Index (GRI) (Guyatt et al., 1987), t-value for independent change scores, receiver operating 
characteristic area curve and correlation coefficients (Spearman’s ρ or Pearson’s r) 
(Scrimshaw & Maher, 2001). 
For a measure to have clinical usefulness it must not only have the above-mentioned 
psychometric properties, but it also must be simple, quick to complete, easy to score, and 
provide useful clinical data.  It is imperative that all validation reports describe the conditions 
under which the validation was conducted, including the demographic characteristics of the 
sample, and the range of illness or symptoms experienced in the sample. 
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Choice of HRQoL Measure 
Choosing a quality of life measure involves two major decisions: 1) should the 
measure be generic in nature or should it be disease/condition specific; and 2) whether the 
measure is sensitive to and appropriate for the patients seen in the particular practice or 
setting.  While designing an optimal strategy for research, investigators need to assign 
priority weights to measurement objectives.  The preference of a generic or disease specific 
measure depends not only on the psychometric properties described in the previous section, 
but also the research question at hand.  Project aims, methodologic concerns, and practical 
considerations usually determine the relative use of generic and disease-specific measures in 
an investigation.  Generic measures may be particularly useful for population-based studies 
used in shaping social policy decisions or in instances where allocation of resource decisions 
are to be made for large numbers of people (Albrecht, 1996).   
Problems may arise, however, if such scales are administered to a broad range of 
persons with different diseases and chronic conditions like MS and arthritis.  Since such 
populations may place different emphasis on the more generic concepts of health, it may be 
preferable to use standardized, generic instruments with disease-specific supplements.  In the 
case of quality of life assessment in routine clinical practice, the intelligent approach is to use 
both generic and disease-specific quality of life measures.  This will allow researchers to 
compare the group of interest with national norms while still staying sensitive to the 
condition in question.  In summary, major factors in selecting a quality of life measure 
include: the intended use of the results, method of administration, ease of use, psychometric 
properties (reliability, validity and responsiveness) and the appropriateness of the scale for 
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the patients being studied and for the location in which it is used (McSweeney & Creer, 
1995). 
 
MS-Related Health and Functional Status Measures 
The first quality of life study in the area of MS was published by Rudick et.al. in 
1992 (Rudick et al., 1992).  This was followed by an increased use of quality of life measures 
based on the belief that such studies contribute knowledge essential to the health and 
healthcare of MS patients that is not captured by traditional measures of disease disability.  A 
review by Nortvedt and Riise (Nortvedt et al., 2003) identified 33 different questionnaires 
used to measure quality of life, of which ten were specifically designed for MS patients.   
This list included the following MS-specific health related quality of life (HRQoL) 
measures: 1) DIP: Disability and Impact Profile; 2) FAMS: Functional Assessment of 
Multiple Sclerosis: 3) HAQUAMS: Hamburg Quality of Life Questionnaire in Multiple 
Sclerosis: 4) LMSQoL: Leeds Multiple Sclerosis Quality of Life; 5) MSQLI: Multiple 
Sclerosis Quality of Life Inventory; 6) MSIS-29: Multiple Sclerosis Impact Scale; 7) 
MSQoL-54: Multiple Sclerosis Quality of Life Inventory- 54 Items; 8) QLI-MS: Quality of 
Life Index- Multiple Sclerosis; 9) QOQL: Quality of Life Questionnaire for Multiple 
Sclerosis and 10) RAYS: a quality of life scale for MS patients.   
The most commonly used scales in MS measure impairment (objective clinical signs 
and symptoms), disability (behaviors that are altered or prevented within the illness), or 
HRQoL (an individual’s assessment of how a health problem and its treatment affect the 
ability to perform valued activities and roles) (Balcer, 2001).    
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Generic and Disease-Specific Measures 
The Medical Outcomes Survey Short Form -36 (SF-36) is considered to be a gold 
standard generic measure of health status and has been adapted cross-culturally in MS (Ware, 
Jr. & Sherbourne, 1992; Sharrack, Hughes, Soudain, & Dunn, 1999b; Nortvedt et al., 2001; 
Brunet et al., 1996; Pfennings et al., 1999b; Pfennings et al., 1999b).  It is comprised of 36 
items selected from a larger pool of items used by the RAND Corporation in the Medical 
Outcomes Study (MOS).  The SF-36 includes eight domains: 1) physical functioning; 2) role 
limitations due to physical problems; 3) bodily pain; 4) general health perceptions; 5) 
vitality; 6) social functioning; 7) role limitations due to emotional problems; and 8) mental 
health.  It also includes a single item that provides an indication of perceived change in 
health.  Factor analyses of the SF-36 health survey provide strong support for a two-factor 
model of health, with physical health reflected primarily by measures of physical 
functioning, pain and role limitations due to physical health problems, and mental health 
reflected primarily by measures of emotional well-being and role limitations caused by 
emotional problems.  Physical and mental component summary scales for the SF-36 health 
survey scales can thus be derived.   
Several studies have shown that problems specific to MS patients are not completely 
captured by such generic measures, thus rendering them less sensitive and less useful.  The 
physical scale has been known to display marked floor effects for severely disabled patients 
(Nicholl et al., 2001; Nortvedt, Riise, Myhr, & Nyland, 1999) and the use of the two 
summary scales seems to be problematic in MS (Nortvedt, Riise, Myhr, & Nyland, 2000; 
Hobart, Freeman, Lamping, Fitzpatrick, & Thompson, 2001).  Hence it is imperative that 
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MS-specific measures be used to assess quality of life in such patients, either alone or in 
conjunction with generic measures.  
The Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS) is 
one such MS-specific instrument which was developed as a self-administered questionnaire 
for HRQoL assessment in MS patients presenting at outpatient clinics (Gold et al., 2001).  
The HAQUAMS consists of 38 items, 28 of which address the major dimensions of HRQoL 
in MS, mainly fatigue and thinking, upper and lower limb mobility and mood.  The ten 
additional items assess sensory symptoms, bladder and bowel control, sexuality, recent health 
changes, disturbed vision and a general self-rating of handicap.  All subscales of this measure 
showed universally high internal consistency reliability except for the mobility scores which 
were less consistent over time (Gold et al., 2001).  Construct validity was supported by 
associations with other scales as well as objective clinical measures.  The HAQUAMS also 
showed no floor or ceiling effects in all of its five scales showing its applicability over a wide 
range of disease status.   
A follow-up to the validation study by Gold (Gold et al., 2001) found that the scores 
on the self-reported form of HAQUAMS had satisfactory reliability, but showed a marked 
discrepancy when compared to scores on clinical rating scales in MS patients with cognitive 
dysfunction (Gold, Schulz, Monch, Schulz, & Heesen, 2003).  It has been used as a HRQoL 
measure in order to examine the impact of aerobic training on quality of life, among other 
outcomes in MS patients (Schulz et al., 2004).  The use of HAQUAMS, despite its promising 
psychometric properties, has been limited only to quality of life research studies in Germany.  
It is the only disease-specific measure besides the FAMS, which addresses all domains of 
health related quality of life in MS and hence may be a potential candidate for use in routine 
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care of MS patients in the United States.  Since it has only been validated in the German 
population, the next logical step would be to test its psychometric properties in English 
speaking patients in order to facilitate cross-cultural adaptation. 
 The Multiple Sclerosis Impact Scale (MSIS-29) is a relatively new disease-specific 
questionnaire that measures the physical and psychological impact of MS from the patient’s 
perspective (Hobart, Lamping, Fitzpatrick, Riazi, & Thompson, 2001).  It was developed 
using the standard psychometric approach which involved reducing an item pool generated 
from people with MS.  Its psychometric properties have been evaluated among randomly 
selected, geographically stratified members of the Multiple Sclerosis Society (MSS) by 
means of large independent postal surveys.  It is simple, easy to administer and takes only a 
few minutes to complete.  Hobart (Hobart et al., 2004) found that it took two minutes and 
forty-four seconds to complete in a sample of ten patients (Range= 1 minute 45 seconds to 4 
minutes 26 seconds).  It was developed to facilitate administration directly to patients in a 
clinical or research setting or via a postal survey. 
Although the MSIS-29 was found to have acceptable psychometric properties in a 
random sample of the MSS, a limitation of this study was that the presence of clinically 
definite MS in patients could not be confirmed.  Separate studies in the following years tested 
the psychometric properties of the MSIS-29 in hospital-based samples (Riazi, Hobart, 
Lamping, Fitzpatrick, & Thompson, 2002; McGuigan & Hutchinson, 2004).  Riazi (Riazi et 
al., 2002) evaluated the psychometric properties of the MSIS-29 in three hospital-based 
samples classified as those admitted for rehabilitation, those obtaining corticosteroid therapy 
and a postal survey of patients with Primary Progressive MS.  These properties were then 
compared with data obtained from a community based sample in an earlier study (Hobart et 
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al., 2001).  Expected differences in mean scores were obtained between the three hospital 
samples with patients in rehabilitation having the worst scores.  In the rehabilitation sample, 
the correlation between the MSIS-29 physical scale and the SF-36 physical functioning scale 
and the Expanded Disability Status Scale (EDSS) was found to be lower that expected.  The 
attenuation of this correlation was believed to be due to the limited score distribution of the 
SF-36 (range 0 to 65).  Overall, the psychometric properties (scaling assumptions, 
acceptability, reliability and validity) of the MSIS-29 scales were similar in both the 
community and the hospital samples.   
Another study out of Ireland compared the responsiveness of MSIS-29 in addition to 
these psychometric properties (McGuigan et al., 2004).  Responsiveness was evaluated by 
comparing mean scores at two time points and was found to exhibit at least moderate effect 
size in the static group and the changed group.  These studies provide evidence of acceptable 
psychometric criteria and preliminary evidence of responsiveness of the MSIS-29 in various 
settings.  Moreover, it has been found to be useful in assessment of the physical impact of 
MS in daily life (Hoogervorst, Zwemmer, Jelles, Polman, & Uitdehaag, 2004).   According to 
Hobart (Hobart et al., 2004), head-to-head comparisons of the psychometric properties of the 
MSIS-29 and other MS specific outcome measures will help to determine the relative 
advantages of different instruments in order to facilitate evidence-based choice of measures. 
 
Functional Status Measures 
The consequences of a chronic illness such as MS on the life of the patient can be 
systematically described using the World Health Organization’s International Classification 
of Impairments, Disabilities and Handicaps (ICIDH) (Wood, 1980).  The ICIDH is a 
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classification of "disablements" and covers three dimensions: 1) body structures or functions, 
i.e. impairments; 2) personal activities, i.e. disability; and 3) participation in society, i.e. 
handicap.  Accurate clinical assessment of disability experienced by patients with MS is of 
great importance in interventions or pharmacological research and also in clinical practice to 
identify problems that may be amenable to treatment (Rossier & Wade, 2002).  Disability in 
MS patients however, does not necessarily arise only from impairments (signs or symptoms 
of MS) but can also occur due to impact on activity domains such as dexterity, 
communication, work, leisure/domestic activities and personal activities of daily living.   
The most commonly used measure of neurological impairment in MS clinical trials is 
the EDSS (Solari, 2005).  The EDSS was derived from the Disability Status Scale (DSS) 
originally introduced by Kurtzke (Kurtzke, 1955) and its ratings range from 0.0 to 10.0, with 
0.5 unit increments (except between 0 and 1).  For a rating lower than 4.0, the EDSS score is 
based on scores from eight functional systems: pyramidal, cerebellar, brainstem, sensory, 
bowel and bladder, visual and mental function.  Scores above 4.0 are highly dependent on the 
patient’s ambulation status – primarily the ability to walk certain distances and a dependence 
on assistive devices.   
In spite of its dominance in MS research, the Kurtzke scale is documented to have 
many weaknesses.  It has been argued that the Kurtzke EDSS is not a general measure of 
disability since it uses information derived from the level of impairment to allocate the first 
three levels and this may be invalid given the variable link between disability and 
impairment.  The six higher grades concentrate on mobility which is just one aspect of 
disability, while the final grade is death, which is not a disability (Rossier et al., 2002).  Since 
the scores above 4.0 are primarily based on ambulation status, EDSS shows reduced 
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sensitivity to detect change in neurological impairment within this range (Balcer, 2001).  
Studies have shown that simple timed measures of dexterity or mobility are much more 
sensitive to change (Cutter et al., 1999; Goodkin, Hertsgaard, & Seminary, 1988).   
The EDSS has limited reliability partly due to poor judging of distances (the main 
differentiating feature between grades) by patients and doctors (Sharrack & Hughes, 1997; 
Noseworthy, Vandervoort, Wong, & Ebers, 1990).  The quantitative distances between 
scores of the EDSS are on an ordinal or a noncontinuous scale, and as a result of this, 
summary statistics such as mean and standard deviation may not be entirely appropriate for 
reporting such scores (Balcer, 2001).  Lastly, it takes time to complete, and requires a trained 
neurologist because the functional systems analysis also needs to be completed (Rossier et 
al., 2002).   
Other commonly used clinical scales in MS research include The Scripps 
Neurological Rating Scale (NRS) (Sipe et al., 1984), The Ambulation Index (AI) (Friedman 
et al., 2005) and the Functional Independence Measure (FIM) (Granger, Cotter, Hamilton, 
Fiedler, & Hens, 1990).  The NRS is a reliable and valid measure of impairment and 
disability but is unresponsive, while the AI which is a reliable and valid ambulation-related 
disability scale is only weakly responsive.  The FIM on the other hand was found to be 
reliable and responsive, but is rather cumbersome to administer with a limited content 
validity (Sharrack et al., 1999b).   
The National Multiple Sclerosis Clinical Outcomes Assessment Task Force 
developed the Multiple Sclerosis Functional Composite (MSFC) in light of the perceived 
problems with existing disability measures (Fischer, Rudick, Cutter, & Reingold, 1999; 
Rudick, Cutter, & Reingold, 2002).  The scale has three components that yield objective and 
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quantitative results 1) the Timed 25-Foot Walk; 2) the 9 Hole Peg Test (9-HPT) and 3) the 3-
second paced auditory serial addition test.  The MSFC can be administered by trained 
technicians as well as other non-physician personnel.  The testing time is about 15 minutes 
and required facilities to include a quiet examination room with a table or desk and a hallway 
for the Timed 25-Foot Walk Test.  The MSFC has also been validated against patient-
reported quality of life measures (Miller et al., 2000).  Strong correlations were found with 
the SIP and SF-36 physical dimensions while significant but slightly weaker correlation was 
observed with the emotional functioning scale of the SIP.     
In order to incorporate a measure focusing on disability in patients with MS, the 
Guy’s Neurological Disability Scale (GNDS) was developed (Sharrack & Hughes, 1999a).  
The GNDS is based on the concept that disability in MS is multi-dimensional and can be 
considered in several separate categories.  The authors identified twelve separate functional 
domains of mutually exclusive human functions which can be commonly observed in 
patients with MS namely: cognition, mood, vision, speech, swallowing, upper limb function, 
lower limb function, bladder function, bowel function, sexual function, fatigue and “others” 
to cover disabilities resulting from impairment of less defined systems such as pain, spasms, 
vertigo, etc..  The GNDS was found to be scientifically sound, displaying good to moderate 
validity, reliability and responsiveness.  The GNDS can be either administered by an 
interviewer or self-administered, with both formats displaying good psychometric properties 
(Rossier et al., 2002).  The necessary time to perform the GNDS has been documented to be 
nine minutes, with an additional five minutes required for scoring (Rossier et al., 2002).     
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Measures of Self-Reported Visual Function 
 Vision targeted patient-based activity assessments did not occur in the literature 
before 1980, but the following decades have seen the development of several patient-based 
visual function assessment instruments and their use in studies among patients with visual 
impairments (Massof et al., 2001).  The National Eye Institute - Visual Function 51-item 
questionnaire (NEI-VFQ) was the first instrument developed specifically for vision-impaired 
patients which included items that assess patients’ ability to cope emotionally and 
psychologically with their vision loss.  This was administered to patients in the Optic 
Neuritis Treatment Trial (ONTT) cohort (Cole, Beck, Moke, Gal, & Long, 2000).  Self-
reported visual dysfunction on the 51-item NEI-VFQ as well as its short-form version Visual 
Function Questionnaire – 25 items (VFQ) was found to be common among those patients 
who developed clinically definite MS in the ONTT.   
The VFQ consists of 25 items presented in the format of a Likert scale and patients 
are asked to rate the level of difficulty of particular visual symptoms or activities such as 
difficulty looking at or using a computer (Mangione et al., 2001).  The following vision-
targeted subscales are generated: global vision rating (1 item), difficulty with near vision 
activities (3 items), difficulty with distance vision activities (3 items), limitations in social 
functioning due to vision (2 items), role limitations due to vision (2 items), dependency on 
others due to vision (3 items), mental health symptoms due to vision (4 items), driving 
difficulties (3 items), limitations due to peripheral (1 item) and color vision (1 item), and 
ocular pain (2 items).  It also contains an appendix of additional items from the original 
version that can be used to expand the scales up to a total of 39 items.  The questionnaire can 
be self-administered by paper and pencil, and also through a personal or telephone interview.  
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The interviewer format takes approximately ten minutes to administer, while the self-
administered format has not been times because it is yet to be tested psychometrically.    
The interviewer-administered format of the VFQ was found to have internal 
consistency and validity comparable to the original 51-item version in a sample of patients 
with evidence of an underlying eye disease such as diabetic retinopathy and age-related 
cataracts.  This format has also been used to assess and compare self-reported visual function 
between MS patients and an eye-disease free reference group (Balcer et al., 2000).  Mean 
VFQ composite and selected sub-scale scores with the exception of color-vision, were found 
to be worse in MS patients compared with the eye-disease free group.   
 
Measures of Depression 
 Depression screening questionnaires are appropriate for many research efforts due to 
the cost and time intensive nature of clinically diagnosing depression (Vahle, Andresen, & 
Hagglund, 2000).  Standardized instruments of depression measure depressive 
symptomatology rather than clinical depression and are commonly used to screen people 
with disabilities.  The Center for Epidemiologic Studies- Depression Scale (CES-D) which 
was derived from previously validated longer depression scales, is the most widely used 
questionnaire for depression screening (Vahle et al., 2000; BECK, WARD, MENDELSON, 
MOCK, & ERBAUGH, 1961; Raskin, Schulterbrandt, Reatig, & McKeon, 1969; BECK et 
al., 1961).  The instrument consists of 20 symptom items associated with depression which 
are indicative of personality attributes such as self-esteem, state anxiety and trait anxiety 
(Orme, Reis, & Herz, 1986).  The focus of the CES-D is on current symptoms (Kohout, 
Berkman, Evans, & Cornoni-Huntley, 1993), in that patients rate the frequency of each 
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symptom item over the past week as a score ranging from 0 (rarely or none of the time) to 3 
(most or all of the time).  A low average administration time of less than seven minutes leads 
to a reduction in administrative and respondent burden (Kohout et al., 1993).   
 The CES-D has been used among individuals with various disabling conditions 
including spinal cord injury, stroke and MS (Holicky & Charlifue, 1999; Shinar et al., 1986; 
Romberg, Virtanen, & Ruutiainen, 2005; Patten, Fridhandler, Beck, & Metz, 2003).  The 
validity and reliability of the CES-D were tested in a large sample of MS patients, general 
practice patients and healthy workers (Verdier-Taillefer, Gourlet, Fuhrer, & Alperovitch, 
2001).  The four factors of the questionnaire explained more than 50% of the variance in 
each of the sample groups.  Reliability was found to be excellent with Cronbach’s α of 0.90 
in patients with MS.  The positive predictive value of the questionnaire was evaluated in 
patients who were candidates for disease-modifying MS treatment (Pandya, Metz, & Patten, 
2005).  The CES-D result was impressive, with 38 (74.5%) of a total of 47 patients with a 
positive test result were found to have a depressive disorder.  
 
Psychometric Comparison of HRQoL Measures 
Only three reported studies have concurrently compared the psychometric properties 
of MS-specific HRQoL measures.  Riazi et.al. (2003) examined and compared the full range 
of psychometric properties of the MSIS-29 with the 59-item FAMS and the SF-36.  The 
analysis however, was limited only to the physical and psychological scales from each of 
these measures in order to ensure that only similar domains were being compared.  The 
comparison was performed in a sample of adults with clinically definite MS who were 
consecutively admitted to a hospital for rehabilitation or intravenous steroid treatment.  The 
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authors examined the complete set of psychometric properties including scaling assumptions, 
acceptability, reliability, convergent and discriminant construct validity, and responsiveness.  
Patients were asked to complete the questionnaires on admission and discharge 
(rehabilitation) or on admission and six weeks later (steroids).   
A substantial floor effect (20%) was detected for the SF-36 physical function scale, 
but not for the physical scales of the other measures.  The reliability of the mobility scale of 
FAMS was lower than the acceptable level set for this study.  With regards to 
responsiveness, the MSIS-29 performed better compared to the SF-36 and FAMS in both the 
physical and psychological scales.  This evidence suggests that the MSIS-29 is more likely to 
detect clinically significant changes in the impact of MS.  Relative efficiency statistics 
indicated that the other scales were 26% (SF-36 physical function) and 63% (FAMS 
mobility) as efficient at detecting change as the MSIS-29 physical scale.  Although the 
MSIS-29 displayed better psychometric properties than the other measures, the authors have 
acknowledged the need for continuing comparisons among MS-specific HRQoL measures.   
Another study of psychometric properties of MS related health status measures, 
evaluated the reliability, scale score distributions and the relationship of the measures to a set 
of specifically designed criterion variables (Vickrey et al., 1997).  The quality of life 
measures included the SF-36 as the generic measure and the Quality of Life Questionnaire 
for Multiple Sclerosis (QOLQ) and the Multiple Sclerosis Activities of Daily Living Scales 
(MS-ADL scales) as the disease-specific measures.  The study involved sending a mail 
survey to 171 patients with definite MS who attended the Multiple Sclerosis Clinic at the 
University of California at Los Angeles (UCLA).  The SF-36 was supplemented with three 
scales which covered dimensions felt by expert opinion and a review of literature to be 
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highly relevant to individuals with MS (Vickrey, Hays, Harooni, Myers, & Ellison, 1995).  
The SF-36 with supplemental scales showed marked floor and ceiling effects on the role 
limitations due to physical problems and role limitations due to emotional problems scales, 
respectively.  The MS-ADL also showed noteworthy ceiling effects on a couple of scales, 
while the QOQL showed no discernable floor or ceiling effects.   
Results from relative validity analysis and the stepwise regression procedure 
indicated that the disease-targeted components (cognitive function scale, mobility and self-
selected physical problems scales from the QOQL and the MS-ADL social and social (help) 
scales) of HRQoL in MS contributed important unique information to researchers.  Although 
supplementing SF-36 with certain disease-specific components was found to be useful, no 
one measure was clearly and consistently superior or worse than others in terms of reliability 
and construct validity.  One important limitation of this study was that the authors did not 
evaluate the responsiveness of these measures to change.  This makes it difficult to 
generalize the findings of this study to all studies of MS, particularly those which are 
longitudinal in nature. 
The MSQoL-54, FAMS and EuroQol (standardized outcome measure developed by 
the EuroQol Group) were administered to 128 MS patients in contact with a rehabilitation 
ward or a consultant in rehabilitation medicine (Nicholl et al., 2001).  The purpose of this 
study was to assess the relative importance of the EuroQol (EQ-5D) compared to a MS-
specific and a generic quality of life questionnaire.  The EQ-5D failed to perform well, owing 
to the three point scale which was found to be lacking in discrimination within a highly 
disabled sample.  Since the visual analogue health state scale on the EQ-5D did not show 
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high correlations with any other mood or disability measures, the claim that it measures 
quality of life remained unsubstantiated.   
The MSQoL-54 was found to have large floor effects on the physical health and role 
limitations due to the physical problems subscales.  The FAMS motility subscale however, 
had no noticeable floor effects even though a large percentage of the study sample were 
restricted to a wheelchair (66.6 %).  Some patients found certain items in all three 
questionnaires to be offensive due to their obvious limitations.  The FAMS was found to be 
the better of the three questionnaires owing to the presence of a number of subscales relevant 
to MS and the lack of floor and ceiling effects.  Since this study included a number of 
disabled MS patients, the generalizability of the results to patients with milder symptoms is 
suspect.  Additionally the important property of responsiveness of these measures was left 
out of this analysis. 
 
Use of Quality of Life Information in Clinical Practice 
Knowledge of usefulness of health related quality of life (HRQoL) assessment in 
clinical practice such as documentation of the natural history of a disease, evaluating 
treatment effectiveness and improving clinical case management has been present since the 
early nineties.  There have been attempts to move the formal evaluation of quality of life 
assessment into the clinical setting, but it has been difficult to anticipate the impact of such 
assessments in physician-behavior and patient care as well as decision making (Greenfield & 
Nelson, 1992).  A shift towards HRQoL assessments, in order to be accepted by clinicians 
should not only benefit the patients, but also enhance the clinician’s ability to function.  This 
requires that the argument for use of HRQoL measures should be made on practical basis and 
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not purely on theoretical grounds (Hayes, 1998).  Although some evidence of practicality of 
MS-related HRQoL measures is available from studies comparing their psychometric 
properties, there remains a need for a study exploring a neurologist’s behavior and attitude in 
relation to QOL information.     
Assessments of the behavior and attitude of physicians regarding routine 
measurement of HRQoL in patients with chronic conditions such as cancer (Bezjak et al., 
1997; Bezjak et al., 2001), hematopoietic stem cell transplantation (Lee et al., 2004), diabetes 
(Meadows, Rogers, & Greene, 1998) and rheumatoid arthritis (Russack et.al; 2003) have 
been well documented.  Such studies have provided varying results regarding physician use, 
knowledge and attitude regarding quality of life information in treating patients with chronic 
conditions.  In a survey of general practitioners (GP) and practice nurses, it was found that 
almost half of the personnel were unclear as to how the health outcomes data obtained during 
routine care of patients with diabetes was used.  In terms of outlook towards QOL 
information, the results conveyed that both GP’s and nurses showed a positive overall 
attitude towards health outcome measurement (Meadows et al., 1998).  Another study in a 
hospital setting found that most physicians had poor knowledge of quality of life assessment 
instruments and this was influenced mainly by the age of the physician and the department of 
practice.  Young physicians and those working in oncological departments seemed to have 
more knowledge about health status measures (Belli et al., 1994).   
Oncology practice has made great strides relating to research regarding quality of life 
assessment in clinical care of cancer patients.  Bezjak and colleagues have published a series 
of research publications regarding the perspectives of oncologists regarding the use of quality 
of life information in clinical practice using the MD-QOL, a self-administered questionnaire 
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developed specifically for this purpose (Bezjak et al., 1997; Bezjak et al., 2001; Bezjak et al., 
1997; Bezjak, Taylor, Ng, MacDonald, & Depetrillo, 1998; Taylor, Macdonald, Bezjak, Ng, 
& Depetrillo, 1996).  The MD-QOL was constructed on the basis of in-depth interviews with 
sixty American and Canadian oncologists and was designed to assess physician perceptions 
of QOL and QOL information.  Another study among rheumatologists noted that although 
63% felt that patient self-report questionnaires were useful in clinical decision making, 48% 
of the respondents stated that none of their patients completed HRQoL self-reports in routine 
care.  Only 19% of the rheumatologists had at least 50% of their patients complete self-report 
health status measures.  Older rheumatologists were found to be most likely to endorse 
patient self-report questionnaires (Russak et al., 2003).           
Quality of life information has been known to provide useful information to 
researchers by adding to existing clinical knowledge.  Velikova and colleagues found that a 
larger proportion of patients in the intervention group (those who regularly completed 
HRQoL measures) showed clinically meaningful improvement in their HRQoL.  Better 
HRQoL and emotional functioning was attributed to the indirect impact of patient-physician 
communication.  Another randomized controlled trial in epilepsy patients at a neurology 
clinic found that routine use of the SF-36 provided physicians with new information in 63 per 
cent of the patients in the intervention group (Wagner et al., 1997).  Thus, the routine use of 
health status measures enhanced patient care by prompting changes in therapy in 13% of the 
patients and by facilitating communication with physicians.  The HRQoL has also been 
reported to be useful for informing patients of common reactions and choices made by 
patients with similar diagnosis (Bezjak et al., 2001). 
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It has been noted that HRQoL instruments are not commonly used in routine care of 
patients with MS.  In order to achieve this practice, it is important to assess the neurologists’ 
attitude, beliefs and barriers to the use of HRQoL information.  However in order to gain a 
complete understanding of the neurologists’ intention to assess HRQoL information, a 
complex approach that considers several factors may be required.  Social psychological 
models such as the Theory of Planned Behavior (TPB) may be helpful in such situations to 
better identify the key determinants of behavioral intention.  The TPB proposes that an 
individual’s behavior is predicted by the strength of their intention to behave in that way.  
There are three variables that predict behavioral intention: attitude, subjective norms and 
perceived behavioral control, which in turn can be predicted from an individual’s belief.  
Attitude towards a behavior is said to be a result of the belief about the likely outcome of the 
behavior (behavioral beliefs) weighted by an evaluation of the importance of the 
consequence (outcome evaluation).  Subjective norm is assumed to be predicted from beliefs 
about the views of other important individuals or groups (normative beliefs) weighted by a 
persons motivation to comply with these groups (motivation to comply).   
Perceived Behavior Control (PBC) is predicted by beliefs about factors likely to 
facilitate or inhibit the behavior (control beliefs) weighted by the person’s evaluation of the 
power that each of these factors has to affect their behavior (power).  The TPB is commonly 
used to study behavioral intentions and behavior in patients but has also been found to be 
relevant to healthcare providers as well (Millstein, 1996).  Hu and Chau, 1999 used the TPB 
to investigate technology acceptance among physicians who practiced in public tertiary 
hospitals in Hong Kong and found that attitude and perceived behavior control are important 
predictors of this behavior.  Another study utilized the framework of the TPB to examine 
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predictors of physicians’ adherence to national guidelines for management of employees with 
mental health problems (Rebergen et al., 2006). 
 Another such model, the Transtheoretical Model of Change (Prochaska, DiClemente, 
& Norcross, 1992) has been used to conceptualize the process of intentional behavior change 
among health care professionals.  Park and colleagues (2003) found this model to be useful in 
establishing future interventions to help understand and guide physician’s behavior towards 
increasing adoption of smoking cessations interventions with their patients.  Similarly Price 
and colleagues (2006) used the model to identify Ohio obstetricians/ gynecologists' use of 
nicotine replacement therapy with pregnant smokers.  The Transtheoretical Model of Change 
focuses on the decision making of the individual where the stage construct is the key 
organizing construct of the model.  The Transtheoretical Model defines change as a process 
involving progress through a series of five stages: precontemplation, contemplation, 
preparation, action and maintainence and has been used in the past to improve physician 
delivered counseling (Keller, Donner-Banzhoff, Kaluza, Baum, & Basler, 2000) and 
adherence to cancer screening guidelines among healthcare professionals (Honda & Gorin, 
2006; Hersberger, Botomino, Mancini, & Bruppacher, 2006).  
Precontemplation is the stage, in which people are not intending to take action in the 
foreseeable future.  People in this stage are generally uninformed or under-informed about 
the consequences of the behavior in question.  In the contemplation stage, people are 
intending to change in the next six months, while in the preparation stage they are intending 
to take action in the immediate future, usually measured as the next month.  Action is the 
stage in which people have made specific modifications in their behavior within the past six 
months and since action is observable, behavior change often has been equated with this 
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stage.  The final stage is that of maintenance in which people are working to maintain the 
behavior change for a long time.  Behavior change is rarely a discrete, single event and an 
individual moves gradually from being uninterested (precontemplation stage) to considering 
a change (contemplation stage) to deciding and preparing to make a change.  Most people 
find themselves recycling through the stages of change several times before the change 
becomes truly established.  The Transtheoretical model also incorporates an intervening or 
outcome variable called decisional balance (the pros and cons of change).  These decisional 
balance measures have become critical constructs in the Transtheoretical model. The pros 
and cons combine to form a decisional "balance sheet" of comparative potential gains and 
losses where the balance between the pros and cons varies depending on which stage of 
change the individual is in. 
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Chapter 3: Methods 
 
Conceptual Model 
The focus of this study was health-related quality of life (HRQoL) in non-
institutionalized patients with multiple sclerosis (MS) and is illustrated by the conceptual 
model in Figure 1.  Health-related quality of life is a multi-dimensional concept which can be 
measured by any one of several patient reported outcome (PRO) measures.  Health-related 
quality of life may be influenced by several factors, especially in a progressive disease such 
as MS.  One objective was to determine factors that have an independent and significant 
impact on HRQoL.  As such, the influence of clinical, demographic and other relevant 
factors was investigated.   
Measurement of HRQoL and identification of its predictors is relevant beyond the 
realm of research and may be very useful if incorporated into clinical practice.  Incorporation 
into practice will depend upon the choice of the measure and the intention of neurologists to 
use such information.  Deciding on a HRQoL measure for use in routine practice can be an 
arduous task and may be best addressed by facilitating evidence-based choice.  This was 
accomplished by comparing currently relevant measures on various psychometric properties 
as well as preferences of MS patients and neurologists regarding these measures.  Preferences 
regarding their relevance, usefulness, wording, and length were assessed.   
Simplifying such decisions may not be sufficient to promote acceptance of HRQoL 
among neurologists.  It is necessary to understand what other factors may be associated with 
the willingness of neurologists to utilize HRQoL information.  These were investigated by  

































Figure 1: Conceptual Model 
Choosing a suitable patient 
reported outcome questionnaire in 
the routine care of MS patients 
Health-Related Quality of Life 
in Multiple Sclerosis 
Factors affecting HRQoL 
Clinical Factors:  
Disability, Depression, and Visual Impairment 
 
Demographic Factors:  
Age, Gender, Marital and Employment Status 
 
Other Factors:  
Duration of disease, Comorbid Conditions 
Application of HRQoL in clinical 
practice 
Intention of the neurologists to 
assess HRQoL information in 
patients with MS 
Subjective Norms (TPB) 
Behavior Control (TPB) 
Demographic Factors:  
Age, Gender 
Other Factors:  
Experience, Patient Load, 
Participation in MS-Related 
Clinical Trial, Place of Practice 
Attitudes (TPB) 
Psychometric Properties: Acceptability, 
Scaling Assumptions, Reliability, Validity 
and Responsiveness 
 
Patient Preferences: Length, wording, 
Relevance to Daily Functioning 
Physician Preferences: Usefulness, 
Wording, Length 
                     =   PHASE I 
                     =   PHASE II 
Stage of Change (TTM) 
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using a framework of the Theory of Planned Behavior (TPB) and the Transtheoretical Model 
of Change (health behavior theories).     
Phase I involved collection of primary data from a sample of non-institutionalized 
MS patients.  Data from Phase I was used to measure HRQoL, identify factors affecting 
HRQoL, compare the HRQoL measures on their psychometric properties, and assess patient 
preferences.  A mail survey of neurologists was performed in Phase II.  This data facilitated 
investigation of: neurologist preferences regarding the HRQoL measures used in Phase I; 
intention of neurologists to use HRQoL information in practice; and factors that have a 




The study design was longitudinal involving a convenience sample of patients with 
multiple sclerosis (MS) at a large university hospital.  The study involved completion of a 
battery of patient-reported outcome (PRO) measures and quantitative tests of motor function 
by the patients at the time of enrollment (Baseline, Time 1).  Those patients who successfully 
completed baseline assessments were asked to complete selected self-report questionnaires 
via mail three to six months later (Time 2).  A monetary reimbursement was given to all 
participants following successful completion of questionnaires and/or tests at each time point.  
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Study Population 
 Patients were included in this study if they were diagnosed as having clinically 
definite MS and were treated for MS by at least one of the staff neurologists prior to baseline 
data collection.  Clinically definite MS was confirmed by neurologists using the McDonald’s 
diagnostic criteria (discussed in the background section).  Following identification of this 
population, patients were excluded for any of the following reasons: 1) patients who had an 
exacerbation (relapse) in the four weeks prior to enrollment; 2) those less than 18 years of 
age; 3) those who were not literate in English; 4) those who were pregnant; and 5) those who 
were not willing, or were unable to complete a series of questionnaires owing to cognitive or 
functional limitations.  These exclusion criteria were adapted from previous MS literature 
(Patti et al., 2003).  One hundred and sixteen patients meeting these criteria were identified 
from the records of the outpatient neurology clinic at Ruby Memorial Hospital in 
Morgantown, West Virginia.  The sample consisted of those MS patients who were seen 
regularly at the clinic, including those having a recent diagnosis of MS being seen for a 
second opinion, as well as patients referred for consultation about management of MS.  
Approval for the study was obtained from the West Virginia University Institutional Review 
Board (WV-IRB).   
Two weeks prior to their scheduled appointment patients were mailed a letter printed 
on university letterhead, endorsed by their attending neurologist (Appendix A).  The letter 
provided a short description of the study and encouraged patients to participate.  It also asked 
them to account for some additional time during their upcoming visit, if they were interested 
in taking part in the study.  Physician endorsement was utilized in order to improve chances 
of patient participation.  Following their arrival at the outpatient clinic at Ruby Memorial 
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Hospital, the attending staff neurologist reminded the patient about the study and introduced 
them to the principal investigator (PI).  The PI then described the study to the patient and 
invited them to participate.  Informed consent statements were read to patients who were 




Selection of Measures for Psychometric Comparison 
Selection of a HRQoL instrument generally depends upon the specific context in 
which the instrument is going to be used (Holcik and Koupilova, 1999).  Since the focus of 
this study was HRQoL assessment in routine clinical practice, brevity of the instrument was 
one of the main inclusion criteria.  Questionnaires that were too long would be tiresome to 
complete and might decrease the number of subjects willing to participate.  The candidate 
quality of life measures were also required to be self-administered, valid, available in 
English, and previously applied in a sample of patients with MS.  Based on these criteria, the 
SF-36 was selected as the generic measure while HAQUAMS and MSIS-29 were selected as 
the MS-specific quality of life measures.  The HAQUAMS is one of the few MS-specific 
measures that addresses most relevant domains of HRQoL.  The MSIS-29 has been shown to 
have good psychometric properties in comparison to commonly used measures such as the 
Multiple Sclerosis Quality of Life – 54 Items (MSQ0L-54) and the Functional Assessment in 
Multiple Sclerosis (FAMS).  Finally, in absence of a gold standard HRQoL measure in MS, 
the SF-36 was chosen as a generic comparator for this study.   
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Reasons for Exclusion of Other HRQoL Measures   
FAMS although commonly used has been shown to have lower reliability on its 
motility scale compared to the MSIS-29 (Riazi et al., 2003).  Additionally, eleven items of 
HAQUAMS were derived from it, as such FAMS was not chosen as a comparator in this 
psychometric comparison.  The MSQoL-54 was excluded due to poor psychometric evidence 
and the respondent burden (patients have to complete 54 items) that it poses.  The MSQoL-
54 was developed as a disease-specific quality of life measure for MS and consists of the 36 
items of the SF-36 and an additional eighteen condition-specific items.  However, in 
comparison with the SF-36, the MSQoL-54 was found to have no better psychometric 
properties than the former and hence excluded.  It was found to display marked floor and 
ceiling effects and poor responsiveness and in addition, its sexual function and satisfaction 
scales had a high proportion of missing data.  Additionally, the MSQoL-54 overall quality of 
life scale showed only moderate correlations (r= 0.34 to 0.45) with four measures of varying 
constructs (Expanded Disability Status Scale, Functional Independence Measure, London 
Handicap Scale, General Health Questionnaire) implying that it does not address a single 
underlying construct (Freeman, Hobart, & Thompson, 2001).  From among the other HRQoL 
measures specific to MS, the Multiple Sclerosis Quality of Life Inventory (MSQLI) was not 
included due to its length (takes approximately forty-five minutes to complete) and RAYS 
Quality of Life Scale in Multiple Sclerosis due to absence of validity and reliability studies in 
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Selection of a Outcome Measure for Objectives 2 and 3 
 Total and sub-scale HAQUAMS scores were used as quality of life outcome variables 
(dependent variable) for Objectives 2 and 3.  The HAQUAMS was chosen for this purpose 
over SF-36 and MSIS-29 because; not only is it MS-specific but it also addresses aspects of 
patients other that just physical and psychological functioning.  Although commonly used, 
the SF-36 is still considered as a generic measure of quality of life, while MSIS-29 is 
reported to be a measure of physical and psychological impact of MS and not of overall 
quality of life 
Data Collection 
The protocol for phase I involved the completion of a battery of PRO measures, and 
quantitative tests of motor function by all patients who consented to participate in the study.  
Data was collected in a private area at the neurology clinic at Ruby Memorial Hospital.  First, 
the PI administered the Guys Neurological Disability Scale (GNDS) (see Appendix B), and 
the Visual Function Questionnaire (VFQ) (see Appendix C) to the patients.  Each patient was 
then asked to complete the Centers for Epidemiological Studies- Depression Scale (CES-D) 
(see Appendix D).  The CES-D assesses depressive symptoms and is not a clinical measure 
of depression.  The terms depressive symptoms and depression will be used interchangeably 
for the purpose of this study.  An additional questionnaire (see Appendix E) gathered 
information regarding age, gender, race, employment status, marital status, number of 
comorbid conditions, and duration of the disease.   
Comorbidity data were collected by asking the respondent specifically if they were 
ever diagnosed or treated for the presence of any of a number of disease conditions (see 
Appendix F).  For the final analysis, comorbidities for each patient were calculated as a 
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simple count of twelve common chronic diseases.  These diseases included: arthritis, 
diabetes, asthma, chronic obstructive pulmonary disease, high blood pressure, high 
cholesterol, back problems, stomach ulcers, sexually transmitted disease, cancer, thyroid 
problems and any category of heart disease.  Duration of disease was expressed as the time 
since diagnosis with MS.  Patti and colleagues (2004b) have suggested that most patients 
with MS remember the exact year they were diagnosed.  However, it is more difficult to 
know exactly when the onset of the disease occurred.  The instructions for each questionnaire 
were reviewed with the patients and the PI sat in a nearby area and was available to clarify 
any questions that the patients had while completing the questionnaires.   
Following the completion of the questionnaires, the patients were asked to complete 
two quantitative tests of motor function from the Multiple Sclerosis Functional Composite 
(MSFC): the Timed 25-Foot Walk Test and the 9-Hole Peg Test (9-HPT).  The MSFC is a 
three-part, standardized, quantitative, assessment instrument for use in clinical studies, 
particularly clinical trials of MS.  The instructions for each quantitative test of motor function 
were given exactly as they appeared in the MSFC manual.  The Timed 25-Foot Walk is a 
quantitative mobility and leg function performance test in which the patient was directed to 
one end of a clearly marked 25-foot course and was instructed to walk the marked distance 
quickly, but safely.  The time was calculated from the initiation of the instruction to start till 
the patient reached the 25-foot mark.  This task was immediately administered again by 
having the patient walk back the same distance.  This test allowed the use of assistive devices 
if necessary and the score was the average of the two completed trials.  Total administration 
time of the test varied from one to five minutes depending on the ability of the patient.   
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Both, the dominant and the non-dominant hands of the patient were tested twice using 
the 9-HPT (a total of four trials).  The patient was asked to sit at a table with a small, shallow 
container holding nine pegs and a wood or plastic block with nine empty holes in it.  The 
patient was then asked to pick up the pegs, one at a time as quickly as possible and put them 
into the nine holes and once all the pegs were in place, the patient was to remove them one at 
a time as quickly as possible and replace them in the shallow container.  The time to 
complete this activity from start to finish was recorded.  The score on the 9-HPT was 
calculated as the average score (time of completion) of the four trials.  Administration time 
for this test was usually less than ten minutes, and varied depending on the ability of the 
patient.  During the administration of these tests (Timed 25-Foot Walk & 9-HPT), only the PI 
and the patient were present in the testing room and all potential external distractions were 
kept to a minimum.   
Following these assessments, the patients were given a booklet (see Appendix G) 
which contained three health-related quality of life (HRQoL) questionnaires along with a 
business reply envelope.  These questionnaires were randomly ordered in each booklet and 
consisted of: (1) the Medical Outcomes Survey Short Form- 36 items (SF-36); (2) the 
Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS); and (3) the 
Multiple Sclerosis Impact Scale (MSIS-29).  Additionally, information regarding 
approximate time of completion and opinion regarding ease of use and relevance of content 
for each of the questionnaires in the booklet was also collected.  Questions assessing these 
additional properties were included at the end of each HRQoL questionnaire.  Patients were 
asked whether they considered each questionnaire to be long, complex or difficult to 
complete.  The responses of these questions were on a scale of 1 to 3 (where 1=not at all, 
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2=somewhat and 3=very much so).  Questions relating to patient preference and assessment 
of practicality have been adapted from pervious research for the purpose of this study 
(Cooley et al., 2005; Bouchet, Guillemin, Paul-Dauphin, & Briancon, 2000).  The patients 
were asked to complete this booklet at home and return it in the mail within one week.   
Three to six months following the initial assessment (Time 2), all patients who 
successfully completed all questionnaires and tasks at the time of the first assessment, were 
mailed a second booklet containing the same set of three quality of life questionnaires, again 
randomly ordered.  The patients were asked to send the booklet back by mail in the 
accompanying business reply envelope within one week of receiving it.  This was done in 




Medical Outcomes Survey Short Form (SF-36) 
 The SF-36 consists of eight sub-scales: physical functioning, role-physical, bodily 
pain, general health, vitality, social functioning, role-emotional and mental health.  These 
sub-scales are scored such that a higher score indicates a better health state, for example, 
functioning scales are scored so that a high score indicates better functioning and the pain 
scale is scored so that a high score indicates freedom from pain.  Scoring for each sub-scale 
in the SF-36 was performed in the following steps 
(1) Data Entry: Data was entered as coded in the questionnaire.  
(2) Recoding for ten items that require recoding:  Item recoding is the process of deriving the 
item values that will be used to calculate scale scores.  Recoding involves changing out-of-
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range values to missing, reverse coding of items and substituting person-specific estimates 
for missing items. 
(3) Dealing with missing data:  It is recommended that a scale score be calculated if the 
respondents answer at least half of the items in a multi-item scale (or half plus one in the case 
of scales with an odd number of items) 
(4) Computing a raw score:  This score is a simple algebraic sum of responses for all items in 
a particular sub-scale 
(5) Transformation of scale scores:  The raw scales are transformed to a 0-100 scale in order 
to convert the lowest and highest possible scores to 0 and 100 respectively.  Scores between 
these values represent the percentage of the total possible score achieved.  This was 
calculated using the following formula: 
Transformed Scale =   (Actual raw score- lowest possible raw score)   x   100 
                                                     Possible raw score range 
Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS) 
The final English version of the HAQUAMS consists of 38 items which are used as 
the basis for computation of five subscale scores reflecting major dimensions of HRQoL in 
MS: fatigue/thinking (four items), lower limb mobility (five items), upper limb motility (five 
items), social function (six items) and mood (eight items).  Most items are scored from one to 
five where “1 = not at all” and “2 = very much”.  A total of eight items (item numbers 15, 23, 
25, 26, 34, 35, 36 and 37) are positively worded for example, “I am satisfied with my sex 
life” or “I get support from my family”.  Sub-scale raw scores were computed by first 
recoding the positively worded questions, so that high scores indicate a low quality of life in 
all questions.  Mean scores were then computed for all subscales and mean substitutions were 
    
66 
allowed for missing items.  Subscales were not calculated if more than 20% of the items were 
missing (Gold et al., 2001).   
Multiple Sclerosis Impact Scale (MSIS-29)  
 The MSIS-29 was used to calculate two scores; physical impact score and 
psychological impact score (Hobart et al., 2004).  The physical impact score was calculated 
by summing item numbers 1 through 20.  This score was transformed to a score on a scale of 
0-100 using the following formula:  
   100 x (observed score – 20) 
    100 – 20 
As in case of the physical impact score, the psychological impact score was calculated by 
summing items 21 through 29, and then transformed to a score on a scale of 0-100 using the 
following formula: 
    100 x (observed score – 9) 
        45 – 9 
Guy’s Neurological Disability Scale (GNDS) 
 The GNDS is divided into twelve separate categories each with an interview and 
scoring section.  Each sub scale was scored from 0 to 5, representing disability grades 
ranging from “0 = normal status” to “5 = total loss of function: maximal help required”.  An 
overall score of the patients total disability was obtained by summing up all different sub-
scores giving a sum score ranging between 0 (no disability) and 60 (maximum possible 
disability) (Sharrack et al., 1999a). 
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Visual Function Questionnaire (VFQ) 
 The VFQ was scored in a two step process.  First, the original numeric values from 
the survey were re-coded following scoring rules outlined in Table 1.  A higher score 
represents better functioning.  Each item was converted to a 0-100 scale so that the lowest 
and highest possible scores were set at 0 and 100 points.  This format allows scores to 
represent to the achieved percentage of the total possible score.  In other words a score of 50 
represents 50% of the highest possible score.  Following this procedure, items within each 
sub-scale were averaged together to create 12 sub-scale scores.  Items contributing to each 
specific sub-scale are presented in Appendix H.  In the case of missing data, the items were 
not taken into account when calculating scale scores.  A sub-scale score was generated only 
when at least one item was answered within that sub-scale.  The VFQ sub-scale scores were 
generated based on the average of all items in the sub-scale that the respondent answers.    
Centers for Epidemiological Studies Depression Scale (CES-D)   
 The Centers for Epidemiological Studies – Depression scale can be scored in three 
steps.  First, sixteen items in this instrument are assigned one value in the following manner 
for each response category; rarely or none of the time (less than one day) = 0; some or a little 
of the time (1-2 days) = 1; occasionally or a more moderate amount of time (3-4 days) = 2 or 
more or all of the time (5-7 days) = 3.  For four items, namely questions 4, 8, 12 and 16, this 
scoring is reversed.  Once the value is assigned for each item, a total is computed by adding 
the values for each of the twenty items.  The resulting score usually ranges between zero and 
sixty.  The total is not computed if more than four answers are missing.  Higher scores on the 
CES-D indicate higher levels of distress (depressive symptomatology and not clinical 
depression).   
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Analysis for Phase I: Objective 1 
For Phase I, Objective 1, the following five psychometric properties were examined 
and compared for the SF-36, HAQUAMS and MSIS-29: scaling assumptions; acceptability; 
validity; reliability; and responsiveness.   
Scaling Assumptions, Acceptability and Patient Preferences  
Item internal consistency was examined by calculating the Pearson’s r between each 
item and total scale score.  An item correlation with its domain (total scale score) of at least 
0.30 was considered a valid indicator of scaling success (Riazi et al., 2003).  Descriptive 
analyses were performed for floor and ceiling effects (percentage of respondents having the 
lowest and highest possible scores respectively), time of completion and patient opinion 
regarding ease of use and relevance of content of the PRO measures.  Floor and ceiling 
effects less than 20% were considered as a criterion of acceptability in this study (McHorney 
et al., 1994).     
Validity 
Construct validity (convergent and divergent validity) was tested using multitrait- 
multimethod (MTMM) analysis (CAMPBELL & FISKE, 1959; Langfitt, 1995; Campbell DT 
& Fisk DW, 1959).  The MTMM is simply a matrix or table of correlations arranged to 
facilitate the interpretation of the assessment of construct validity.  The MTMM makes it 
possible to examine both convergent and divergent validity of various scales simultaneously 
using one matrix.  The general principle of this technique is that two or more methods, for 
example different instruments can each be used to assess the same traits such as quality of 
life aspects, items or subscales (Fayers PM et al., 2000).   
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In the present study, scales assessing both, similar and different dimensions were 
chosen from each measure based on scale names.  The physical and psychological sub-scales 
from each of the HRQoL measures were used: SF-36 physical functioning, MSIS-29 physical 
impact scale and the HAQUAMS upper and lower mobility subscales.  Convergent validity 
was examined as the average of the correlations among pairs of scales measuring the same 
concept.  Divergent validity was tested by comparing validity coefficients between scales 
measuring different dimensions.  An example of divergent validity is to compare the mental 
health scale (SF-36) with the lower limb scale (HAQUAMS).  It would be expected that 
comparisons of similar domains will display higher intercorrelations, while comparisons of 
differing domains will exhibit lower intercorrelations.  Convergent validity was also 
established by observing the intercorrelations between the mobility subscales of SF-36, 
HAQUAMS and MSIS-29 with the scores of the patients on the quantitative tests of motor 
function from the multiple sclerosis functional composite (Timed 25-Foot Walk and the 9-
hole Peg Test).    
Concurrent validity was compared for all measures by examining differences in 
HRQoL scores across level of disability and level of ambulation.  Disability, for the purpose 
of this study was defined using patient self-report on the GNDS which is a new clinical 
disability scale for patients with MS.  Disability grades on the GNDS were classified as 
having no disability (score of 1 to 12), mild disability (score of 13 to 24), moderate disability 
(score of 25 to 36), severe disability (score of 37 to 48) and total loss of function (score of 49 
to 60) (Sharrack et al., 1999a).  Similarly, responses of the participants on question 7 of the 
GNDS allowed us to categorize each of the participants in one of three groups based on 
ambulation status: (1) able to walk independently (corresponding to a score of 0 to 2 on 
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question 7 of GNDS); (2) requiring either a unilateral or bilateral support to walk 
(corresponding to a score of 3 or 4 on question 7 of GNDS); or (3) confined to a wheelchair 
(corresponding to a score of 5 on question 7 of GNDS).     
Relative validity (relative efficiency) analysis was also performed.  This analysis 
provides an estimate of the sensitivity of the different PRO measures to important clinical 
differences measured on external criteria such as level of disability.  It was expected that 
patients reporting a lower grade of disability on the GNDS would report better HRQoL 
compared to the other patients.  Analysis was performed using analysis of variance 
(ANOVA), which compared the scale scores between all three HRQoL measures for the 
different disability grades and one way ANOVA F-ratios were computed for each scale.  
These F-ratios were then compared as a basis for evaluating the relative sensitivity (validity) 
of individual scales to the known group differences.  The relative validity was reported as the 
ratio of the F-ratio of each scale to the F-ratio of a designated reference scale, usually the 
scale with the smallest F-ratio.  Standard parametric methods may be used to analyze quality 
of life data, as recent evidence has shown that non-parametric testing methods produce 
results similar to those presented by standard parametric tests (Walters & Campbell, 2004).  
Additionally, post hoc comparisons were performed to identify which ambulation groups 
differ significantly from each other.  Duncan's multiple-range test which is a specialist 
multiple comparison test that maintains a low overall type I error was utilized.  A 
significance level of p = 0.05 was used for this analysis.   
Reliability 
Cronbach’s alpha (α) coefficients were calculated for the total and subscale scores of 
the included measures to estimate the internal consistency reliability.  Evidence of 
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satisfactory internal consistency reliability was set at the criterion of α > 0.70 (Nunnnally JC, 
1978; Bennett et al., 2003; Meyer-Rosberg et al., 2001).  Cronbach’s α coefficient of 0.80 or 
greater was used as a more rigorous indicator of satisfactory internal consistency reliability 
of the instruments.  
Responsiveness 
All psychometric properties specified above, except for responsiveness, were 
assessed using cross-sectional data obtained at baseline (Time 1).  Responsiveness of the 
three measures was assessed using self-report data at two time points i.e. at baseline (Time 1) 
and at three to six months following the initial assessment (Time 2).  Change scores were 
calculated as the difference between baseline (Time 1) and Time 2 scores for each domain of 
the three questionnaires.  Responsiveness was assessed using the following statistics: ES and 
SRM (Kazis et al., 1989; Liang et al., 1990).  At Time 2, each patient was asked to respond 
to a transition question adapted from a study in rheumatoid arthritis (Fitzpatrick, Ziebland, 
Jenkinson, Mowat, & Mowat, 1993b): “Thinking of any overall effects MS may have on you; 
how would you describe yourself compared with the last time you completed these 
questionnaires: Do you feel that you are much better, slightly better, the same, slightly worse 
or much worse?”  The ES is a standardized measure of change obtained by dividing the 
average change between the initial and follow-up measurement by the standard deviation of 
the initial measurement.  The SRM is also a standardized measure of change which is 
calculated by dividing the average change between initial and follow-up measurements by 
the standard deviation of the change scores.  These measures are commonly used in study 
designs in which health status measures are administered at two points in time (Stratford, 
Binkley, & Riddle, 1996), and hence are appropriate for this objective.  ES has also been 
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used as a responsiveness measure in an earlier comparison of MS related quality of life 
measures (Riazi et al., 2003).  Usually an ES of approximately 0.20 is considered to be a 
small change, one of 0.50 indicates a moderate change, and those of 0.80 or above reflect a 
large change (Cohen J, 1977).         
Sub-scales for each of the PRO measures were examined in terms of ES and SRM, 
among a sub-sample of patients stratified into one of the following two groups on the basis of 
their response to the transition question: (1) Worse: those patients who reported worsening in 
their health status (those who reported slightly worse or much worse in response to the 
transition question); (2) Better: those who considered themselves to have stayed the same 
(those who reported much better or slightly better or the same).  Investigators have often used 
such indices because such questions have been shown to be useful bench-marks against 
which to compare change scores on health status instruments (Guyatt et al., 1987; 
MacKenzie et al., 1986).     
 
Analysis for Phase I: Objectives 2 and 3 
Objective 2 for Phase I was to identify predictors of HRQoL in patients with MS and 
to determine the relative contribution of visual impairment on HRQoL in addition to 
depressive symptomatology, level of disability and other clinical factors.  This was achieved 
by constructing a hierarchical regression model.  Hierarchical regression models involve 
entry of one predictor variable or a block of variables at a time, based on some a priori 
criteria.  Each step is a separate regression model and the resulting model is similar to the 
model which is obtained by adding all variables simultaneously.  An additional advantage of 
such models over the multiple linear regression approach is that a change in R2 is computed 
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at each step.  This allows researchers to test whether a significant amount of additional 
variance is accounted for by the variable or variables entered at that step.      
In this model, the dependent variable was the HRQoL score on the HAQUAMS, and 
the independent variables were: (1) visual impairment as measured by the visual function 
questionnaire (VFQ); (2) as measured by the Guy’s Neurological Disability Scale (GNDS); 
(3) age; (4) gender; (5) marital status; (6) race; (7) employment status; (8) depression; and (9) 
duration of the disease.   Bivariate analyses were performed to examine the extent to which 
the individual variables were associated with overall HRQoL.  Pearson’s correlations were 
computed to examine the intercorrelations between the predictor variables and the HRQoL 
scores.  The degree of association between nominal and interval variables were assessed by 
using the eta squared statistic.  Eta squared is a measure of strength of relationship based on 
sums of squares computed in analysis of variance and can be interpreted as the percent of 
variance in the dependent variable explained linearly or nonlinearly by the independent 
variable.  The significance of the level of correlation in this case was determined by the F-
test analysis of variance.   
If a given variable had an association with the significance level of p ≤ 0.10, that 
variable was included in the multiple regression analysis.  The exceptions to this rule were 
disability as measured by the GNDS and depression score on the CES-D, based on their 
significant associations with quality of life as evidenced by past research.  The selected 
independent variables were then entered into the model in blocks, with all variables within a 
block entered in a single step 
The change in R2 showed the amount of unique variance explained by every new 
variable or block added to the model.  Because one focus of this objective was the relation 
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between the HRQoL and visual impairment, the score on the VFQ was added last in the 
model. The change in R2 for visual impairment (VFQ score) represented the unique variance 
explained by visual impairment when all other factors were accounted for.  
Separate multiple linear regression analyses were performed to determine factors that 
have a significant impact on the various domains of HRQoL for Phase I, Objective 3.  The 
domains of quality of life were identified by the HAQUAMS: fatigue, upper mobility, lower 
mobility, mood and social function.  The selection process of the independent variables for 




Phase II of this project was a cross-sectional survey of neurologists with descriptive 
and analytic components.  Data from one section of the survey was used in conjunction with 
Phase I which compared properties of three HRQoL measures in patients with MS.   
 
Study Population 
Surveys were mailed to neurologists currently working in the United States.  The list 
of neurologists was supplied by SK&A Information Services Inc., a private mailing list firm 
located in Irvine, California.  This firm researches, formats and maintains contact and 
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Sample Size Calculation 
 Sample size was calculated using the following formula: 
SS =  Z2 x (p) x (1-p) 
                       C2 
Where, 
Z = Z value 
p = population proportion, expressed as a decimal 
c = confidence interval, expressed as a decimal 
 The sample size for the study using a 95% confidence level (Z = 1.96 for a 95% 
confidence level) and a 5% confidence interval (c = 0.05) was estimated.  The population 
proportion (p) is the percentage of people in the population who will provide a given 
response to a survey question.  Since there was no population proportion for the sample, a 
conservative estimate of 50% (p = 0.5) was used.   Substituting these values for Z, p and c in 
the above formula, the sample size was estimated to be 384.  A response rate of about 25% 
was assumed.  This was a conservative estimate as compared to the mean response rate of 
54%, typically seen in published surveys of physicians (Asch, Jedrziewski, & Christakis, 
1997).    
 
Survey Questionnaire Development & Validation 
 The survey instrument used was a five page questionnaire consisting of six sections 
(see Appendix J).  Information was collected on neurologists’: opinion regarding two 
HRQoL questionnaires which were used in Phase I of this study, attitudes, subjective norms 
and perceived behavior control regarding HRQoL assessment in patients with MS; intention 
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to assess HRQoL information in patients with MS; perceived barriers and facilitators to 
HRQoL assessment; current behavior regarding HRQoL assessment and inclination to use 
HRQoL information in clinical practice; knowledge regarding specified HRQoL 
questionnaires; and socio-demographic information (age-group, gender, practice site, years in 
practice, participation in MS clinical trials, and patient load per week). 
 The members of the research committee which included one neurologist and four 
health outcomes researchers, were approached to asses the clarity, readability and the 
appropriateness of the instrument.  This was done in order to improve the face and content 
validity, assess the relevance of the questions and clarity of the instructions and ease and time 




 Approvals for all Phase II survey related material was obtained from the WVU 
Institutional Review Board in July 2006.  Three thousand mailing labels were purchased 
from SK & A, and a simple random sample of 2,400 neurologists was produced using 
Microsoft Excel’s random number generator function.  The decision to include 2,400 
neurologists in the final sample was taken in order to meet the sample size requirement of 
384, assuming a 25% response rate.  
The questionnaires mailed to the neurologists were printed on colored paper and 
accompanied by a personalized cover letter on WVU letterhead (Appendix I), describing the 
study and encouraging them to complete the survey.  Neurologists were asked to return it 
anonymously in an accompanying pre-addressed postage paid envelope.  Four weeks 
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following the contact, a second mailing consisting of the survey instrument, cover letter and a 
pre-addressed postage paid envelope was sent to all non-responding neurologists. 
At the end of eight weeks following the initial mailing, all respondents were broken 
down into three groups: Non-respondents: those who did not return the survey; Returned but 
not applicable: this group included those who indicated that they were not involved in the 
routine care of patients with MS or when the survey was returned as undeliverable by the 
postal service; and Returned responses: this group included those who returned the survey 
(either partially or entirely filled out).  At the end of data collection, the response rate was 
calculated by dividing the total number of respondents in the returned responses group by the 




 Operationalization of the variables for the descriptive and analytic components of the 
study is listed below: 
The variables for the descriptive study are as follows: 
Neurologists’ opinion regarding the usefulness, length and the wording of two MS-
specific HRQoL measures were assessed using three questions on a 7-point Likert scale 
(Page 1 of the questionnaire).  A list of potential barriers and facilitators to the utilization of 
HRQoL information were adapted from previous research (Bezjak et al., 2001).  Six items 
formed the barriers scale while the facilitators scale consisted of the remaining four items.  
Each statement was rated on a 7-point Likert scale reflecting the degree to which each item is 
perceived to be a barrier or facilitator to HRQoL assessment where ‘1 = Strongly Disagree’ 
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to ‘7 = Strongly Agree’.  Barrier items addressed issues such as difficulty in scoring HRQoL 
questionnaires and irrelevance of such information to neurologists.  (Barrier and facilitator 
items can be found on Page 4 of the questionnaire) 
Current behavior regarding HRQoL assessment in patients with MS and 
categorization of the neurologists based on their knowledge and inclination to use HRQoL 
information (Page 4 of the questionnaire).  Neurologists’ knowledge of and experience with 
using specified HRQoL measures used in MS were also assessed.  These questionnaires were 
identified from the literature as being the most commonly used in MS research.  The list 
consisted of generic as well as MS-specific quality of life measures (Page 5 of the 
questionnaire) 
Socio-demographic characteristics (Page 5 of the questionnaire): Gender, age group, 
primary practice site, number of MS patients seen per week, participation in MS-related 
clinical trial, year of board certification and number of years in practice.  The independent 
and dependent variables for the study of the neurologist’s intention to use HRQoL 
information in patients with MS were operationalized as follows: 
Dependent Variable 
Intention to use HRQoL information:  Behavioral intention was measured by a single 
question on a seven point Likert scale where ‘1 = strongly disagree’ and ‘7 = strongly agree’. 
(last item on page 3 of the questionnaire). 
Independent Variables 
An elicitation study was conducted among eight neurologists at the neurology clinic 
at West Virginia University to assess attitude, subjective norms and perceived behavior 
control.   
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Attitude 
 Indirect measures of attitude were used by conducting separate interviews with 
several neurologists and neurology residents at the West Virginia University Neurology 
Clinic.  The interviewees were asked about their beliefs regarding the consequences of 
assessing HRQoL information using validated formal questionnaires in routine practice.  
Using the results of the elicitation interviews seven attitudes were identified that are common 
among neurologists about the consequences of assessing HRQoL information in patients with 
MS during routine practice.  Neurologists were asked to make judgments regarding each of 
these consequences (outcomes): an assessment of how strongly they agreed that an 
consequence would occur if they assessed HRQoL information in patients with MS; and an 
assessment of how desirable or undesirable each outcome is in their opinion (outcome 
evaluation).  Questions regarding outcomes were constructed on a seven point Likert scale 
where ‘1= strongly disagree’ and ‘7= strongly agree’.  Outcome evaluations were measured 
on a scale of -3 to +3 where ‘-3= extremely undesirable’ and ‘+3 = extremely desirable’.  
Product scores for each of the seven consequences were computed by multiplying the 
neurologists’ probability rating regarding the outcome by the outcome evaluation score.  
These scores were then summed to create the attitude score. (Items 2 through 8 on pages 2 
and 3) 
Subjective Norms  
Two salient referents were identified from the elicitation interviews.  One was the 
American Academy of Neurology (AAN), which is a medical specialty society for 
neurologists and the other was colleagues or other neurologists.  Neurologists were asked to 
assess the position of these referents with respect to HRQoL assessment in MS patients and 
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how motivated they were to adhere to those positions.  Both judgments were scored on 
seven-point bipolar scales.  The scales ranged from ‘1 = strongly disagree’ to ‘7 = strongly 
agree’ for the position assessments and from ‘1 = not at all’ to ‘7 = very much’ for the 
motivation assessments (Items 9 and 10 on page 3).  The score for social norms was 
computed by summing across the neurologists’ position rating and the motivation measure.   
Perceived Behavior Control 
Neurologists were asked whether the decision to assess HRQoL information from 
patients with MS was beyond their control.  Responses were scored on a seven-point Likert 
scale where ‘1 = strongly disagree’ to ‘7 = strongly agree’.  They also assessed whether it 
was difficult or easy to assess HRQoL information in their patients with MS on a seven-point 
scale where ‘1= extremely difficult’ and ‘7= extremely easy’. The two scores were averaged 
to give the perceived behavior control score. 
 
Analysis for Phase II 
To determine whether there was any difference in the opinion of neurologists 
regarding the HAQUAMS and MSIS-29, the Wilcoxon signed rank test was utilized.  
Statistically significant differences were identified at p < 0.05.  The Wilcoxon signed rank 
test also referred to as the Wilcoxon matched pair test, is a non-parametric technique used to 
test the median difference in paired data.  This test was utilized due to the non-normality of 
the responses to these items.  Wilcoxon signed rank test is the non-parametric counterpart of 
the paired t test.  The assumption of normality is avoided in the Wilcoxon signed rank test, 
because the test is based on rank order of the differences rather than the actual value of 
differences.   
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Frequency distributions for categorical data and means and standard deviations for 
continuous variables were calculated using descriptive analyses to present an overall picture 
of barriers and facilitators of HRQoL information use, knowledge and current behavior 
regarding HRQoL assessment in patients with MS.   
Multiple linear regression analysis was used to determine the predictors of behavioral 
intention.  Linear regression is a statistical technique for measuring the strength of a linear 
relationship between a dependent variable (Y) and one or more independent variables (X1, 
X2, X3 … Xn).  The dependent variable is the one being affected (intention to use HRQoL 
information) and the independent variables are the causes of that effect.  The independent 
variables included in the model were: attitude; subjective norms; perceived behavioral 
control; primary practice site; years in practice as a neurologist; age; participation in a MS 
trial and number of patients seen per week.   
 
Regression Diagnostics 
All regression models were inspected for assumptions of normality using the Shapiro-
Wilk W test.  One assumption of linear regression analysis that assures that the t-tests are 
valid is that residuals are normally distributed.  The p value of the Shapiro-Wilk test statistic 
is based on the assumption that the distribution is normal.  Assumption of normality was 
rejected if p ≤ 0.05 for the Shapiro-Wilk (W) statistic.  The White test which is a formal test 
for the presence of heteroscedasticity was performed to establish homogeneity of the 
variance of residuals.  Significance of the test statistic (p ≤ 0.05) for the White test indicated 
that the variance is not homogenous.  Variance inflation factor (VIF) values were used for 
each predictor to detect possible multicollinearity among predictors in the model.  
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Multicollinearity is when variables are highly correlated and multicollinearity statistics 
expose the redundancy of variables and the need to remove variables from the analysis.  
Increased multicollinearity leads to difficulty in partitioning out the individual effects of 
independent variables.  The VIF measures how much multicollinearity has increased the 
variance of a slope estimate.  The VIF ranges from 1 to infinity, where a high VIF value (>1) 
indicates that the variable may be affected by multicollinearity.  The VIF value less than 4.0 
is a common rule of thumb for acceptable multicollinearity in a regression model (Fisher JC 
& Mason RL, 1981).   
 
Power Considerations  
Concurrent validity of PRO measures 
 A priori power analysis are conducted in order to ascertain sample size required to 
perform the analyses necessary at a level of power desired prior to the start of the study.  In 
order to perform sample size calculations, researchers need to decide upon an alpha level; the 
desired power, and the effect size.  Alpha is the probability of making a Type I error that is 
rejecting the null hypothesis when it is true.  Effect size is a name given to a family of indices 
that measure the magnitude of a treatment effect and unlike significance tests; these indices 
are independent of sample size.  Cohen (Cohen J, 1988) established a measure of effect size 
termed Cohen’s d, which is the number of standard deviations separating two group means.  
Although there is no universally accepted criteria for determining whether a given d is large 
enough, researchers often use Cohen’s recommendations of small (d= 0.2), medium (d= 0.5) 
and large (d= 0.8) effect sizes.  A conservative effect size (d=0.3) along with a target power 
of 0.8 and alpha level of 0.05 was selected for comparing patients classified into groups by 
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disability levels as well as ambulation levels.  Using these criteria produced the sample size 
estimate of 111 subjects for Phase I, Objective 1.   
 
Regression analyses for Phases I and II 
The anticipated effect size index for regression is denoted by f2, where  f2 reflects the 
proportion of variance accounted for by some source in the population (PVs) relative to the 
residual variance proportion (PVe), such that f2= PVs/PVe.  For Phase I, the hypothesis being 
tested was that the correlation of the visual impairment and other independent variables with 
the overall quality of life score in the population to which the results are to be generalized is 
zero.  For a set of predictors explaining 20% of the variance in the dependent variable, f2is 
0.25, and with nine predictors, a sample size of 72 subjects was necessary to achieve a power 
of 0.8 and 89 subjects to achieve a power of 0.9 for Phase I, Objective 3 of this study.   
For Phase II, Objective 4, the hypothesis being tested was that the correlation 
between the independent variables (attitude, subjective norms, perceived behavior control 
and demographic variables) and the intention to assess HRQoL information is zero for the 
population to which the results are to be generalized.  For a set of predictors explaining 20 
percent of the variance in the dependent variable, f2 is 0.25, and with eight predictors, a 
sample size of 66 subjects was necessary to achieve a power of 0.8 and 84 subjects to achieve 
a power of 0.9.   
All power analyses were performed by using G*Power, a general power analysis 
program (Erdfelder, 1996).  The G*Power program uses the number of predictors in the 
analysis and expected effect size to calculate sample requirements.  It should be recognized 
however, that several rules of thumb exist to guide sample size selection in studies examining 
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relationships between variables of interest.  For testing individual predictors and assuming a 
medium-sized relationship, a conservative estimate of sample size is N > 50 + 8 m (N= 
sample size, m is the number of independent variables) (Green SB, 1991).  Although Green’s 
formula is comprehensive, there are a few other guidelines that may be considered.  For 
regression equations using six or more predictors, Harris (1985) recommends an absolute 
minimum of ten participants per predictor variable.  Still others have suggested a minimum 
total sample of 400 (Cohen & Cohen, 1984) while some have declared a minimum of forty 
subjects per predictor (Tabachnick BG & Fidell LS, 1996a).  Generally speaking, such rules 
are only approximations and the number of observations required may change based on two 
important factors, the effect size (large or small) and the correlations among predictors (e.g. 
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Chapter 4: Results 
 
Phase I 
 Sample Characteristics 
One hundred and thirty-six patients with MS agreed to participate in this study and 
completed the self-report measures and the quantitative tests of motor function in the clinic.  
Of these, 116 patients returned the completed HRQoL questionnaires in the mail.  Table 1 
shows the characteristics of the patients who completed both the in clinic assessments and the 
HRQoL questionnaires.  The mean age for this group was 44.8 years (range = 19 to 79 years) 
with over 70% of them being women.  Sixty-two participants failed to complete the 
questionnaires at follow-up, leaving only 54 patients who completed the questionnaires at 
both time points (Time 1 and Time 2).   
Almost all of the participants were White (97.4%), while the remaining 2.6% were 
African-American.  Fifty-six percent of the participants were currently married and 33.6% 
were currently working for pay; either full-time or part-time.  Of those who were 
unemployed, 75% mentioned that multiple sclerosis (MS) was the main reason for 
unemployment.  The mean duration of having MS was 8.8 years (range = 0 to 41).  
Approximately 43% of the sample reported having no comorbidites, while 12.3% of the 
patients said that they had at least three comorbid conditions from the checklist described in 
the methods section.  Based on the scores on question 7 (regarding lower limb problems) in 
the Guys Neurological Disability Scale (GNDS), almost 16% of the participants were 
restricted to a wheelchair, 27.6% used some type of aid for walking while 56% could walk 
independently.    
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Table 1: Characteristics of the sample 
 
Variable N (%) 
Sample Size 116 (100.0) 
  
Gender  
     Female 82 (70.7) 
  
Age (in years)  




     White  113 (97.4) 
  
Marital Status  
      Married  65 (56.0) 
  
Employment  
     Unemployed due to MS  57 (49.1) 
     Unemployed 19 (16.4) 
     Employed 39 (33.6) 
  
Ambulation  
     Walks unaided 65 (56.0) 
     Walks with aid 32 (27.6) 
     Uses wheelchair 19 (16.4) 
  




Mean (SD) 8.8 (8.5) 
Range 0-41 
  
Comorbid conditions  
     0 46 (43.4) 
     1 32 (30.2) 
     2 15 (14.2) 
     3 or more 13 (12.3) 
  
 
SD= Standard Deviation 
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Comparison of Health-Related Quality of Life Questionnaires 
Acceptability 
 Mean scale scores and percentage of scores at the floor and ceiling are shown in 
Table 2.  Scales for all HRQoL questionnaires had relatively small floor and ceiling effects 
except for the SF-36 role-physical function (59.5%) and role-emotional (39.7%) scales.  The 
floor effects for the Hamburg Quality of Life Questionnaire in Multiple Sclerosis 
(HAQUAMS) upper mobility (14.7%) and social function (12.9%) scales were slightly high, 
but were still below the maximum value of 20% set as a criterion for this study.   
The HAQUAMS upper mobility scale however, did not display any ceiling effects 
(0.0%).  Ceiling effects for scales measuring similar domains were 0.9% for the Multiple 
Sclerosis Impact Scale (MSIS-29) physical impact scale, 5.2% for the SF-36 physical 
function scale and 6.9% for HAQUAMS lower mobility.  The HAQUAMS lower mobility 
scale had the smallest floor effect (1.7%), followed by the MSIS-29 physical impact scale 
(3.5%), SF-36 physical function scale (8.6%) and the HAQUAMS upper mobility scale 
(14.7%).  
With regards to the psychological domain, floor and ceiling effects for the 
HAQUAMS mood scale fell in between those of SF-36 and MSIS-29.  SF-36 displayed the 
least floor effects on the mental health scale (0.0%), while this percentage was 0.8 for the 
HAQUAMS mood scale and 2.6 for the MSIS-29 psychological impact scale.  Only 0.9 % of 
the respondents had a maximum score on the MSIS-29 psychological impact scale compared 
to 1.7% on the HAQUAMS mood and 2.6% on the SF-36 mental health scale.    
There were marked differences in the acceptability for the HAQUAMS and SF-36 
social function scales.  The HAQUAMS social scale had much higher floor effects than the  
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Table 2: Acceptability for HRQoL Measures (n=116) 
 
Scale No. of 
Items 






SF-36       
   Physical Function  10 41.0 31.1  8.6  5.2 0.87 
   Role-Physical  4 23.3 35.0 59.5 12.1 0.87 
   Bodily Pain 2 56.3 27.7  1.7 14.7 0.87 
   General Health 5 45.3 23.1  0.9  0.0 0.87 
   Vitality  4 39.9 21.0  2.6  0.0 0.87 
   Social Functioning  2 57.5 25.9  3.5 12.1 0.86 
   Role-Emotional 3 45.7 44.1 39.7 35.3 0.88 
   Mental Health  5 62.8 22.1 0.0  2.6 0.87 
       
HAQUAMS       
   Fatigue 4 11.8 4.1  1.7  3.5 0.82 
   Lower Mobility 5 14.1 6.1  1.7  6.9 0.80 
   Upper Mobility 5 10.6 5.0 14.7  0.0 0.79 
   Social Function 6 13.0 5.5  12.9  0.8 0.84 
   Mood 8 21.6 7.9  0.8  1.7 0.79 
       
MSIS-29       
   Physical  20 42.8 26.1  3.5  0.9 0.84 
   Psychological 9 42.0 24.7  2.6  0.9 0.84 
       
 
No. = Number 
SF-36= Medical Outcomes Survey Short Form – 36 Items 
HAQUAMS= Hamburg Quality of Life Questionnaire in MS 
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SF-36 social functioning (12.9% vs. 3.5%) but significantly lower ceiling effects (0.8% vs. 
12.1%).  When comparing the HAQUAMS fatigue and SF-36 vitality scales a pattern opposite 
to the one for the social functioning domain was observed.  The HAQUAMS fatigue scale had 
lower floor effects (1.7% vs. 2.6%) but higher ceiling effects (3.5% vs. 0.0%) compared to 
the SF-36 vitality scale.      
Reliability 
   Cronbach’s alpha for the scales and summary scales are also shown in Table 2.  A 
majority of the scales exceeded the internal consistency reliability criteria of 0.80 set for this 
study.  Only the upper mobility and the mood sub-scales for the HAQUAMS did not meet 
these recommendations, however the alpha values were 0.79 for both scales, which is still 
high enough to be considered acceptable.  With regards to scales measuring physical and 
psychological domains, the SF-36 scales had the highest values of Cronbach’s alpha 
followed by the MSIS-29 and HAQUAMS.  The SF-36 vitality scale and social functioning 
scales had a slightly higher internal consistency reliability coefficients compared to their 
HAQUAMS counterparts: 0.87 vs. 0.82 for the HAQUAMS fatigue scale and 0.86 vs. 0.84 for 
the HAQUAMS social scale.   
Scaling Assumptions 
 For all sub-scales, frequency distributions for the items were almost the same; items 
within each scale had similar means scores and standard deviations (see Table 3).  The 
percentage of missing data was highest for the HAQUAMS lower (18.1%) and upper (3.5%)  
mobility scales.  The percentage of missing responses for all the remaining scales ranged 
from 0.0 to 2.6%.  Scales measuring the physical dimension of HRQoL displayed better 
item-total correlations for the HAQUAMS (Range = 0.67-0.87) compared to the SF-36  
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Table 3: Scaling Assumptions for HRQOL Measures (Total N=116) 
 
Scale Item Mean 
Scores 
Item SD % Missing Item Total 
Correlation 
SF-36     
   Physical Function  1.3-2.5 0.6-0.8 0.0-0.9 0.59-0.86 
   Role-Physical  1.2-1.3 0.4-0.5 0.0 0.63-0.75 
   Bodily Pain  3.6-4.0 1.4 0.0-0.9 0.89 
   General Health  2.4-3.0 1.0-1.4 0.9-2.6 0.44-0.75 
   Vitality  2.9-3.4 1.3-1.4 0.0-0.9 0.64-0.75 
   Social Functioning 3.2-3.4 1.2 0.0-2.6 0.55 
   Role-Emotional 1.4-1.5 0.5 0.0 0.74-0.86 
   Mental Health  3.4-4.7 1.4-1.5 0.0-0.9 0.53-0.78 
     
HAQUAMS     
   Fatigue 2.4-3.3 1.2-1.3 0.0-0.9 0.60-0.72 
   Lower Mobility 2.5-4.0 1.4-1.5 0.9-18.1 0.68-0.87 
   Upper Mobility 1.6-2.8 1.0-1.4 0.0-3.5 0.67-0.82 
   Social Function 2.0-2.5 1.3-1.4 0.0-2.6 0.38-0.74 
   Mood 2.2-4.0 1.1-1.4 0.9-2.6 0.59-0.78 
     
MSIS-29     
   Physical  2.0-3.3 1.2-1.5 0.9-2.6 0.58-0.82 
   Psychological 2.5-2.8 1.2-1.4 0.9 0.13-0.80 
     
 
SF-36= Medical Outcomes Survey Short Form – 36 Items 
HAQUAMS= Hamburg Quality of Life Questionnaire in MS 
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physical function (Range = 0.59-0.86) and MSIS-29 physical impact scale (Range = 0.58-
0.82).  Similar observations were made for the psychological scales: item-total correlations 
for the HAQUAMS mood scale ranged from 0.59 to 0.78 and from 0.53 to 0.78 for the SF-36 
mental health scale.  Item 21 (In the past two weeks, how much have you been bothered by 
feeling unwell) of the MSIS-29 psychological impact scale had a very low correlation with 
the total scale score (0.13). 
The HAQUAMS fatigue scale had item-total correlations (Range = 0.60 to 0.72) 
similar to that of the SF-36 social function scale (Range = 0.64 to 0.75).  With respect to the 
social functioning dimension, item 25 of the HAQUAMS social scale (I get support from 
friends and neighbors) had an item-total correlation of 0.38, while the highest correlation 
within this scale was 0.74 for item 29 (I feel separated).  The average item-total correlation 
for the two items of the SF-36 social function scale (items 6 and 10) was 0.55.  Overall, the 
item-total correlations for all scales except for item 21 of the MSIS-29 exceeded the target 
criterion of 0.30.   
Construct Validity 
This study attempted to provide evidence that the HAQUAMS and MSIS-29 scales 
measure the underlying constructs of physical and emotional impairments that they are 
known to represent.  Table 4 depicts the matrix comparing the physical and mental scales for  
SF-36, HAQUAMS and MSIS-29.  All scale correlations within and across the measures 
were statistically significant at the p ≤ 0.05 level.  Evidence of convergent validity was 
drawn from examination of the coefficients in the monotrait-multimethod triangles, enclosed 
by the solid lines.  For example, the coefficient of -0.69 corresponding to row 2 and column 1  
 
    
92 
Table 4: Construct Validity of SF-36, HAQUAMS and MSIS-29 Physical and 
Psychological Scales 
 
Instrument/Scale 1 2 3 4 5 6 7 
        
1) SF-36 Physical Function        
2) HAQUAMS Upper Mobility -0.69       
3) HAQUAMS Lower Mobility -0.82       
4) MSIS-29 Physical Impact Scale -0.79 0.76 0.82     
        
5) SF-36 Mental Health 0.31 -0.29 -0.33 -0.41    
6) HAQUAMS Mood -0.54 0.58 0.58 0.71 -0.51   
7) MSIS-29 Psychological Impact Scale -0.50 0.54 0.54 0.70 -0.68 0.62  
        
 
Note: N=116  
SF-36= Medical Outcomes Survey Short Form – 36 Items 
HAQUAMS= Hamburg Quality of Life Questionnaire in MS 
MSIS-29= Multiple Sclerosis Impact Scale 
Monotrait-Multimethod correlations are underlined: Correlations between two scales of two different 
questionnaires measuring similar constructs  
Multitrait-Monomethod correlations are in bold: Correlations between two scales of the same questionnaire 
measuring different constructs 
Multitrait-Multimethod correlations are italicized: Correlations between two scales of two different 
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of Table 4 indicates the correlation between two scales measuring a similar trait or construct 
(physical function and upper mobility) using multi or different methods (SF-36 and 
HAQUAMS).  The construct validity for the physical sub-scales for all three questionnaires 
was found to be consistent with the predictions.  The upper mobility scale of HAQUAMS 
correlated more highly with the SF-36 physical function scale (r = -0.82) compared to the 
physical impact scale of the MSIS-29 (r= -0.79).  The negative correlation coefficients were 
expected because a higher overall score indicates better quality of life on the SF-36 but 
poorer quality of life on both, the HAQUAMS and MSIS-29.  The correlation between the 
physical scales (Range= 0.69-0.82) was higher than the correlations among the physical and 
the psychological scales (Range= 0.31-0.71).  However, this was not the case with the 
psychological scales.  The correlation among the mood subscales was substantial (Range= 
0.51-0.68) but not as high as observed for the physical domain scales.     
To demonstrate divergent validity the multitrait-multimethod and the multitrait-
monomethod correlation coefficients must be lower than the monotrait-multimethod 
correlation coefficients.  In other words, the correlation coefficient between two scales of the 
same or different questionnaires, measuring different underlying constructs must be lower 
than the correlation between two scales from different questionnaires measuring the same 
underlying construct.  For example, the correlation coefficient between the MSIS-29 physical 
and psychological impact scales (0.71 in Table 4) and between the MSIS-29 physical and SF-
36 mental health scale (-0.41 in Table 4) must be higher that the correlation coefficient 
between the MSIS-29 physical impact and SF-36 physical function scales (-0.79 in Table 4).  
In Table 4, multitrait-monomethod correlations are bolded, while multitrait-multimethod 
correlations are italicized and are represented in the rectangle enclosed by the broken lines.  
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As would be expected, most of the scales that are supposed to measure different underlying 
constructs are weakly to moderately correlated, independent from the method that is used 
(range = 0.29 to 0.58).  The only exception to this is the HAQUAMS mood scale, whose 
correlation of 0.70 with the MSIS physical impact scale (see row 6/column 4) is higher than 
its correlation with the SF-36 mental health (0.51) and MSIS-29 psychological impact scales 
(0.62).   
Criterion Validity 
Objective Tests of Motor Function and Depression Scale 
Convergent validity of the physical scales of all three questionnaires with respect to 
the quantitative tests of motor function such as Timed 25-Foot Walk Test and 9-Hole Peg 
Test (9-HPT), ranged from 0.28 to 0.39 (see Table 5).  The SF-36 physical function scale had 
the highest correlation with 9-HPT (-0.42) followed by the MSIS physical impact scale 
(0.41).  It was expected that the HAQUAMS upper mobility scale would correlate strongly 
with the 9-HPT scores, however, this correlation was found to be lower compared to that of 
the other scales (0.33).  The HAQUAMS lower mobility scale on the other hand, correlated 
as expected with the scores on 25-Foot Walk Test.  This correlation coefficient was matched 
by the SF-36 physical function scale (-0.39) and was higher that the correlation between 
MSIS-29 physical impact scale and 25-Foot Walk Test (0.28).  Evidence for divergent 
validity of scales measuring physical dimensions was provided by their correlations with 
scores on the depression scale (Range = 0.30 to 0.44).  The psychological scales for all three 
questionnaires exhibited strong correlations with the Centers for Epidemiological Studies – 
Depression Scale (CES-D) (refer to Table 5).  The correlation was strongest for the MSIS-29    
psychological impact scale (0.71) and lowest for the HAQUAMS mood scale (0.62).   
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Table 5: Concurrent Validity of SF-36, HAQUAMS and MSIS-29 Physical and 
Psychological Scales against External Criteria 
 
Instrument/Scale CES-D 9-HPT 25-Foot Walk 
    
1) SF-36 Physical Function   -0.38†  -0.42†      -0.39† 
2) HAQUAMS Upper Mobility    0.32†   0.33†       0.29† 
3) HAQUAMS Lower Mobility    0.30†   0.33†       0.39† 
4) MSIS-29 Physical Impact Scale    0.44†   0.41†       0.28† 
    
5) SF-36 Mental Health   -0.68†  -0.27†      -0.02 
6) HAQUAMS Mood    0.62†   0.48†       0.11 
7) MSIS-29 Psychological Impact 
Scale 
   0.71†   0.34†       0.07 
 
† Significant at p < 0.01 
CES-D: Centers for Epidemiological Studies- Depression scale 
9-HPT: 9 Hole Peg Test & 25-Foot Walk Test: Objective clinical tests of motor function 
Note: Negative correlations between external criteria variables (CES-D, Timed 25-Foot Walk Test and 9-HPT) 
and SF-36 are due to differences in scoring.  Higher scores indicate better quality of life on the SF-36 but higher 
level of depressive symptomatology and poorer physical function 
SF-36= Medical Outcomes Survey Short Form – 36 Items 
HAQUAMS= Hamburg Quality of Life Questionnaire in MS 
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Correlations for scales measuring the psychological dimension of HRQoL were low to 
moderate with measures of motor function (Range = 0.02 to 0.48).  Negative correlations 
between SF-36 and CES-D as well as the quantitative tests of motor function were due to the 
inverse relationship between them as a result of scoring methods.  Higher scores on the SF-
36 indicate better quality of life but poor physical function according to CES-D and the tests 
of motor function.     
 
Degree of Disability 
 Mean scores on the HRQoL measures for the sub-groups classified by disability of 
the disease using GNDS are shown in the Table 6.  Since the overall sample was less severe, 
the participants were classified in to three groups: No Disability (N=40); Mild Disability 
(N=54) and Moderate Disability (N=22).  For the scales on all questionnaires, ordering mean 
scores tended to follow the hypothesized order of better HRQoL scores in the group having 
no disability, with progressively lower scores in the groups reporting mild and moderate 
disability.   
There were significant group differences on scores for all scales (p ≤ 0.01).  The 
physical impact scale of the MSIS-29 and the physical function scale of the SF-36 had the 
highest relative validities of all scales, 7.5 and 5.8, respectively.  The relative validity 
coefficients for the HAQUAMS were 4.9 for the upper mobility scale and 4.8 for the lower 
mobility scale.  However, the overall QoL score for the HAQUAMS had the highest relative 
validity coefficient (= 8.2) of all scales, indicating that it most sensitive to discriminate 
between groups of MS patients based on disability.  The mental health scale of the SF-36 was 
the least sensitive to group differences in disability scores.  Overall, all scales of the  
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Table 6: Relationship between HRQoL Scores and Disability (Concurrent Validity) 
 


















      
SF-36      
   Physical Function  65.9c 32.2d 17.5e 33.0 5.8 
   Role-Physical  46.9c 14.4d 2.3d 19.6 3.4 
   Bodily Pain 71.0c 53.1d 37.4e 13.6 2.4 
   General Health  57.5c 43.7d 26.8e 16.0 2.8 
   Vitality  50.3c 37.9d 26.1e 11.7 2.1 
   Social Functioning 69.1c 57.9c 35.8e 14.5 2.5 
   Role-Emotional  60.0c 45.7c 19.7e 6.5 1.1 
   Mental Health  69.7c 62.7c 50.7e 5.7 1.0 
      
HAQUAMS      
   Fatigue 9.4c 12.0d 15.5e 22.7 4.0 
   Lower Mobility 9.6c 15.5d 18.6e 27.5 4.8 
   Upper Mobility 7.5c 10.8d 15.6e 27.9 4.9 
   Social Function 10.3c 13.4d 17.5e 15.0 2.6 
   Mood 17.1c 22.0d 28.8e 21.2 3.7 
   Total QoL 10.7c 14.6d 19.2e 46.5 8.2 
      
MSIS-29      
   Physical  21.0c 48.2d 67.4e 42.6 7.5 
   Psychological 27.7c 43.9d 68.8e 21.6 3.8 
      
 
All F ratios were significant at p ≤ 0.01 
a One way ANOVA of the HRQoL scales and the MS levels of disability classified using the Guys Neurological 
Disability Scale (GNDS) 
b Reference scale for calculating relative validities is the Mental Health subscale (SF-36) 
c,d,e Means within a row with different superscripts differ significantly (p ≤ 0.05, Duncan’s Multiple Range Test) 
SF-36= Medical Outcomes Survey Short Form – 36 Items 
HAQUAMS= Hamburg Quality of Life Questionnaire in MS 
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HAQUAMS were quite sensitive to group differences, with four scales having relative 
validity coefficients of 4.0 or greater, compared to the reference scale (SF-36 mental health 
scale).  As can be observed from the post hoc comparison, all scales of HAQUAMS and 
MSIS-29 successfully discriminated each of the three disability groups (none, mild and 
moderate.  From the SF-36, only the physical function, bodily pain, general health and 
vitality scale has significantly different scores for each of the three groups. 
 
Current Ambulation Status 
 The ability of the HRQoL measures to discriminate between patients with MS, 
classified on the level of ambulation are reported in Table 7.  Sixty-five patients reported that 
they were able to walk unaided, 32 patients indicated that they needed either unilateral or 
bilateral support to walk, and 19 patients indicated that they were confined to a wheelchair 
both indoors and outdoors.  For the scales on all questionnaires, ordering mean scores tended 
to follow the hypothesized order of better HRQoL scores in the group which could walk 
unaided, with progressively lower scores in the groups requiring some support to help with 
ambulation.   
The results of the ANOVA indicated that the scores on the scales measuring physical 
domain of all three questionnaires differed significantly between the three ambulation 
groups: the SF-36 physical function scale (F= 60.3, p < 0.01); the HAQUAMS upper 
mobility (F= 40.0, p < 0.01) and lower mobility (F= 71.6, p < 0.01) scales; and the MSIS 
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Table 7: Relationship between HRQoL Scores and Level of Ambulation (Concurrent 
Validity) 
 


















      
SF-36      
   Physical Function  60.2c 23.0d 6.1e 60.3† 35.5 
   Role-Physical  33.9c 11.8d 8.6d 7.6† 4.5 
   Bodily Pain  64.7c 46.2d 45.1d 7.8† 4.6 
   General Health  54.1c 38.4d 26.7e 15.2† 8.9 
   Vitality 44.9c 34.1d 33.9d 4.4* 2.6 
   Social Functioning  66.9c 52.3d 34.2e 16.0† 9.4 
   Role-Emotional  50.8c 44.8c 29.8c 1.7 1.0 
   Mental Health 66.2c 59.0c 57.9c 1.7 1.0 
      
HAQUAMS      
   Fatigue 10.7c 12.6c, e 14.0e 5.9† 3.5 
   Lower Mobility 10.4c 16.6d 22.3e 71.6† 42.1 
   Upper Mobility 8.0c 12.3d 16.4e 40.0† 23.5 
   Social Function 12.1c 13.6c, e 15.8e 3.5* 2.1 
   Mood 18.3c 24.9d 27.2d 16.6† 9.8 
   Total QoL 11.8c 16.0d 19.1 e 37.6† 22.1 
      
MSIS-29      
   Physical  27.5c 54.1d 74.3e 52.9† 31.1 
   Psychological 34.5c 49.4d 61.7d 9.6† 5.6 
      
 
† Significant at p ≤ 0.01 
* Significant at p ≤ 0.05 
a One way ANOVA of the HRQoL scales and the level of ambulation classified using responses on question 7 
of the Guys Neurological Disability Scale (GNDS) 
b Reference scale for calculating relative validities is the Mental Health subscale (SF-36) 
c,d,e Means within a row with different superscripts differ significantly (p ≤ 0.05, Duncan’s Multiple Range Test) 
SF-36= Medical Outcomes Survey Short Form – 36 Items 
HAQUAMS= Hamburg Quality of Life Questionnaire in MS 
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There was no significant differences between the three groups based on scores of the 
SF-36 mental health scale (F= 1.7, p = 0.18).  However, the HAQUAMS mood scale (F= 
16.6, p < 0.01) and MSIS-29 psychological impact scale (F= 9.6, p < 0.01) scores differed 
significantly.  There was a significant difference in the scores of the HAQUAMS social scale 
(F= 3.5, p < 0.05), but this was not as significant as the difference observed for the SF-36 
social function scale (F= 16.0, p < 0.01). 
As would be expected, the sensitivity of the HRQoL scales to these known group 
differences was much higher for the scales assessing physical function (the SF-36 physical 
function, MSIS-29 physical impact scale and HAQUAMS upper & lower mobility scales) 
than for psychological scales (the SF-36 mental health, MSIS-29 psychological impact scale 
and HAQUAMS mood scales).  The lower mobility scale of the HAQUAMS had the highest 
relative validity (Relative validity coefficient= 42.1) followed by the physical function scale 
of the SF-36 (Relative validity coefficient= 35.5) and finally the MSIS-29 physical impact 
scale (Relative validity coefficient= 31.1).  The sensitivity of the overall QoL score of 
HAQUAMS was also quite high, as evidenced by a relative validity coefficient of 22.1.  
Duncan’s multiple range analysis illustrated that scales assessing physical domain for 
all three questionnaires displayed significant differences in their scores for each of the three  
ambulation groups.  Other scales that displayed significant differences were: the general 
health and social function scales of the SF-36 and the overall QoL score of the HAQUAMS. 
Responsiveness 
 Effect sizes (ES) and standardized response means (SRM) have been reported for two 
sub-groups classified based on the response to the global transition question.  Effect size was 
calculated as the mean change score (difference between Time 1 and Time 2) divided by the 
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standard deviation of the Time 1 scores.  Standardized response mean was calculated as the 
mean change score divided by the standard deviation of the change score.  Fifty-four of the 
116 participants successfully completed the assessment at Time 2 and were included in the 
calculation of the responsiveness indices.   
Responsiveness indices (ES and SRM) for those patients whose global perception of 
change was either “slightly worse” or “much worse” (N=20) compared to baseline (worse 
sub-group) are shown in Table 8.  In the worse sub-group, only the general health scale from 
the SF-36 was found to have the appropriate direction for the change score and at least a 
small change in scores (ES= 0.29; SRM=0.55).  Appropriate direction of the change score 
refers to a change score value with a negative sign for HAQUAMS and MSIS-29 scales and a 
positive sign for the SF-36 scales.  This difference in the expected sign or direction for these 
measures exists because; a higher score indicates better quality of life on the SF-36 but 
poorer quality of life or functioning on the HAQUAMS and MSIS-29.  Hence, patients in the 
worse sub-group are expected to have lower scores compared to baseline on the SF-36 scales 
(indicating decreased functioning in the various SF-36 domains), but higher scores compared 
to baseline on the HAQUAMS and MSIS-29 (indicating decreased functioning in the various 
domains for these measures).  Other scales of the SF-36 with appropriate sign for the change 
score were: the bodily pain scale (+5.0); the vitality scale (+1.8); and the social functioning 
scale (+0.6).  Of these, only the bodily pain scale had slightly higher responsiveness indices 
(ES= 0.19; SRM= 0.22).  Four of the six scales of the HAQUAMS had negative change 
scores, that is, change scores with the appropriate sign.  These included fatigue (-0.4), lower 
mobility (-0.8), social function (-0.7) and overall quality of life scales (-0.3).   
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Table 8: Responsiveness of the HRQoL measures for Those Who Reported Their 
Overall Condition Having Worsened Over the Last Three-Six Months 
 
Instrument/Subscale Time 1 Time 2 Change Effect Size† SRM¶ 
 Mean (SD) Mean (SD) Mean (SD)   
      
SF-36      
   Physical Function  17.3 (17.7) 19.7 (20.9) -2.1 (10.5) 0.12 0.20 
   Role-Physical  5.0 (10.3) 7.9 (23.7) -2.6 (26.2) 0.25 0.10 
   Bodily Pain  49.1 (26.0) 44.1 (26.7)  5.0 (22.5) 0.19 0.22 
   General Health 35.3 (19.6) 29.6 (17.8)  5.7 (10.4) 0.29 0.55 
   Vitality 30.3 (18.8) 28.5 (18.5)  1.8 (16.7) 0.10 0.11 
   Social Functioning  49.4 (14.3) 48.8 (34.0)  0.6 (25.2) 0.04 0.02 
   Role-Emotional  30.0 (34.0) 33.3 (43.0) -3.5 (42.9) 0.10 0.08 
   Mental Health  57.2 (23.3) 57.4 (18.4) -0.2 (12.1) 0.01 0.02 
      
HAQUAMS      
   Fatigue 13.4 (3.6) 13.8 (3.0) -0.4 (2.6) 0.11 0.15 
   Lower Mobility 18.1 (4.7) 18.9 (4.9) -0.8 (1.9) 0.17 0.42 
   Upper Mobility 15.1 (4.3) 15.0 (4.8)  0.2 (2.6) 0.05 0.08 
   Social Function 14.7 (6.5) 15.4 (5.7) -0.7 (3.9) 0.11 0.18 
   Mood 25.9 (6.3) 25.8 (6.6)  0.2 (5.9) 0.03 0.03 
   Total QOL 17.44 (3.7) 17.8 (4.0) -0.3 (2.1) 0.08 0.14 
      
MSIS-29      
   Physical  60.7 (19.7) 57.5 (18.3)  3.2 (15.4) 0.16 0.21 
   Psychological 49.4 (19.9) 50.7 (20.4) -1.3 (10.8) 0.07 0.12 
 
† Mean change score divided by standard deviation of Time 1 scores 
¶  Standardized response mean= mean change scores divided by standard deviation of change scores 
   Note: Change scores that had a sign (direction) that was expected for that group have been bolded. Total    
   N=20 
   SF-36= Medical Outcomes Survey Short Form – 36 Items 
   HAQUAMS= Hamburg Quality of Life Questionnaire in MS 
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For the MSIS-29, the psychological impact scale displayed a negative change score (-1.3).  
Of these scales, the HAQUAMS lower mobility scale with a SRM of 0.42, was much more 
responsive than all other scales (ES or SRM < 0.20). 
Responsiveness for the thirty-four patients who responded as having gotten better 
compared to baseline has also been reported (see Table 9).  None of the scales in the better 
sub-group had both: an appropriate direction for the change scores (i.e. change score with a 
positive sign) and a responsiveness index of at least 0.20.  Appropriate direction for the 
change score refers to a change score value with a positive sign for HAQUAMS and MSIS-
29 and a negative sign for the SF-36.  This is because; a higher score indicates better quality 
of life on the SF-36 but poorer quality of life or functioning on the HAQUAMS and MSIS-
29.   
The scales for the PRO measures in the better sub-group are expected reflect an 
improvement relative to their scores at baseline.  Based on this information, one would 
expect either the same or a lower score on the scales for the HAQUAMS and MSIS-29 at 
Time 2 compared to baseline.  On the other hand, the same or a higher score would be 
expected on all scales of the SF-36 at follow-up to indicate some improvement in the HRQoL 
and its domains.  Only the MSIS-29 displayed a change score with the appropriate sign 
(positive) for the better group for both its scales (physical and psychological impact scales).  
The mean change in the psychological impact scale was +3.0 with an effect size of 0.12 and 
SRM of 0.21, while the responsiveness for the physical impact scale was minimal (ES and 
SRM < 0.5).  Change scores with appropriate signs were also observed for: the HAQUAMS 
fatigue and upper mobility scales (+0.1 and +0.3 respectively), and the SF-36 role-physical (-
4.5), social function (-0.2) and physical function scales (-1.3).    
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Table 9: Responsiveness of the HRQoL Measures for Those Who Reported Their 
Overall Condition Having Gotten Better Over the Three-Six Month Time Period 
 
Instrument/Subscale Time 1 Time 2 Change Effect Size† SRM¶ 
 Mean (SD) Mean (SD) Mean (SD)   
      
SF-36      
   Physical Function  47.8 (30.5) 49.1 (29.4) -1.3 (11.9) 0.04 0.11 
   Role-Physical  28.3 (37.1) 32.8 (38.4) -4.5 (34.7) 0.14 0.15 
   Bodily Pain  61.0 (29.3) 60.1 (26.4) 0.9 (21.4) 0.01 0.01 
   General Health  49.7 (23.8) 49.1 (23.5) 0.6 (19.6) 0.14 0.17 
   Vitality  46.1 (20.5) 42.2 (22.1) 3.9 (17.9) 0.24 0.30 
   Social Functioning  66.9 (21.2) 67.1 (26.3) -0.2 (18.5) 0.09 0.10 
   Role-Emotional  61.2 (44.1) 59.8 (44.0) 1.4 (41.4) 0.02 0.02 
   Mental Health 69.1 (22.3) 68.4 (23.7) 0.7 (19.5) 0.01 0.02 
      
HAQUAMS      
   Fatigue 11.2 (4.1) 12.6 (3.9) 0.1 (2.1) 0.03 0.05 
   Lower Mobility 11.9 (5.1) 12.1 (5.3) -0.2 (2.8) 0.08 0.14 
   Upper Mobility     9.4 (3.9)   9.1 (3.5) 0.3 (2.9) 0.05 0.07 
   Social Function 12.1 (5.1) 12.3 (5.4) -0.2 (3.7) 0.06 0.08 
   Mood 19.0 (7.5) 19.4 (8.3) -0.4 (5.6) 0.17 0.26 
   Total QoL 12.1 (4.2) 13.1 (4.0) -1.0 (2.0) 0.10 0.2 
      
MSIS-29      
   Physical  32.9 (22.1) 33.1 (19.4) 0.6 (14.2) 0.03 0.04 
   Psychological 36.8 (25.1) 32.7 (26.0) 3.0 (14.2) 0.12 0.21 
 
† Mean change score divided by standard deviation of Time 1 scores 
¶  Standardized response mean= mean change scores divided by standard deviation of change scores 
   Note: Change scores that had a sign (direction of change) that was expected for that group have been bolded.    
   Total N=34 
   SF-36= Medical Outcomes Survey Short Form – 36 Items 
   HAQUAMS= Hamburg Quality of Life Questionnaire in MS 
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Responsiveness indices for all these scales were below 0.20. 
Time for completion and patient opinion 
 The average time for completion of the SF-36 and HAQUAMS were 9.9 minutes and 
9.5 minutes respectively (see Table 10).  The MSIS-29 took the least amount of time to 
complete: 6.9 minutes.   With respect to the length of the HRQoL questionnaires, 7% of the 
sample thought that the number of questions in HAQUAMS was “too many” compared to 
8.9% for MSIS-29, and 11.7% for the SF-36.  Overall, 88.7% of the patients thought that the 
length of HAQUAMS was just right; more than that for MSIS-29 (82.0%) and SF-36 
(82.3%).  A higher percentage of participants (90.4%) thought that the wording of the MSIS-
29 was “mostly easy to understand”, while this number was slightly lower for HAQUAMS 
(87.0%), and much lower for SF-36 (78.1%).  A small proportion of participants reported that 
the wording was “mostly difficult to understand” for HAQUAMS (1.7%) and SF-36 (5.3%) 
but none for MSIS-29 (0.0%).  The percentage of participants that thought that the content of 
the questionnaires was relevant to most of the problems faced in their day-to-day activities 
were 86.1% for MSIS-29, 81.7% for HAQUAMS, and 72.8% for the SF-36.   
Although the mean time of completion was highest for HAQUAMS, a higher 
percentage of respondents indicated that the number of questions were just right (about 89%).  
This may imply that although HAQUAMS takes a slightly longer time to complete, its 
content is more relevant to patients with MS.  
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Table 10: Completion Time and Patient Opinion Regarding the HRQoL Measures 
 
Variables SF-36 HAQUAMS MSIS-29 
    
Time of completion in 
minutes: mean (SD) 
9.9 (7.7) 9.5 (7.9) 6.9 (7.7) 
Number of Questions¶    
     Too many (%) 11.7 7.0 8.9 
     Too few (%) 6.3 4.4 8.9 
     Just Right (%) 82.0 88.7 82.3 
Wording¶    
     Mostly easy (%) 78.1 87.0 90.4 
     Mostly difficult (%) 5.3 1.7 - 
     No Opinion (%) 16.7 11.3 9.6 
Relevance of content¶    
     Mostly Yes (%) 72.8 81.7 86.1 
     Mostly No (%) 9.7 4.4 5.2 
     Not Sure (%) 17.5 14.0 8.7 
    
 
¶ Numbers corresponding with each option indicate the percentage of participants  
SF-36= Medical Outcomes Survey Short Form – 36 Items 
HAQUAMS= Hamburg Quality of Life Questionnaire in MS 














    
107 
Preliminary Analysis 
 Table 11 shows interrelationships between the investigated independent variables and 
the quality of life domains (as measured by the HAQUAMS).  Interrelationships between 
interval variables were reported as Pearson’s correlation coefficients while eta values were 
calculated to illustrate associations between nominal and interval variables.  The significance 
level of each correlation was determined by the F test of the analysis of variance (ANOVA).  
Disability, depression, visual impairment and employment status displayed significant (p < 
0.01) correlations with all HRQoL domains such as overall quality of life, fatigue, upper and 
lower mobility, mood and social function.   
As would be expected, disability was most strongly correlated with overall quality of 
life score (0.77), while gender, race and marital status had the weakest correlation with 
overall quality of life (0.01 to 0.03).  Similarly, significant correlations were observed 
between overall quality of life score and visual impairment (-0.68, p < 0.01), depression 
(0.56, p < 0.01), employment status (0.47, p < 0.01), number of co-morbid conditions (0.27, 
p < 0.01), duration of disease (0.19, p < 0.05) and age (0.25, p < 0.01).  The correlation 
between overall HRQoL measured by the HAQUAMS and visual impairment measured by 
the visual function questionnaire (VFQ) was negative, owing to differences in scoring.  A 
higher score on the HAQUAMS indicates better quality of life but poorer visual function on 
the VFQ.   
Where disability, visual impairment and employment status had a moderate to strong 
correlations with the mobility scales, other variables such as depression, age, duration of the 
disease and comorbid conditions also displayed significant (p < 0.01) but relatively weaker 
associations with these scales.  Among these variables, depression had the highest correlation  
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Table 11: Bivariate Relationships (Correlations) Between Interval Predictor Variables 
and HRQoL Domains 
 
 Total QoL Fatigue Upper Lower Mood  Social 
       
Disability¶ 0.77† 0.63† 0.65† 0.62† 0.60† 0.52† 
Depression¶ 0.56† 0.46† 0.29† 0.27† 0.60† 0.55† 
Visual Impairment¶ -0.68† -0.51† -0.53† -0.53† -0.59† -0.54† 
Age¶ 0.25† 0.16# 0.28† 0.35† 0.12 0.12 
Duration of Disease¶ 0.19* 0.12 0.22* 0.30† 0.08 0.04 
Comorbid Conditions¶ 0.27† 0.18# 0.23* 0.19* 0.18# 0.26† 
Gender‡ 0.02 0.20* 0.11 0.03 0.08 0.04 
Race‡ 0.03 0.05 0.09 0.01 0.04 0.12 
Marital Status‡ 0.01 0.04 0.08 0.09 0.07 0.06 
Employment‡ 0.47† 0.40† 0.43† 0.46† 0.34† 0.27† 
       
 
#  Significant at p < 0.10 
* Significant at p < 0.05 
† Significant at p < 0.01 
¶  The association between two interval variables was estimated with Pearson’s correlation coefficient 
‡ The association between nominal and interval variables was estimated with the association measure Eta.  
   The significance level of the correlation was determined by the F-test on the analysis of variance (ANOVA) 
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with the HAQUAMS upper mobility score (0.29, p < 0.01), whereas age had the highest 
correlation with the HAQUAMS lower mobility score (0.35, p < 0.01).  Number of comorbid 
conditions was found to be significantly correlated with the fatigue (0.18, p < 0.10), mood 
(0.18, p < 0.10) and social functioning (0.35, p < 0.01) dimensions of HRQoL.  None of the 
demographic variables showed any significant correlations with any of the quality of life 
dimensions.  Gender had a significant but weak correlation with the fatigue scale (0.20, p ≤ 
0.05) but not with the other dimensions.  The remaining demographic variables (marital 
status and race) were not significantly correlated (p > 0.05) with any of the quality of life 
domains including overall quality of life score.    
 
Predictors of Overall Quality of life 
 The results of the hierarchical regression analysis, which identified demographic and 
disease-related factors that were most strongly associated with overall HRQoL, are presented 
in Table 12.  Disability, depression, visual function and age were significantly associated 
with poor HRQoL in relation to multiple sclerosis.  Disability accounted for the greatest 
increment of variance for HRQoL; with approximately 59% of the model being explained by 
this variable.  Higher scores on the GNDS (higher disability) were associated with higher 
scores on the HAQUAMS (poorer quality of life).  The results indicated that increase in 
disability can lead to a significant decrease in HRQoL in patients with multiple sclerosis (β= 
0.37, p ≤ 0.05).   
In the second step [ΔR2 0.04, F (2,113) = 97.12], whether depression explained any 
variance in HRQoL was examined.  The results showed that depression (β= 0.10, p < 0.05) 
was also a significant predictor of quality of life.  In the third step [ΔR2 0.03, F=53.48],  
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Table 12: Hierarchical Regression Analysis to predict quality of life by disability, 
















* Significant at p < 0.05 
† Significant at p < 0.01 
Δ R2 = R2 change from previous step 
± Variance Inflation Factor 
¶ Duration of disease measured in Years 
Dependent Variable: Quality of Life measured as overall quality of life score on the HAQUAMS 
Independent Variables: Disability measured using Guys Neurological Disability Scale (GNDS); Visual 
Impairment measured using Visual Function Questionnaire (VFQ); Depression measured using Centers of 









  Step 1 Step 2 Step 3 Step 4 Step 6 Step 5 VIF± 
Block 1        
     Disability 0.37† 0.31† 0.27† 0.29† 0.29† 0.23† 2.26 
        
Block 2        
     Depression - 0.10† 0.10† 0.10† 0.10† 0.08† 1.46 
        
Block 3        
     Age - - 0.03 0.04* 0.04 0.05* 1.77 
     Employment Status - - -0.99 -1.00 -1.01 -0.66 1.35 
        
Block 4        
     Comorbidity - - - -0.29 -0.29 -0.21 1.43 
        
Block 5        
     Duration¶ - - - - -0.01 -0.01 1.49 
        
Block 6        
     Visual Impairment - - - -  -0.07† 1.92 
        
R2 0.59 0.63 0.65 0.66 0.66 0.70  
Δ R2 - 0.04 0.02 0.01 0.00 0.04  
F 160.44 97.12 51.55 42.36 34.99 35.19  
        
    
111 
it was explored whether patient demographics would explain any changes in HRQoL scores.  
Neither age nor employment was significantly associated with HRQoL scores.  This was 
followed by steps 4 and 5, whereby number of comorbid conditions and duration of disease 
were added to the model.  These variables were not significantly associated with HRQoL 
scores comorbidity (β= -0.29, p = 0.10); duration (β= -0.01, p = 0.88) and both steps 
collectively explained only 1% of the variance in the dependent variable.  The last variable 
that was added to the model was visual impairment (scores on the VFQ).  Participants with a 
high level of visual impairment (lower scores on the VFQ) reported significantly lower 
HRQoL (higher scores on the HAQUAMS) (β= -0.07, p < 0.05).  Visual impairment 
explained an additional 4% variance in the HRQoL scores independent of disability and 
depression [ΔR2 0.04, F (7,108) = 35.19].  As presented in Table 11, predictors at all but one 
step explained significantly more variance in the total HRQoL scores and the final model 
explained 70% of the total variance in HRQoL.  The variance inflation factors of all predictor 
variables ranged from 1.35 to 2.26 and were less than the conventional cutoff of 4.0 
indicating absence of any significant multicollinearity in the model.  
 
Predictors of other Quality of Life Dimensions 
 Results of the separate multiple linear regression analyses to examine predictors for 
each of the HRQoL dimensions are given in Table 13.  The regression model of each 
dimension had a different set of predictor variables.  Independent variables for each model 
were selected based on the strength of their correlation with that particular HRQoL 
dimension (refer to Table 11).  The depression variable was left out of the regression model
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Table 13: Separate Multiple Linear Regression Analyses for Each of the Five Quality of Life Domains (HAQUAMS Sub-
Scales) 
 
Independent Variables Fatigue 
      β           SE 
Upper Mobility 
β           SE 
Lower Mobility 
β           SE 
Mood 
β           SE 
Social Function 
β           SE 
           
Disability 0.20† 0.05 0.26† 0.05 0.27† 0.07 0.31† 0.09 0.12 0.06 
Depression 0.06* 0.03 -0.04 0.04 -0.04 0.04 - - 0.16† 0.04 
Visual Impairment -0.03 0.02 -0.06* 0.03 -0.08* 0.03 -0.15† 0.04 -0.08* 0.03 
Employment -0.64 0.68 -1.36 0.83 -2.28* 1.0 -0.45 1.38 0.61 0.99 
Comorbid Conditions -0.31 0.21 -0.18 0.25 -0.54 0.31 -0.15 0.40 0.32 0.28 
Age 0.02 0.02 0.05 0.03 0.10* 0.04 - - - - 
Duration of Disease - - -0.01 0.05 0.04 0.06 - - - - 
Gender -1.64* 0.63 - - - - - - - - 
           
 
* Significant at p < 0.05 
† Significant at p < 0.01 
  Missing values for beta coefficients and standard error indicate that the independent variable was not included in that particular model. Total N= 116. 
  β = Beta Coefficient 
  SE= Standard Error
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for mood (measured by HAQUAMS), since both these scales measure the same underlying 
concept.  Only variables that were significantly correlated with the dependent variable at an 
alpha level of 0.10 or less were included in the models.       
 Disability was the main determinant of fatigue (β= 0.20) followed by gender (β= -
1.64) and depression (β= 0.06).  With respect to gender, males with MS seem to have less 
fatigue compared to females.  Visual impairment was not found to be a significant predictor 
of fatigue.  However, it had a small but significant impact on mobility (β= -0.06 for upper 
mobility and β= -0.08 for lower mobility).  The negative sign for the correlation was 
expected because a higher score indicates better visual functioning on the VFQ, but lower 
functioning on the HRQoL scales.  Employment status (β= -2.28) and age (β= 0.10) were 
also found to be significant predictors of lower mobility.  The negative β coefficient for the 
employment status indicates that those who are employed have lower scores on the 
HAQUAMS lower mobility scale, that is, they are more likely to have better mobility than 
those who are not employed.  Similarly, it is possible that an increase in age will lead to 
lower scores on the HRQoL domains (β= 0.10).  Number of comorbid conditions and 
duration of disease were not significantly related to mobility in patients with multiple 
sclerosis. 
 In addition to visual impairment (β= -0.08), only depression was found to 
significantly predict social function (β= 0.16).  The main determinants of mood were 
disability (0.31) and visual impairment (β= -0.15).  The β coefficients indicate one point 
increase in disability leads to a 0.31 point increase in the depression score.  Similarly, a one 
point increase in VFQ scores leads to a 0.15 point decrease in the depression scale score.  
The negative correlation coefficient between VFQ and CES-D is due to the differences in 
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scoring.  A higher score on the VFQ indicates better visual function but increased depression 
symptoms as measured by the CES-D.  All models were significant at p < 0.05. 
 
Regression Diagnostics for Phase I: Objectives 2 and 3 
 Variance inflation factors of independent variables were less than 2.5 for all Phase I 
regression models implying absence of any significant multicollinearity.  Tests for normality 
of residuals (Shapiro-Wilk Test) and homogeneity of variance (White Test) were not 
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Table 14: Tests of Normality and Homogeneity of Variances of Residuals for All 
Regression Models 
 
Dependent Variable W p value Chi-Sq p value 
     
Total Quality of Life 0.98 0.15 39.47 0.24 
Fatigue 0.99 0.30 48.50 0.41 
Upper Mobility 0.98 0.06 37.26 0.82 
Lower Mobility 0.98 0.35 37.64 0.77 
Mood 0.99 0.27 13.25 0.43 
Social Function 0.98 0.24 19.14 0.45 
     
 
W= Shapiro-Wilk Statistic for testing normality of the residuals  
Chi-Sq= White test for homogeneity of variance of the residuals 
Significance determined at p ≤ 0.05 
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Phase II 
Response Rates and Physician Characteristics 
 The mailing list from SK & A consisted of 6500 neurologists within the United 
States.  Of these, a randomly selected sample of 2400 neurologists was mailed the final 
survey.  The response rate was 4.6% after those who were ineligible or unreachable (i.e. 
those who had left the practice, had retired, or were not involved in the routine care of 
patients with MS) were deducted from the 2400 approached, as these were not true refusals 
(See Figure 2).   
One hundred and seven questionnaires were completed and returned by neurologists 
involved in the routine care of patients with MS.  Table 15 depicts the key characteristics of 
these respondents.  Males comprised 84% of the sample.  Eighty-one percent of the 
neurologists had been practicing for at least ten years.  There were a higher proportion of 
neurologists between the ages of 51 and 60 years (40.2%) compared to any other age group, 
and a majority of them were practicing in office based settings (83.2%).  Only 15% of the 
respondents had participated in a MS-related clinical trial with a HRQoL component once in 
the past.  There was an observable difference in the perceived usefulness of HRQoL 
information use among neurologists.  The overall consensus was that HRQoL information 
can be advantageous (Mean: 5.3; SD: 1.0 on the facilitator scale) and that there were fewer 
drawbacks associated with using this information in the routine care of patients with MS 
(Mean: 2.9; SD: 1.0 on the barriers scale).  Cronbach’s alpha for the statements comprising 
the barrier (0.76) and facilitator (0.74) scales exceeded the minimum requirement of 0.70 
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 Total number of neurologists in mailing list 
6500 
First mailing  
2400 Neurologists 
Second mailing  
1800 Neurologists 
80 Usable 
51 Returned but Unusable 
22 Unreachable 
26 Usable 
37 Returned but Unusable 
10 Unreachable 
106 Usable 
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Table 15: Characteristics of the Responding Neurologists (Total N=107) 
 
Variable N (%) 
Gender  
     Male 90 (84.1) 
     Female 17 (15.9) 
  
Age Group  
     31 to 40 years      16 (15.0) 
     41 to 50 years 23 (21.5) 
     51 to 60 years 43 (40.2) 
     61 or older 25 (23.4) 
  
Primary site of practice  
     Hospital 3 (2.8) 
     University Hospital 15 (14.0) 
     Solo, Office Based 38 (35.5) 
     Group, Office Based 51 (47.7) 
  
Participation in MS Clinical Trial  
     Yes  16 (15.0) 
     No 91 (85.1) 
  
Number of years as neurologist  
     5 years or fewer  13 (12.2) 
     6 to 10 years 13 (12.2) 
     10 years or more 81 (75.7) 
  
Stage of Change†  
     Stage 0 24 (22.6) 
     Stage 1 45 (42.5) 
     Stage 2 20 (18.9) 
     Stage 3 11 (10.4) 
     Stages 4 & 5 6 (5.7) 
  
Facilitator Scale Score   
     Mean (SD) 5.3 (1.0) 
  
Barrier Scale Score  
     Mean (SD) 2.9 (1.0) 
  
No. of patients seen per week  
     Median (Range) 4 (1-150) 
 
†Stage 0= unaware of any HRQoL questionnaires; Stage 1= aware of HRQoL questionnaires, but never    
  thought about using them; Stage 2= thinking of using HRQoL questionnaires within the next 6 months;    
  Stage 3= thinking of using HRQoL questionnaires within the next month; Stage 4= have been using  
  HRQoL questionnaires for less than six months; Stage 5= been using HRQoL questionnaires for more  
  than six months 
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The number of patients with MS seen per week by the neurologists ranged from 1 to 150 
(Median= 4).   
 
Classification Based on the Transtheoretical Model 
The staging of HRQoL related behavior based on the Transtheoretical Model has also 
been reported (refer to Table 15).  About 65% of the neurologists were either unaware of 
HRQoL questionnaires and their use, or had not thought about using formal standardized 
questionnaires in routine practice (Stages 0 and 1).  Approximately 19% of the respondents 
were planning on using standardized HRQoL questionnaires in routine practice within the 
next six months (Stage 2) while about 10% of the respondents reported that they were 
planning on using such questionnaires within the next month (Stage 3).  Only 6% indicated 
that they were currently using such questionnaires in the routine care of patients with MS 
(Stages 4 and 5).   
Subgroup analyses of pre-contemplators (Stages 0 and 1) and contemplators (Stages 2 
and 3) revealed significant differences between the two groups in terms of perceived barriers 
and facilitators to HRQoL assessment in patients with MS  (see Table 16).  As would be 
expected, the contemplator group such as those who were planning to use HRQoL 
information within at least the next six months, had higher scores on the facilitator scale 
[Mean (SD): 5.7 (1.0) vs. 5.2 (1.0), p < 0.05] and lower score on the barrier scale [Mean 
(SD): 2.5 (0.9) vs. 3.1 (1.0), p < 0.01] compared with that of the pre-contemplator group i.e. 
those who were unaware or had not thought of using HRQoL information.   
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Table 16: Differences Between Pre-Contemplators and Contemplators  
 
Variable Pre-Contemplators Contemplators p* 
 Mean (SD) Mean (SD)  
    
Importance of HRQoL information† 5.1 (1.5) 5.9 (1.1) <0.01 
    
Facilitator Scale Score  5.2 (1.0) 5.7 (1.0) 0.03 
    
Barrier Scale Score 3.1 (1.0) 2.5 (0.9) <0.01 
    
 
* Independent sample t-tests 
† Mean score on the following question from the neurologist survey: How important is it to collect HRQoL   
  information in the routine care of patients with multiple sclerosis?  
  Note: Data excludes those who are currently using HRQoL information in routine practice. Total N=101.   
  Pre-Contemplators included respondents classified under stages 0 & 1.  Contemplators included   
  respondents classified under Stages 2 & 3.  
  SD= Standard Deviation 
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In other words, unlike the pre-contemplator group, contemplators perceived greater 
usefulness of HRQoL information and fewer disadvantages and/or problems associated with 
HRQoL assessment in the routine care of patients with MS.  In terms of their degree of 
agreement with the following question: “How important is it to collect HRQoL information 
in the routine care of patients with multiple sclerosis?” the contemplator group (mean= 5.9; 
SD= 1.1) had significantly (p < 0.05) higher perceived importance of HRQoL assessment in 
MS compared to the pre-contemplator group (mean=5.1; SD= 1.5).  
 
Comparison of HAQUAMS and MSIS-29 
With respect to HAQUAMS and MSIS-29, the opinion of neurologists regarding: 1) 
the questionnaires’ ability to provide any additional useful information compared to what is 
normally available; and 2) their ease of use from the perspective of the patients with MS, 
were compared using the Wilcoxon Sign Ranked test (see Table 17).  There was a significant 
difference between the scores on the questions assessing additional usefulness (p < 0.05), as 
well in the perception of the length of the questionnaire (p < 0.01) from the patient’s 
perspective for both questionnaires.   
According to the neurologists, the HAQUAMS does a better job of providing 
additional useful information compared to what is available from conventional physical 
exams and clinical testing methods than does the MSIS-29 (Median: 6.0 vs. 5.0).  However, 
the HAQUAMS was reported to be longer to complete as compared to the MSIS-29.  There 
was no difference in the opinion of the neurologists regarding the way in which the questions 
for the two HRQoL measures were worded, as evidenced by the same median score (2.0) on  
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Table 17: Median Scores of Neurologists’ Opinion About HAQUAMS and MSIS-29 
Regarding their Usefulness and Ease of Use in Patients with MS  
 
Opinion Questions HAQUAMS† MSIS-29† p* 
    
Additional useful information 6.0  5.0 0.02 
Length 5.0 4.0 <0.01 
Wording 2.0 2.0 0.10 
    
 
†Median values for each opinion question 
* p values for Wilcoxon Signed Rank Test 
  HAQUAMS= Hamburg Quality of Life Questionnaire in Multiple Sclerosis 
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that particular item.  The median score of 2.0 indicated that in the neurologists’ opinion, both 
questionnaires comprised of questions which were relatively easy to understand. 
 
Knowledge and Use of Specific HRQoL Questionnaires 
 Overall, utilization of any of the commonly used HRQoL questionnaires in MS 
research listed in this survey was very low among responding neurologists (see Table 18).  
Only six percent reported having used the Functional Assessment of Multiple Sclerosis 
(FAMS) questionnaire in the past.  Minimal use of the Medical Outcomes Survey Short 
Form, Multiple Sclerosis Quality of Life-54, and the Multiple Sclerosis Quality of Life 
Inventory was also reported (Range= 3.1%  to 4.1%).  With respect to knowledge about 
existing HRQoL measures however, a much larger proportion of the neurologists reported 
that they had heard of the HRQoL questionnaires included in this survey.  More than 40% of 
the respondents had heard of the Multiple Sclerosis Quality of Life – 54 as well as the 
Multiple Sclerosis Quality of Inventory.  Awareness about the other questionnaires ranged 
from 25% to 37% among the responding neurologists with 12% reporting knowledge of other 
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Table 18: Numbers and Percentages of Neurologists that Reported Having Used or 
Heard of MS-related HRQoL Questionnaires 
 
Questionnaire Used Heard of 
 N (%) N (%) 
   
Medical Outcomes Survey Short Form (SF-36) 3 (3.1) 34 (34.7) 
Multiple Sclerosis Quality of Life 54 (MSQoL-54) 4 (4.1) 43 (43.9) 
Functional Assessment of Multiple Sclerosis (FAMS) 6 (6.1) 33 (33.7) 
Multiple Sclerosis Quality of Life Inventory (MSQLI) 4 (4.1) 41 (41.9) 
Multiple Sclerosis Impact Scale (MSIS-29) 1 (1.0) 31 (31.6) 
Hamburg Quality of Life Questionnaire in MS 
(HAQUAMS) 
1 (1.0) 37 (37.8) 
Sickness Impact Profile (SIP) 1 (1.0) 25 (25.5) 
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Predictors of the Neurologists’ Intention to Use HRQoL Information 
 The results of the multiple linear regression model used to examine predictors of the 
neurologists intention to use HRQoL information are presented in Table 19.  The primary 
independent variables included in this model were: attitude (measured by items 2 to 8 on the 
neurologist survey, see Appendix J); subjective norms (where referents were the American 
Academy of Neurology and Fellow Neurologists), and perceived behavioral control 
(measured by items 9 and 10 on the neurologist survey. See Appendix J).  Other independent 
variables were gender (male vs. female), age-group, primary place of practice (hospital vs. 
office based), years in practice as a neurologist, number of MS patients seen per week and 
participation in a MS related clinical trial (yes vs. no). 
Attitude was found to be a significant predictor of behavioral intention (β = 0.03, p < 
0.01), where a positive attitude was associated with an increased intention to use HRQoL 
information.  Number of years in practice as a neurologist (β = -0.46, p = 0.03) was 
significantly but inversely associated with the intention to use HRQoL information in the 
routine care of patients with MS.  This means that neurologists who had been practicing for 
10 years or more were less likely to show any intention of assessing HRQoL in patients with 
MS compared to those who had been practicing for fewer than 10 years.  Subjective norms 
were also significantly associated with intention to assess HRQoL information (β = 0.01, p = 
0.05).  This indicates that positive social pressure (from referents such as the American 
Academy of Neurology and Fellow Neurologists) is associated with an increased likelihood 
of HRQoL assessment in the routine care of patients with MS.  Among other variables, age-
group had a slight tendency towards predicting behavioral intention (β = 0.26, p = 0.06).   
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Table 19: Factors Associated with the Intention to Use HRQoL Information in Routine 
Practice 
 
Independent Variable β Estimate Std. Error p VIF 
     
Attitude 0.03 0.003   <0.01 1.14 
Years practice as neurologist -0.43 0.21 0.03 2.23 
Subjective Norms 0.01 0.01 0.05 1.15 
Age group 0.26 0.14 0.06 2.04 
Gender -0.14 0.28 0.63 1.15 
Place of practice 0.43 0.30 0.16 1.42 
Behavioral control 0.14 0.10 0.20 1.09 
Number of patients per week 0.01 0.01 0.42 1.35 
Involved in MS-related trial 0.22 0.32 0.49 1.50 
     
 
Note: Data from the original sample (N=106).   
Independent variables: Attitude, subjective norms, behavioral control, gender, years of practice as neurologist, 
primary place of practice (hospital vs. office), age, number of MS patients seen per week and involvement in a 
MS clinical trial.   
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None of the other independent variables in the model were found to be significant.  The 
overall model was found to be significant (F = 16.19, p < 0.01) and explained almost 61% of 
the variation in the dependent variable (behavioral intention).  The variance inflation factors 
for all independent variables were well within the acceptable limit of 4.0 (VIF < 2.5 for all 
variables), indicating absence of any significant multicollinearity within the model. 
 
Regression Diagnostics for Phase II: Objective 4 
 The residuals for behavioral intention, which was the dependent variable, departed 
radically from normal distribution (Shapiro-Wilk W = 0.96, p = 0.0016).  To deal with this 
problem, studentized residuals, which are a type of standardized residual, were examined to 
identify outliers.  If a single observation is substantially different from all other observations 
(an outlier), it can make a large difference in the results the regression analysis.  One 
observation with a studentized residual greater than -4.0 was dropped from the dataset in the 
interest of validity of the coefficients of the regression model.    
 The regression model was then rerun using data for 106 respondents (Refer to Table 
19).  None of the variance inflation factors exceeded 2.5, indicating that multicollinearity was 
not a problem with the data.  Variance inflation factor was 2.23 for the variable years in 
practice as a neurologist and 2.04 for age group.  Both these variables were retained in the 
final model since these values did not exceed the value of 4.0, which is a generally accepted 
limit for multicollinearity (Fisher JC et al., 1981).  The residuals for the final model met the 
criteria of normality (Shapiro-Wilk W = 0.98, p = 0.12) as well as homogeneity of variance 
(Chi Sq = 40.29, p = 0.86)       
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Chapter 5: Discussion and Conclusions 
 
The overall goal of this study was to investigate several research questions relevant to 
the area of health-related quality of life (HRQoL) in patients with multiple sclerosis (MS).  
Currently, there are several patient reported outcome (PRO) measures intended for use in 
patients with MS.  However, there is no general consensus as to which measure is most 
suitable or appropriate to assess HRQoL in MS, especially in the routine clinical practice 
setting.  One aim of the current study was to compare the psychometric properties, as well as 
neurologists’ and patients’ opinions regarding two PRO measures: the Hamburg Quality of 
Life Questionnaire in Multiple Sclerosis (HAQUAMS) and the Multiple Sclerosis Impact 
Scale (MSIS-29), with the intention of enabling evidence-based selection of PRO measures 
for use in the routine care of patients with MS.   
Information obtained from such head-to-head comparisons can guide neurologists’ 
choice of a PRO suitable for use in their routine clinical practice.  An exhaustive comparison 
of the PRO measures which have been shown to be relevant to MS and have displayed 
desirable psychometric properties as evidenced by prior published studies (Gold et al., 2001; 
Hobart et al., 2001; Riazi et al., 2002) was performed.  In the absence of a “gold standard” 
PRO measure in MS research, the Medical Outcomes Survey Short Form – 36 items (SF-36), 
which is a commonly used generic measure of MS-related HRQoL was used in this 
comparison.   
In addition to addressing issues relating to HRQoL assessment, several research 
studies have been conducted whose main focus was to identify and examine the influence of 
several factors on the quality of life of patients with MS (Benedict et al., 2005; Amato et al., 
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2001; Lobentanz et al., 2004; Wang et al., 2000).  Disability and depression have been 
identified as primary determinants of HRQoL in patients with MS.  Problems with visual 
functioning are also very common in MS.  Visual impairment and its impact on HRQoL in 
MS had not been thoroughly studied, due to the absence of validated vision-related PRO 
measures in this population.  However, research in this area has recently gained some 
attention in the last few years, following the validation of the Visual Function Questionnaire 
(VFQ) in a sample of patients with MS (Ma et al., 2002b; Balcer et al., 2000).  Another aim 
of the current study was proposed in order to substantiate findings regarding the predictors of 
HRQoL and also investigate the influence of additional relevant variables such as visual 
impairment and chronic comorbid conditions such as heart disease, diabetes and arthritis, 
which had not been studied in the past.   
Although commonly used in research and clinical trials, the utilization of HRQoL 
information in clinical practice has been limited.  For the provision of optimum care to 
patients with MS, HRQoL assessment needs to transcend the realm of research into routine 
clinical practice.  In order to do this however, it is necessary to identify current utilization, 
and areas that need to be targeted to facilitate the acceptance of HRQoL information by 
neurologists.  Hence, a nationwide survey of neurologists was performed to provide 
empirical evidence of current practices regarding use of HRQoL information in patients with 
MS.  In order to identify factors that have an influence on the intention to use such 
information in clinical practice, a framework of two health behavior theories was used.  The 
Trans-Theoretical Model was used to categorize neurologists based on their stage of change 
regarding HRQoL information use.  Additionally, the Theory of Planned Behavior was used 
in order to identify predictors of HRQoL intention (behavioral intention) in this population.   
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Phase I: Objective 1 
Head-to-head Comparison of PRO Measures 
Comparison of the PRO questionnaires (MSIS-29 and HAQUAMS) was performed 
on their psychometric properties and the opinions of patients and neurologists regarding their 
usefulness and ease of use.  The first step for the psychometric comparison was to evaluate 
summated ratings scales, for example, HAQUAMS upper and lower mobility scales.  This 
was done by determining the extent of missing data at the item level.  A summated rating 
score cannot be estimated with the same degree of confidence if there is a large amount of 
missing data for a particular item.  Missing responses might indicate problems with the 
wording of the response choices for those items.  It also might indicate that respondents did 
not understand how to complete or provide the most suitable answer for that part of the 
questionnaire.   
It can be observed from the findings of this study that one item on the lower mobility 
scale of the HAQUAMS had unusually high percentage of missing data.  This item asked the 
respondents to estimate the distance that they could walk in metric units (meters).  It was not 
surprising to encounter missing data for this question as respondents in the United States 
(US) may not be accustomed to using this system of measurement.  The English language 
version of HAQUAMS was made available for the purpose of this study and hence no 
changes were made to maintain its validity.  Correcting this issue however, may require 
replacement of the response choices with commonly used units of measuring length such as 
feet, yards or miles followed by a small scale validation study for use in patients in the US.      
Item means and standard deviations were also examined for the two PRO measures.  
Item means are required to be approximately equivalent within a scale under traditional 
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Likert scaling criteria and were found to meet this criterion for both MSIS-29 and 
HAQUAMS.  Item standard deviations should also be roughly equivalent; the rule of thumb 
being a standard deviation of around 1.0 for scales with five-choice response such as the 
HAQUAMS and MSIS-29 (Ware, Jr. & Gandek, 1998).  The variances of the items within 
the scales for two PRO measures did not vary greatly and hence are consistent with this 
criterion.  Further standardization of the items is probably not necessary as there is little to be 
gained by making such adjustments (Ware JE, Harris WJ, Gandek B, Rogers BW, & Reese 
PR, 1997)      
Ideally, item-total correlations should be fairly high for items with their own 
corrected scale score.  Items for all scales except for item 21 of the MSIS-29 (psychological 
impact scale: 0.12) were found to be stronger than the pre-determined correlation of 0.30.  A 
low item-total correlation means the item is little correlated with the overall scale and the 
researcher should consider dropping it.  Hence, the inclusion of item 21 of the MSIS-29 in 
calculating the psychological impact score needs to be re-assessed.  Item-total correlations 
greater than 0.30 for all scales of HAQUAMS provide greater confidence that they are 
precisely measuring the underlying singular concept, thereby permitting comparison between 
two or more distinct groups of patients with MS.   
Among scales measuring similar domains (physical and mental domains for each of 
the three measures), the HAQUAMS upper mobility scale displayed a somewhat high floor 
effect compared to the other physical function scales, although these were still well within 
the acceptable range of 20% (van der Putten, Hobart, Freeman, & Thompson, 1999).  Floor 
effects displayed by this scale may represent its limited ability to discriminate between non-
institutionalized samples of adults with MS based on self-reported upper physical 
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functioning.  Floor and ceiling effects can also have an influence on responsiveness of the 
measures.  The scale range for any measure must extend beyond the range of function 
(absence of floor or ceiling effects) of the patients for whom it will be used, or it will be 
incapable to demonstrating further improvement or deterioration between two or more time 
points.  On the whole, HAQUAMS and MSIS-29 did not show any significant floor and 
ceiling effects.  This may be partially due to the nature of the response sets to the questions, 
which are not limited to dichotomous answers.  High floor and ceiling effects are observed 
for questions 4 and 5 of the SF-36, partly due to presence of ‘yes/no’ response options.   
Pearson’s r was calculated for physical and psychological domain scale scores of 
each instrument, and then correlations between them were analyzed using a multitrait-
multimethod matrix.  This well accepted method of evaluating convergence and divergence 
requires that at least two traits or constructs each be assessed by at least two disparate 
methods.  Although the intercorrelations observed for the HAQUAMS mood scale with its 
upper and mobility scales were similar to what was reported by Gold and colleagues (2001), 
patterns of construct validity with respect to other PRO measures and quantitative tests of 
motor functions were inconsistent with their predictions.  Divergent validity for the 
HAQUAMS mood scale would be supported if its correlation with MSIS-29 psychological 
and SF-36 mental health was higher than its correlation with MSIS-29 physical and SF-36 
physical function.  However, compared with the MSIS-29 psychological impact scale, the 
HAQUAMS mood scale had relatively a weaker relationship with the SF-36 mental health as 
well as with scores on the CES-D.  Moreover, its associations with scores on the 9-Hole Peg 
Test and the Timed-25 Foot Walk Test (quantitative tests of motor function) were higher than 
that for the MSIS-29 psychological scale.   
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Interestingly, the correlation coefficient (0.71) between the HAQUAMS mood scale 
and the MSIS-29 physical impact scale (scales from two different instruments measuring 
different constructs) was almost the same as the correlation (0.70) between the physical and 
psychological impact scales of the MSIS-29 (two scales from the same instrument measuring 
different constructs).  The intercorrelation between the MSIS-29 scales observed in this study 
(0.70) was much higher than what was reported previously (0.438) by McGuigan and 
colleagues (2004).  One explanation may be that the shared features of the method of 
assessment could lead to the high correlation coefficient amongst MSIS-29 physical and 
psychological impact scales.  However, the relatively large correlation coefficient between 
the HAQUAMS mood and MSIS-29 physical impact scales does not conform with the 
expectation that the multitrait-multimethod correlation should be lower compared to 
monotrait-multimethod correlations.  These observations suggest relatively poor divergent 
validity of the mood scale of HAQAUMS, and to some extent the physical impact scale of 
the MSIS-29.   
To gain a better understanding of where this anomaly arises, correlation coefficients 
between the HAQUAMS mood and MSIS-29 physical impact scales were calculated 
separately for the demographic variables.  With respect to gender, this analysis revealed a 
higher correlation in males (0.81) compared with the females (0.66) implying an overlap in 
the mood and physical domains of these specific scales among community dwelling males 
with multiple sclerosis.  Although the correlation was weaker among females, it was still at 
the upper extreme of acceptable limits (0.66 compared with the initial value of 0.71).  With 
respect to other demographic variables, the correlation coefficients between the HAQUAMS 
mood and MSIS-29 physical impact scales were still quite high: 0.77 for those who were not 
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married; 0.69 for participants who were employed, and 0.67 for participants who were 
currently married.  A comparatively low correlation between these scales was only seen for 
those who reported that they were currently unemployed (0.57).  Poor construct validity may 
limit the legitimacy of the inferences that can be made regarding the underlying theoretical 
constructs for the HAQUAMS mood and MSIS-29 physical impact scales.   
In summarizing this section on construct validity, it is important to consider the basic 
tenet of the multitrait-multimethod matrix that, “the pattern of relationships is more 
important than the absolute magnitude of the correlation coefficients”.  The correlations 
between the scores of the HAQUAMS mobility and MSIS-29 physical scales were 
significant and relatively large suggesting well-established convergence (monotrait-
multimethod triangle for physical domain scales).  These coefficients were also larger than 
most of the coefficient scores within the same instrument (multitrait-monomethod triangles) 
which provided evidence of divergence.  Although the MSIS-29 physical impact scale had 
high correlation with the other mood scales, the overall pattern of correlations was consistent 
with the expectations of the multitrait-multimethod matrix.  All of its correlations with the 
physical domains scales (0.76 and 0.82 with HAQUAMS mobility; -0.79 with SF-36 
physical function scales) were consistently higher than multitrait-multimethod (-0.41 and 
0.71) and multitrait-monomethod correlations (0.70) (pattern over magnitude).  Negative 
correlations with SF-36 were due to differences in scoring for the two measures.  A high 
score indicates better quality of life on the SF-36, but poor quality of life on the HAQUAMS.   
The HAQUAMS mood on the other hand, failed to correlate as expected with other 
scales, thus violating the assumptions of the multitrait-multimethod matrix.  The monotrait-
multimethod correlations for this scale were not consistently higher than the multitrait-
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monomethod or multitrait-multimethod triangles.  This problem could either be a snag in the 
construct underlying one or all of these instruments, faults in the scales themselves or a 
combination of both.  However, its abnormally high correlation with both self-report and 
clinical measures of physical domain implies that the problem lies with the HAQUAMS 
mood scale.  The MSIS-29 appears to meet all the assumptions of the multitrait-multimethod 
matrix whereas the construct mismatch of the HAQUAMS mood scale implies poor construct 
validity and may need further evaluation in a U.S. population.   
Concurrent and well as relative validity was examined for all measures included in 
this study against two external criteria variables: level of disability and ambulation.  Relative 
validity analysis identifies those scales that contribute important distinctive information to 
each criterion variable.  Based on the results of the relative validity analysis, the MSIS-29 
physical impact scale was most strongly related to level of disability followed by the physical 
function scale of the SF-36 and the upper and lower mobility scales of HAQUAMS.  Similar 
patterns were observed for the psychological domain scales with the MSIS-29 psychological 
impact scale performing slightly better that the HAQUAMS mood and SF-36 mental health 
scales.  The overall HRQoL score on the HAQUAMS however, had the strongest relative 
validity to discriminate between levels of disability in this sample of patients with MS.  
HAQUAMS lower mobility scale had a much stronger relative validity coefficient with 
respect to the level of ambulation (second criterion variable), compared with the MSIS-29 
physical impact and SF-36 physical function scales.  Furthermore, relatively lower but still 
significant associations were also observed for the lower mobility and total quality of life 
score of the HAQUAMS.  Thus relative validity analysis elucidates the superior sensitivity of 
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the mobility and overall quality of life score of the HAQUAMS to important clinical 
differences in level of disability and ambulation status in patients with multiple sclerosis. 
A retrospective method was used to detect clinically important change over time by 
comparing change scores (baseline score minus follow up score) with an external criterion of 
change such as a transition question (Juniper, Guyatt, Willan, & Griffith, 1994).  The change 
scores for all sub-scales of the three PRO measures were compared in this study.  As would 
be expected in a non-institutionalized sample not undergoing an intervention or treatment 
(e.g. steroids), the responsiveness showed minimal effect sizes and standardized response 
means for both HAQUAMS and MSIS-29.  One reason for this may be the fact that change is 
caused by natural progression over time rather than by treatment effect following a treatment 
(Norman, Stratford, & Regehr, 1997).  Changes due to natural progression are generally 
expected to be very small and may be difficult to discern compared to immediate changes 
due to effect of say, a treatment.  The responsiveness indices (effect size and standardized 
response mean) for scales of both measures that are important from the stand point of routine 
care such as overall quality of life scale of the HAQUAMS; physical and psychological 
impact scales of the MSIS-29, had insignificant effect sizes (less than 0.20).  The results of 
the responsiveness indices however, need to be considered with care due to the small sample 
size used in this study.   
 Although past head-to-head comparisons of HRQoL measures have incorporated the 
standard criteria (data quality, scaling assumptions, validity, reliability and responsiveness), 
the present study also elicited patient and neurologist opinions regarding the usefulness of 
HAQUAMS and MSIS-29.  Overall, the MSIS-29 was preferred by the patients in terms of 
ease of understanding, time for completion and relevance of content.  These observations are 
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only generalizable the patients with MS included in this study and hence lack external 
validity.  According to the results of the survey, neurologists believe that the HAQUAMS 
provides useful information, in addition to what can be obtained from conventional tests in 
MS, to a greater extent than the MSIS-29.   
 
Recommending a PRO Measure for Use in Clinical Practice 
In summary, this objective of the study extensively compared two PRO measures in 
MS.  Each measure has attractive features which would lend itself to clinical practice as well 
as clinical trial settings.  The results of this study support the evidence of the psychometric 
soundness of MSIS-29 as a measure of impact of MS on patients (Riazi et al., 2003; 
McGuigan et al., 2004; Hobart, Riazi, Lamping, Fitzpatrick, & Thompson, 2005).  In 
addition it was found to be relevant from the patients standpoint, easy to score and concise.  
From this perspective, it would be practical to be incorporate this in the routine care of 
patients with MS.   
However, MSIS-29 fails to address other aspects of the disease that may be relevant 
to patients with MS.  In addition to having all the desirable properties of MSIS-29, 
HAQUAMS also emphasizes domains of fatigue and social complications that form part of 
the total burden experienced by patients with MS.  Relative to the social function and vitality 
scales of the SF-36, the HAQUAMS social and fatigue scales displayed comparable criterion 
validity for level of disability.  Both scales were also moderately correlated with their SF-36 
counterparts (social scales: -0.43; fatigue and vitality: -0.58) indicating that they measured 
similar constructs.  The negative correlation was observed because a higher score on the SF-
36 indicates better quality of life but a poorer quality of life on the HAQUAMS and MSIS-
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29.  On an average, the HAQUAMS took less than ten minutes to complete and could be 
easily administered by members of a multidisciplinary team or junior medical staff.  It could 
also be self-administered by the patients themselves in the waiting room, prior to be seen by 
the neurologist.   
Based on these analyses no one measure emerged clearly or consistently better or 
worse than the other in terms of psychometric properties or neurologists’ and patients’ 
opinion.  Hence, a recommendation of one particular PRO measure for use in MS-related 
clinical practice cannot be substantiated.  This study conveys that HAQUAMS and MSIS-29 
can both be effectively used in clinical practice, but seems unlikely that one measure will 
satisfy all the requirements deemed necessary by specific neurologists or practices.  The 
choice of a quality of life measure ultimately rests on the clinician and may be indirectly 
related to their perception of the usefulness and intention to use such information in the 
routine care of MS patients.  
 
Phase I: Objectives 2 and 3 
Predictors of HRQoL in MS 
As described earlier, assessment of HRQoL information is especially relevant to MS, 
which is linked with a broad spectrum of physical and social impairments.  Several studies 
have found a significant influence of certain clinical variables on HRQoL in patients with 
MS.  A substantial body of evidence has shown that impairment and disability has an 
independent but modest contribution to HRQoL in patients with MS.  Other predictors that 
have been shown to have an influence on HRQoL are: course of MS, depression and fatigue.  
In the present study many of these variables were controlled for and for the first time an 
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attempt was made to investigate the influence of visual impairment and concomitant 
comorbid conditions (both self-reported).   
Considering the research question posed (which factors have a unique contribution to 
HRQoL in patients with MS?), inspection of regression coefficients indicated that disability 
was the strongest significant and independent factor associated with HRQoL.  The 
importance of disability in patients with MS is in agreement with other findings (Miller & 
Dishon, 2006; Benedict et al., 2005).  Besides disability, we also found that depressed mood 
and increasing age were related to lower HRQoL.  Finally, the results of this study 
demonstrated that visual impairment explained a significant amount of the variance in overall 
HRQoL and almost every HRQoL domain except for fatigue.   
Interestingly, comorbid chronic conditions did not have a significant negative impact 
on overall HRQoL in patients with MS.  Simple counts of comorbid conditions based on 
patient self-report were used to calculate comorbidity.  Simple counts of comorbidities have 
been commonly used in HRQoL literature (Wensing, Vingerhoets, & Grol, 2001; Michelson, 
Bolund, & Brandberg, 2000; Cheng et al., 2003).  The commonly used Charlson index of 
comorbidity was not considered for this study because of evidence of its inability to 
comprehensively explain variations in physical or mental aspects of HRQoL (Fortin et al., 
2005a).  Also, quality of life outcomes have been shown to correlate most strongly with self-
reported comorbid conditions weighted by severity, followed by number of conditions by 
chart review and finally well-known comorbidity measured such as the Charlson 
Comorbidity Index (Bayliss, Ellis, & Steiner, 2005).   
After accounting for the other predictors, visual impairment explained an additional 
4% of the variance in overall HRQoL in the proposed model.  The results of this study are 
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notable due to the fact that we measured disability using the Guys Neurological Disability 
Scale instead of the commonly used Expanded Disability Status Scale (EDSS).  In contrast to 
the EDSS, the GNDS is capable of embracing a whole range of disabilities which can be 
encountered in the course of MS (Sharrack et al., 1999a).  Thus, controlling for a wide range 
of other potential predictors provides us with a true representation of the impact that visual 
impairment can have on HRQoL in MS.  The validity of these results is further strengthened 
by the fact that the visual function questionnaire (VFQ) has been established as a sensitive 
and useful tool in assessing visual function in patients with MS (Noble, Forooghian, Sproule, 
Westall, & O'Connor, 2006; Balcer et al., 2000; Ma et al., 2002a).  
Seperate studies have suggested that HRQoL in MS is significantly affected by 
impairment and disability measured by the Expanded Disability Status Scale (Janardhan et 
al., 2000), cognitive impairment (Cutajar et al., 2000) and fatigue (Merkelbach, Sittinger, & 
Koenig, 2002b).  Depression has been also shown to have a strong association with HRQoL 
in MS, independent of clinical course and disability (Provinciali, Ceravolo, Bartolini, 
Logullo, & Danni, 1999; Bakshi et al., 2000; Wang et al., 2000).  The results of this study 
corroborated the prior evidence as disability (as measured by the GNDS) and depressive 
symptoms (as measured by the CES-D) both, had a strong and significant influence on 
HRQoL.  Since patient and physician perceptions regarding these influential aspects of the 
disease (disability, depression, etc) differ, the results of the current study re-emphasize the 
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Importance of Visual Impairment to HRQoL in MS 
The findings of this study regarding the role of visual impairment can have important 
implications in the routine care of patients with MS.  Asymptomatic patients with MS, those 
who have no history of optic neuritis, subjective signs of visual impairment and normal 
visual acuity; may still have visual field defects that may not be detectable with conventional 
tests of visual acuity.  Vidovic and colleagues (2005) reported that almost 58% of the 
symptom-free patients with MS had visual field defects, a finding similar to what was 
recorded by others in the past (Patterson & Heron, 1980).  It has been suggested that these 
visual field defects, located in the peripheral areas of the field of vision, may evolve slowly 
and go unnoticed by patients with MS.  Given the prevalence of visual impairment and the 
influence that it has on overall HRQoL, it may be necessary to routinely screen patients with 
MS using standard ophthalmic examination procedures or self-administered questionnaires 
such as the VFQ and others.  A recent study has also published preliminary evidence of the 
ability of a supplementary questionnaire which increases its capacity of the VFQ to capture 
self-reported visual dysfunction in patients with MS (Raphael et al., 2006).    
 
Phase II: Objective 1, 2, 3 and 4 
Utilization of HRQoL Information in Routine Practice 
 Research paves the way for evidence-based selection of an appropriate measure of 
HRQoL, and identification of important variables that have a significant influence on 
HRQoL in patients with MS.  However, in order to make effective use of such information, it 
is necessary that it is translated by practicing neurologists into the routine care of patients 
with MS.  MS literature does not provide any evidence regarding the extent of the current use 
    
142 
of HRQoL questionnaires in routine clinical practice.  Physicians in general, do not favor 
HRQoL assessment and this may be true for neurologists who are involved in the routine 
care of patients with MS.   
Based on the Theory of Planned Behavior a hypothesis for exploration was 
developed: that neurologist’s intention to use HRQoL information in patients with MS would 
be most influenced by their attitudes towards such information, their social norms and their 
perceived control over this behavior among other things.  As hypothesized, neurologists’ 
attitude towards HRQoL information in MS, strongly predicted their intention to use this 
information in routine practice.  This suggests that interventions that strengthen or promote 
positive attitude towards HRQoL information may be effective in changing current practices.  
However, the mean score on the attitude scale [Mean (SD) = 61.7 (35.5); Range= -147 to 
+147] reflected a weak to moderate positive attitude in favor of assessing HRQoL in MS.  
Hence, programs that are created with the aim to promote acceptance of HRQoL assessment 
in practice, may not show significant improvements in neurologists’ attitude.  Such programs 
will need to have a rigorous study design and an evaluation strategy to detect changes in 
attitudes.   
In accordance with the theory, normative beliefs - reflecting the neurologists’ general 
perception of utilization of HRQoL information by their colleagues in MS and the stance of 
the American Academy of Neurology (AAN) - also predicted intention to use this 
information in practice.  Although normative beliefs were strongly predictive of behavioral 
intention, the mean score on the subjective norm scale was very low [Mean (SD): 4.16 (1.3); 
Range= -42 to +42).  In other words, the referents chosen for this study (AAN and other 
neurologists), seem to exert an influence on the behavioral intention of neurologists, but 
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these normative beliefs need to be strengthened.  This indicates that support for HRQoL 
assessment in MS by professional organizations such as the AAN in the future, may increase 
use of such information among practicing neurologists.  It is also possible that neurologists, 
who start incorporating HRQoL assessment in routine care of their patients with MS, may 
influence their colleagues follow suit.  Perceived behavior control, that is, neurologists’ 
perception of how much the behavior (HRQoL assessment) is under their control was not 
found to have a significant influence on intention.           
Although neurologists expressed an interest in the topic and thought that HRQoL 
information was trustworthy, this aspect of the patients’ perspective was far from being 
incorporated into everyday practice.  Those who obtained quality of life information, did so 
in a relatively unstructured way as part of their clinical interview and only a minimal number 
of neurologists reported using HRQoL questionnaires routinely.  Based on their responses 
and comments in the survey it appears that this could be because they are very busy and lack 
resources as well reimbursement for the extra time required to administer and score HRQoL 
questionnaires.  Similar organizational problems including time, staff, resource constraints, 
as well as lack of reimbursement for services provided have been identified as major hurdles 
for physicians in provision of preventive care services in clinical practice (Carter, Belcher, & 
Inui, 1981).   
This study also examined the relationship of the barriers and facilitators for HRQoL 
assessment to self-reported intention to assess such information in practice.  In order to 
investigate this relationship, the barriers and facilitators scales were used as a proxy for 
decisional balance constructs.  The decisional balance that a person feels may be thought of 
as a balance between the pros and the cons (barriers and facilitators in this study) associated 
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with the particular target behavior, which in this case is HRQoL assessment in clinical 
practice.  According to those in the precontemplation stage may weigh in more heavily on the 
side of the cons toward a particular behavior.  As individuals become conscious of the desire 
for change (contemplation stage), the decisional balance becomes less unipolar.   
This study exhibited the expected decisional balance pattern in the sample of 
surveyed neurologists.  Neurologists in the precontemplation group had a significantly higher 
score on the barrier scale and a significantly lower score on the facilitator scale compared to 
the contemplators.  Thus, this study provides some evidence that changes in intention to 
assess HRQoL information may follow stages of change, which reflect a decisional balance 
between the barriers and facilitators of making such a change.  Future research may be 
required to validate the proxy measure of decisional balance (barriers and facilitators scale).  
Improvements in this model may provide researchers with a framework that can be helpful in 
evaluating long term programs aimed at improving HRQoL acceptance by neurologists. 
 
Improving HRQoL Acceptance among Neurologists 
Based on these findings, certain important points come to light.  Firstly, training 
efforts need to be targeted towards neurologists to facilitate assessment (administering and 
scoring of HRQoL questionnaires) as well as evaluating quality of life outcomes in patients 
with MS.  Dealing with the issue of payment for the additional time required to assess 
HRQoL information can be problematic, since HRQoL assessment is not standardized in 
routine practice.  One possible way to overcome this problem may be to establish a relative 
value-based payment system based upon Current Procedural Terminology (CPT) codes 
which has also been recently applied to the provision of medication therapy management 
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services by pharmacists (The Lewin Group, 2005).  Although, one should keep in mind that 
such payment structures can only be brought into existence following the backing of relevant 
authorities (such as the American Academy of Neurology) and further legislative mandates 
for the incorporation of such information in the routine care of patients with MS.   
Contrary to what has been documented regarding other specialists (Bezjak et al., 
1998), a majority of the neurologists conveyed that they did not have problems in 
understanding how to use HRQoL information in the routine care of patients with MS, and 
did not think that scoring HRQoL questionnaires was difficult.  Other explanations for the 
lack of utilization of HRQoL information in clinical practice may be that most of the 
neurologists, while considering the topic of HRQoL as very relevant and beneficial, seem 
unacquainted with available HRQoL instruments.  Additionally, only a few of them actually 
had experience using HRQoL or any other PRO questionnaires.  Lack of familiarity and 
comfort with HRQoL measurement may be one factor that hinders their use in daily practice.   
Doctors are trained to obtain subjective information through clinical interviews.  
Using standardized HRQoL questionnaires to assist with treatment and monitoring is neither 
a standard component of medical training nor a familiar part of routine practice (Skevington, 
Day, Chisholm, & Trueman, 2005).  Neurologists probably rely on their own clinical 
judgments, and are more acquainted with interpretation of a wide variety of clinical tests on a 
daily basis e.g. MRI scans.  Hence, lack of use of HRQoL information may not be due to 
issues with the HRQoL questionnaires themselves, but may represent the hesitancy of 
neurologists to use unfamiliar techniques over the perceived assurance of familiar techniques.  
This may explain the finding that the intention to use HRQoL information was negatively 
associated with the number of years the respondent had been practicing as a neurologist.  
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Neurologists, who have been practicing for ten years or more, are less likely to show the 
behavioral intention compared to someone who had been practicing for fewer than ten years.  
It may be that neurologists who have been practicing for a long time may tend to adhere too 
strongly to their specific routine or beliefs and be less likely to be open to using relatively 
newer methods such as HRQoL questionnaires.   
One suggestion that has been recommended to address this, is the incorporation and 
use of HRQoL measures during medical training leading to repeated exposure to these 
methods (Russak et al., 2003).  Repeated use of health status and HRQoL questionnaires 
causes clinicians begin to instinctively make sense of the ranges over which scores can be 
expected and the meanings associated with the deviations from these values (Pincus & 
Wolfe, 2000; Wolfe & Pincus, 1991).  Clinicians may also begin to comprehend the changes 
in scores reported across two or more visits using the patients as their own referents or 
controls.  Initial (graduate) training in the use of HRQoL questionnaires would be able to 
provide the familiarity that may be necessary to facilitate their acceptance by neurologists 
and physicians in general.  
This study provided evidence of the ease of administration (face-to-face and by mail) 
and scoring of recently developed questionnaires assessing functioning and HRQoL of 
patients with MS in an outpatient clinic.  In a clinic setting, such questionnaires can be 
administered by health care professionals other than neurologists such as nurses, interns or 
even research assistants.  Alternatively, the HRQoL and health status information may be 
collected by mail.  The data collected can then be stored in a database on the clinic premises.  
Having access to such a database may allow neurologists to continually monitor their patients 
with MS without the need for frequent clinic visits, thus conserving time and resources.  
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Such questionnaires may also improve communication with patients and allow neurologists 
to understand aspects of the disease which are more relevant from the patient’s perspective.  
 
Limitations 
Overall, Phase I (Objectives 1, 2 and 3) of this study was adequately powered and the 
sample size of 116 fell within the target range for all proposed analyses (testing concurrent 
validity and regression analyses to determine predictors of HRQoL and its domains).  This 
sample size also met the recommendations of most statistical “rules of thumb” discussed 
earlier.  However, the generalizability of the results will be somewhat limited because the 
sample was a convenience sample and included only regional patients with MS (mostly from 
West Virginia but also included some residents of Pennsylvania, Maryland and Ohio).   
Item-scale and scale-domain structure of the questionnaires could have been tested to 
investigate some deviations observed in their psychometric properties such as, the high 
correlation coefficient between MSIS-29 physical impact and HAQUAMS mood scales as 
and the low item-total correlation for item 21 of MSIS-29.  Testing the structure of the 
HRQoL questionnaires however, would require the utilization of statistical tests such as 
confirmatory factor analysis.  A good general rule of thumb for factor analysis is a sample 
size of at least 300 (Tabachnick BG & Fidell LS, 1996b).  The sample size of 116 in this 
study precluded the use of such techniques.   
The course of MS for each patient, for example, whether the type of MS was 
Secondary Progressive, Primary Progressive, Relapsing Remitting, or Primary Relapsing, 
could not be identified due to unavailability of this information from many of the patient 
medical records.  Course of MS has been shown to be a significant predictor of MS-related 
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HRQoL in the past and would have been a relevant variable to include in this study.  Hence, 
the results of the regression analyses to identify predictors of HRQoL and its domains in this 
study may be subjected to omitted-variable bias.   
Another limitation of this study was that time since last relapse was not assessed for 
patients who were included in the final sample.  Exclusion of this variable may have 
implications for our findings.  First, since the effects of a relapse can last for months or even 
a year, it is possible that some patients in our sample may not have completely recovered 
from a relapse that they had more than four weeks (inclusion criterion) prior to the first 
assessment.  This may have affected their responses to the HRQoL questionnaires at the time 
of administration, as they were not at their true baseline state at that time.  Second, 
differences may exist even between those who have completely recovered from a relapse.  
For example, someone who has completely recovered from a relapse three months ago may 
perceive their health status or quality of life differently than someone who completely 
recovered from a relapse more than two years ago.   
Simple counts of comorbid conditions were used to calculate the comorbidity variable 
for the regression models (Phase 1, Objectives 2 and 3).  One disadvantage of this approach 
was the reliance on a simple count of comorbid chronic conditions from a limited list of 
diseases, regardless of their severity.  Also, the number and type of medical conditions may 
differ from those used elsewhere and limit the comparison of these results with other relevant 
studies.  Future research that intends to adjust for comorbidity in relation to quality of life 
outcomes in MS can consider using other recommended multi-morbidity indices such as the 
Cumulative Illness Rating Scale (CIRS) and the Functional Comorbidity Index (FCI) (Fortin 
et al., 2006; Fortin et al., 2005b). 
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Responsiveness of the HRQoL measures was calculated using scores at baseline 
(Time 1) and follow-up (Time 2).  In order to accurately calculate responsiveness, the time 
difference between the baseline and follow-up assessment is very important.  This study was 
initially designed to determine responsiveness of the measures in the sample after three 
months.  Hence, the follow-up assessment for each patient should have been made exactly 
three months following initial administration.  However, due to difficulties encountered in 
scheduling patient visits exactly three months following baseline assessment, follow-up 
assessments were made during a three to six month time period following the baseline 
administration for each patient.   
Only 54 of the 116 participants completed the assessments at Time 2 and the 
calculation of responsiveness was limited only to these participants.  One reason for a low 
number of participants at follow-up was the short timeline for the study (March 1 to October 
31, 2006).  Since time to follow-up was decided to be at least three months following initial 
administration, the first follow-up assessment in the study period occurred after May 31, 
2006.  Similarly, follow-assessments were not done for anyone whose first administration 
was on or following August 1, 2006, because these assessments fell beyond the study period.  
Hence, follow-up data was collected only for those patients who had their first administration 
on or before July 31, 2006 
A sample of 278 would be required in order to calculate responsiveness with a 
conservative effect size of 0.3 and a power level of 0.8.  With respect to this estimation, the 
sample size for responsiveness analysis in this study was very small.  The interpretation of 
the responsiveness should therefore be made with attention to the issues encountered with 
data collection and the small sample size.  The responsiveness indices displayed no 
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significant change in the HRQoL of the patients with MS, irrespective of the direction (or 
sign) of the change score.  However, the follow-up time was six months at the most and this 
may not have been sufficient to capture changes in non-institutionalized patients with MS.  
Longer follow-up periods ranging from 12 to 24 months would have been better able to 
capture such changes.  A longer timeline can provide data that would not only allow for easy 
interpretation of responsiveness but also increase the overall sample size of the study. 
Since this study relied exclusively on patient reported questionnaires, its conclusions 
may be affected by self-report or reporting bias.  Self-report bias is inherent to the area of 
quality of life and involves an exaggeration or diminution of symptoms/functioning by the 
patients.  Another type of reporting bias is called recall bias.  Recall bias occurs when the 
way the respondent answers a question is affected not just by the correct answer, but also by 
the respondent's memory.  Such a bias may have affected data regarding the year of diagnosis 
of MS (patient self-report).  This is a limitation since the actual year of clinical diagnosis 
may have been different from what was reported by the patient.  However, because of 
unavailability of such information in the patient medical records, the actual year of diagnosis 
could not be confirmed.  It should be noted that prior to the first assessment, neurologists 
approached patients with MS and requested their participation in the study.  Hence, it is 
possible that patient reports may have been influenced by their belief of how the treating 
neurologist may perceive their responses to the questionnaires in the study (similar to social 
desirability bias). 
The findings of Phase II of this study are fairly generalizable since the respondents to 
the survey were a national sample of neurologists practicing in outpatient settings.  One 
threat to the validity and generalizability of the results was a lower than usual response rate 
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(4.6%).  This low response rate may have occurred due to absence of incentives provided to 
the neurologists.  Monetary and non-monetary incentives can increase response rates among 
physicians and usually more impact when delivered with the initial questionnaire than when 
promised upon its return (Hopkins KD & Gullickson AR, 1992; Everett SA, Price JH, Bedell 
AW, & Telljohan Sk, 1997).  Using lotteries has also been demonstrated as a cost-effective 
method to increase response rates among physicians in larger surveys (Baron, De Wals, & 
Milord, 2001).  Lotteries involve a promise of an incentive (e.g. an opportunity to win a cash 
prize) in order to stimulate a better response rate.   
A larger proportion of the sample (65%) reported that they were in the pre-
contemplation stage (either unaware or not planning on using HRQoL information in 
practice).  These respondents also indicated that it was less important to assess HRQoL 
information in patients with MS compared to contemplators.  Based on these findings it may 
be that many neurologists may not assign sufficient importance to HRQoL assessment to 
warrant even completion of the HRQoL-related survey such as the one in this study.  This 
could be a common trend amongst neurologists and another reason for lack of response.   
In any case achieving a high response rate on physician surveys has been known to be 
a challenging task and physician response rates as low as 11% have been documented (Asch 
et al., 1997; Cummings, Savitz, & Konrad, 2001).  The low response rate of this study may 
be incidental either to the length of survey (five pages plus two HRQoL questionnaires each) 
or to the target population i.e. neurologists.  Differences may exist in the response rates of 
medical specialists (e.g. neurologists) compared to that of primary care physicians, and any 
such potential variations may still need further exploration.  Response rates among 
neurologists may be improved by sending pre-screening cards asking whether they would be 
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willing to participate in an upcoming mail survey.  The final survey instrument would then be 
sent only to those who respond positively to the pre-screening mailing in order to improve 
response rate.   
The results of this study may also be susceptible to non-response bias (differences 
between responders and non-responders that may have an impact on the generalizability of 
the results).  As a continuation of this study, follow-up letters will be mailed in order to 
collect non-response data from the neurologists in the sample.  Another way to assess non-
response bias could be to perform a telephone survey and determine whether there were any 
significant differences between those who returned the completed questionnaires and those 
who did not on variables such as age-group, gender, practice characteristics etc.  This method 
would involve making a clinical appointment with the neurologist over the phone to collect 
this data and reimbursing them for their time.  Such a non-response analysis can be 
performed in future surveys of neurologists.  Other studies have assessed non-response bias, 
by comparing demographics of physicians based on their time of response.  Late responders, 
that is, those that did not respond to the first mailing, were considered as proxies for non-
responders.   A review of these studies showed that minor differences were observed in 
medical practice variables (e.g. number of years in practice), while income, area and type of 
practice, gender and age on did not differ significantly among physicians (Kellerman & 
Herold, 2001).   
 Since information regarding HRQoL assessment is self-reported, results of this study 
may also be susceptible to social desirability bias.  In some circumstances, respondents may 
be tempted to give the socially desirable response rather than describe what they actually 
think, believe, or do.  This bias may have affected responses to questions that asked about the 
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intention to assess HRQoL information in clinical practice or the usefulness of such 
information in the routine care of patients with MS.     
 
Considerations for Future Research 
This study was the first of its kind to incorporate all psychometric properties as well 
as neurologist and patients’ opinion regarding two currently relevant PRO measures in MS 
(MSIS-29 and HAQUAMS).  Neither of the measures was found to be psychometrically 
superior to the other.  However, it is clear that these measures are more suitable for use in 
MS compared to generic measures of HRQoL such as SF-36.  The sample size for this study, 
although adequate to measure the psychometric properties of the measures, was modest.  It is 
possible that stronger evidence of reliability, validity and item-level scaling success might 
have been found with a larger sample size and increased power.  This study is one of the few 
that compared responsiveness for the PRO measures in a sample of non-institutionalized 
patients with MS.  Although the analysis was not sufficiently powered to detect the changes 
in such patients, this study provides preliminary evidence of responsiveness of HAQUAMS 
and MSIS-29 and also insights into methodological problems that can be encountered when 
collecting data from non-institutionalized MS patients.  Hence, further comparisons of these 
PRO measures should preferably be conducted as multi-site studies with a large and diverse 
(patients with varying levels of severity) population of patients with MS, in order to improve 
generalizability of the findings.   
Incorporating HRQoL assessment in routine practice an as aid to clinical decision-
making in MS patients is a logical follow up to the evidence that has been provided by this 
study using MS-related PRO measures.  As can be observed from these findings, PRO 
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measures can not only be succinct, easy to score and administer but can also shed light on 
factors that are most relevant to non-institutionalized patients with MS for example, visual 
impairment.  Pilot studies utilizing PRO measures (VFQ, GNDS) should be undertaken in the 
future to monitor critical factors affecting HRQoL (HAQUAMS) in patients with MS in 
routine clinical practice and this evidence should be corroborated with objective clinical tests 
(visual acuity, quantitative tests of motor function).  In addition to known determinants of 
HRQoL the impact of other variables such as type of treatment should also be investigated.  
This is important because newer medications such as Tysabri (Natalizumab), a recombinant 
monoclonal antibody, may improve HRQoL in patients with MS not only due to patient-
friendly dosing regimens (once a week administration) but also due to a different mechanism 
of action than that of conventional drugs (Interferons).  
A shift of emphasis needs to take place with increased focus on practical applications 
of HRQoL questionnaires and their inclusion in clinical decision-making and policy 
decisions.  Very few neurologists if any are utilizing even the most basic and standard 
instruments such as the SF-36.  A larger push from professional organizations such as the 
American Academy of Neurology and the National Multiple Sclerosis Society is necessary to 
ensure that HRQoL questionnaires play a significant albeit an auxiliary role in the routine 
care of patients with MS. 
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The Departments of Neurology and the School of Pharmacy at West Virginia University, 
have come together to conduct a research study in the area of multiple sclerosis.  You may be 
aware of the various symptoms of this condition which can have an impact on your quality of 
life.  The objective of this study is to determine where the focus of care needs to be directed to 
enable us to ensure that you are receiving the best care possible for your multiple sclerosis and 
also identify ways to allow the neurologist to understand the issues which are most important 
from your perspective.  I would like to encourage you to participate in this study during your 
next visit scheduled on the ________________.  Your participation will entail completion of a 
set of questionnaires and two non-invasive clinical tests.  This study may provide useful 
information which will serve as a guide for your attending neurologist.  Your input will be a 
source of tremendous help in providing general information which will be used by neurologists 
to help others who have your same health concerns. 
 
The information that you provide, when participating in the study, will be kept as 
confidential as legally possible and results will be presented only in an aggregate format.   
 
You do not have to answer every question in the questionnaire and participation in the 
study is completely voluntary.  You may choose not to participate at any time; however, after 
you have provided the information, it will become anonymous and you will be unable to 
withdraw your data since there will be no way to identify individual information.  If you choose 
not to participate, this will not jeopardize in any way your relationship with me or with the WVU 
neurology clinic.   
 
Please allow about forty-five minutes during your upcoming visit to participate in this 
study.  You may answer the questions during the wait period before your consultation and 
complete the rest later.  The study coordinators thank you in advance for your time and your 
contribution to a greater understanding of the health concerns of patients with multiple sclerosis.  
If you have any questions or need more information, please contact Vivek Pawar MS at (304) 







Department of ______________________ 
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Appendix E: Additional Questions 
The following section will ask some questions you and your multiple sclerosis. 
Please check or fill in the appropriate responses. Thank You! 
 




2) What is your age?  ______ Years 
 
3) What is your current marital status? 





A member of an unmarried couple 
 






5) What is your current employment status? 
Employed 
Unemployed 
Unemployed due to multiple sclerosis 
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Appendix F: Comorbidities 
Please check if you have had or been treated for the following conditions in 
the past.  If you have had a diagnosis or treatment for a condition not noted in 
the table, please describe under “Other conditions not noted in the table”.  If 
you have not had any diagnosis or treatments in the past, please check the box 
at the bottom of the page. 
 
_____ Abnormal mammogram   _____ Ear/nose/throat trouble  _____ Kidney problem 
 
_____ Abnormal PAP smear  _____ Eating disorder   _____ Learning disabilities 
 
_____ Alcohol/other substance use  _____ Eye problems   _____ Measles/Mumps/Rubella 
 
_____ Anemia     _____ Gout    _____ Mental health condition 
 
_____ Arthritis/joint disease   _____ Diabetes   _____ Insomnia 
 
_____ Asthma     _____ Head injury   _____ Mononucleosis 
 
_____ Back problems    _____ Headaches   _____ Neck injury 
 
_____ Bleeding trait    _____ Hearing loss   _____ Seizures 
 
_____ Broken bones    _____ Heart disease   _____ Heart murmur   
 
_____ Sinusitis    _____ Chicken pox   _____ Hepatitis  
  
_____ Skin diseases   _____ Chronic cough   _____ High blood pressure 
  
_____ Thyroid problem   _____ Congenital defect  _____ High cholesterol 
 
_____ Dizziness or fainting spells  _____ Joint injuries       
 
_____ Cancer  Type ___________________________________ 
 
_____ Sexually transmitted disease  Type ___________________________________ 
 
_____ Ulcer / stomach or digestive problems 
 






     I have not had any diagnosis or treatment in the past for any of the conditions noted above or 
any other conditions 
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 SECTION 2 
The following questions are regarding the section (Section 1) that you just completed. 
 
1. Approximately how long did it take for you to complete this section? _____ minutes 
 
2. What is your opinion regarding the number of questions in this section? 
 
 The questions were too many 
 The questions were too few 
 The number of questions was just right 
 
3. What is your opinion regarding the way the questions in this section were written? 
 
 The questions were mostly easy to understand 
 The questions were mostly difficult to understand 
 No opinion 
 
4. Do you feel that this section helped you express your opinion regarding most problems 
that you face in your day-to-day activities? 
 
 Mostly Yes 
 Mostly No 
 Not Sure 
 



















The following questions are regarding the section (Section 2) that you just completed. 
 
1. Approximately how long did it take for you to complete this section? _____ minutes 
 
2. What is your opinion regarding the number of questions in this section? 
 
 The questions were too many 
 The questions were too few 
 The number of questions was just right 
 
3. What is your opinion regarding the way the questions in this section were written? 
 
 The questions were mostly easy to understand 
 The questions were mostly difficult to understand 
 No opinion 
 
4. Do you feel that this section helped you express your opinion regarding most problems 
that you face in your day-to-day activities? 
 
 Mostly Yes 
 Mostly No 
 Not Sure 
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The following questions are regarding the section (Section 3) that you just completed. 
 
1. Approximately how long did it take for you to complete this section? _____ minutes 
 
2. What is your opinion regarding the number of questions in this section? 
 
 The questions were too many 
 The questions were too few 
 The number of questions was just right 
 
3. What is your opinion regarding the way the questions in this section were written? 
 
 The questions were mostly easy to understand 
 The questions were mostly difficult to understand 
 No opinion 
 
4. Do you feel that this section helped you express your opinion regarding most problems 
that you face in your day-to-day activities? 
 
 Mostly Yes 
 Mostly No 
 Not Sure 
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Appendix H: VFQ Items 
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Appendix I: Cover Letter for the Neurologist Survey 
 
March, 2006
Dear Dr.               
We are conducting a survey to determine neurologists’ opinions regarding the use of health-
related quality of life (HRQoL) information in the routine care of patients with multiple sclerosis 
(MS). We are also interested in your opinion regarding two HRQoL questionnaires designed for use in 
patients with MS (printed on colored paper) which have been included with this mailing.   
It is our understanding that you may be involved in providing direct medical care to patients 
with MS in an outpatient setting.  We are contacting a random sample from a nationwide selection of 
neurologists to ask them their views about HRQoL assessment in patients with MS, and whether or 
not they use HRQoL information in clinical practice. 
Your input is essential for us to understand what neurologists feel about HRQoL assessment 
in patients with MS.  Results from our study will allow us to identify the areas where efforts are 
needed to facilitate translation of HRQoL findings into usable information for clinical practice.  
Furthermore, your opinion regarding the specific enclosed questionnaires will aid in determining 
suitability of their use in the routine care of patients with MS.   
It will only take a few minutes to complete the attached questionnaire and your responses will 
be kept as confidential as legally possible.  On receiving your completed questionnaire, responses will 
be combined with responses from other neurologists and analyzed and the results of this study will be 
only reported in aggregate format.  The survey is voluntary, however, we hope you will share your 
experiences and opinions about MS-related HRQoL information.   
If you choose to participate, please mail the completed survey back to us in the self-addressed 
business reply envelope included alongside.  This research is being conducted as part of a larger 
doctoral dissertation study in Pharmaceutical Sciences at West Virginia University.  If you need any 
help completing this survey or have any questions, please contact Vivek Pawar at (304) 685-7812 or 
Lesley-Ann Miller, PhD at (304) 293-0228.  Thank you in advance for providing this information.   
 
Sincerely 
 _________________                 __________________
  Vivek Pawar, MS        Lesley-Ann Miller 
  Doctoral Candidate        Assistant Professor 
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Appendix J: Neurologist Survey 
HEALTH-RELATED QUALITY OF LIFE ASSESSMENT IN PATIENTS WITH MULTIPLE SCLEROSIS (MS) 
Neurologist Survey 
 
Are you directly involved in the routine care of patients with multiple sclerosis? 
 No   ---   Please stop here and return this survey in the enclosed business reply envelope. Thank you for your time.
 Yes  ---   Please continue with the next question 
    
INSTRUCTIONS: Please spend a few minutes to look through the HRQoL questionnaire printed on the blue paper 
followed by the questionnaire printed on the yellow paper (enclosed) before you begin answering the questions.  
We would like your opinion regarding the enclosed HRQoL questionnaires.  Kindly CIRCLE ( ) the desired response.   
 
First, about the blue questionnaire… 
  
a. Do you think that using the blue questionnaire in your patients with MS will provide additional useful information, 
compared to what you normally have available from conventional physical exams & clinical testing methods? 
 
           Mostly No           Mostly Yes 
       
1 2 3 4 5 6 7    
 
b. What do you think about the length of the blue questionnaire? 
 
            Too Short                Too Long 
       
1 2 3 4 5 6 7    
 
c. From the perspective of patients with MS, what is your opinion regarding the way the questions are worded? 
 
          Mostly Easy to Understand            Mostly Difficult to Understand 
       
1 2 3 4 5 6 7    
 
Now, about the yellow questionnaire…. 
 
d. Do you think that using the yellow questionnaire in your patients with MS will provide additional useful information, 
compared to what you normally have available from conventional physical exams & clinical testing methods? 
 
           Mostly No          Mostly Yes 
       
1 2 3 4 5 6 7    
 
e. What do you think about the length of the yellow questionnaire? 
 
           Too Short               Too Long 
       
1 2 3 4 5 6 7    
 
f. From the perspective of a patient with MS, what is your opinion regarding the way the questions are worded? 
 
       Mostly Easy to Understand     Mostly Difficult to Understand 
       
1 2 3 4 5 6 7    
   Not Sure
   Just Right
   Not Sure
   Not Sure
   Just Right
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INSTRUCTIONS: The following questions will ask your opinion regarding HRQoL assessment in routine care of
patients with MS.  Kindly CIRCLE ( ) the desired response  
 
1) a.  How important is it to collect HRQoL information in the routine care of patients with multiple sclerosis?  
 
                  Not at all important 1 2 3 4 5 6 7   Very important 
 
2)  a.  HRQoL information may help address problems which the patients with MS will not bring up or think of  
 
                    Strongly Disagree  1 2 3 4 5 6 7   Strongly Agree 
 
b.  Knowing about problems which patients with MS will not bring up or would not think of is…  
 
             Extremely Undesirable  1 2 3 4 5 6 7   Extremely Desirable 
 
3)  a.  Assessing HRQoL information will make the patients feel like I am concerned about their overall well-being 
 
                    Strongly Disagree  1 2 3 4 5 6 7   Strongly Agree 
 
b.  For patients with MS to feel that I am concerned about their overall well-being is  
 
             Extremely Undesirable  1 2 3 4 5 6 7   Extremely Desirable 
 
4)  a.  HRQoL information will help me understand the impact that MS is having on an individual’s life 
 
                    Strongly Disagree  1 2 3 4 5 6 7   Strongly Agree 
 
b.  Knowing what kind of impact MS is having on the life of my patient with MS is…  
 
             Extremely Undesirable  1 2 3 4 5 6 7   Extremely Desirable 
 
5)  a.  HRQoL information can provide subjective information about the patient over and above the information   
                  provided by standard objective tests 
 
                    Strongly Disagree  1 2 3 4 5 6 7   Strongly Agree 
 
b.  Having a subjective assessment of my patient’s condition in addition to standard objective tests is  
 
             Extremely Undesirable  1 2 3 4 5 6 7   Extremely Desirable 
 
6)  a.  HRQoL information can be used to monitor changes or responses to treatment in patients with MS 
         
                    Strongly Disagree  1 2 3 4 5 6 7   Strongly Agree 
 
b.  Monitoring changes or responses to treatment using HRQoL information in patients with MS is 
 
             Extremely Undesirable  1 2 3 4 5 6 7   Extremely Desirable 
 
7) a.  HRQoL information assessment in patients with MS can facilitate shared clinical decision making  
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b.  Making shared clinical decisions with MS patients is 
 
             Extremely Undesirable  1 2 3 4 5 6 7   Extremely Desirable 
 
8)  a.  Use of HRQoL questionnaires will lengthen the consultation with the patient 
 
                    Strongly Disagree  1 2 3 4 5 6 7   Strongly Agree 
 
b.  Lengthening consultation time with patients with MS to collect HRQoL information is… 
 
             Extremely Undesirable  1 2 3 4 5 6 7   Extremely Desirable 
 
9)  a.  I feel confident that I could assess HRQoL information from patients with MS if I wanted to 
 
                    Strongly Disagree  1 2 3 4 5 6 7   Strongly Agree 
 
b.  Assessing HRQoL information from patients with MS is __________ for me  
 
                Easy 1 2 3 4 5 6 7   Difficult 
 
10)  a.  The decision whether or not to assess HRQoL information from patients with MS is beyond my control 
 
                    Strongly Disagree  1 2 3 4 5 6 7   Strongly Agree 
 
b.  Whether I assess HRQoL information from patients with MS is entirely upto me 
 
                    Strongly Disagree  1 2 3 4 5 6 7   Strongly Agree 
 
11) a.  The American Academy of Neurology recommends that I should assess HRQoL in patients with MS 
 
                    Strongly Disagree  1 2 3 4 5 6 7   Strongly Agree 
 
 b.  What the American Academy of Neurology thinks regarding my decision about HRQoL assessment in patients 
                  with MS is important to me 
 
                                 Not at all  1 2 3 4 5 6 7   Very Much 
 
12)  a.  Other neurologists believe that HRQoL information should be assessed in patients with MS 
 
                    Strongly Disagree  1 2 3 4 5 6 7   Strongly Agree 
 
b.  Doing what other neurologists believe regarding HRQoL assessment in patients with MS is important to me 
 
                      Not at all 1 2 3 4 5 6 7   Very Much 
 
 
I intend to assess HRQoL information from patients with MS 
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INSTRUCTIONS: The following questions will ask your opinion regarding HRQoL information in general.  Kindly 
CIRCLE ( ) the desired response  
 
              Strongly                          Not                               Strongly    
         Disagree                     Sure                                 Agree 
1) I do not understand how HRQoL information   
would be used in routine care of patients with MS 1 2 3 4 5 6 7 
 
2) HRQoL information facilitates better 
communication with patients    1 2 3 4 5 6 7 
 
3) HRQOL is not relevant to neurologists  1 2 3 4 5 6 7 
 
4) HRQoL information allows for identification 
and prioritization of problems    1 2 3 4 5 6 7 
 
5) There are no benefits of using HRQoL 
information in patients with MS    1 2 3 4 5 6 7 
 
6) HRQoL information can be used to screen for 
hidden problems (e.g. psychological)   1 2 3 4 5 6 7 
 
7) Scoring HRQoL questionnaires is difficult  1 2 3 4 5 6 7 
 
8) HRQoL information requires too much 
resources or time     1 2 3 4 5 6 7 
 
9) HRQoL information is not trustworthy  1 2 3 4 5 6 7 
 
10) HRQoL information can be used to really 
treat the “whole” patient    1 2 3 4 5 6 7 
 
Are there any other factors which influence your decision whether or not to use HRQoL information in patients with MS?
    ____________________________________________________________________________________________ 
    ____________________________________________________________________________________________ 
    ____________________________________________________________________________________________ 
 
 
INSTRUCTIONS: Please indicate whether you currently assess HRQoL information using formal standardized 
questionnaires in routine care of MS patients with MS? Kindly CHECK ( ) your response 
       
       Yes          No  
   
 
  I am thinking of using HRQoL questionnaires in my practice within the next month 
  I am thinking of using HRQoL questionnaires in my practice within the next 6 months 
  I am aware of HRQoL questionnaires, but have not thought about using them in my practice 
  I am unaware of any HRQoL questionnaires and of how to use them in my practice 
 
I have been using HRQoL questionnaires in my practice for more than six months 
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INSTRUCTIONS: Please indicate whether you have used in clinical practice or heard of the following HRQoL 
questionnaires. Kindly CHECK ( ) your response 
 
                          I have used             I have heard of  
Medical Outcomes Survey Short Form (SF-36)                                                                
Multiple Sclerosis Quality of Life 54 (MSQOL-54)                                         
Functional Assessment of Multiple Sclerosis (FAMS)                                                                                 
Multiple Sclerosis Quality of Life Inventory (MSQLI)                                                
Multiple Sclerosis Impact Scale (MSIS-29)                                                                      
Hamburg Quality of Life Assessment in Multiple Scleroris (HAQUAMS)                                
Sickness Impact Profile (SIP)                   
Other- _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _               
 
 
INSTRUCTIONS: This section will ask information about you and your practice. Kindly CHECK ( ) your response 
 
1. Please indicate your gender:       Male          Female 
 
2. Please indicate your age-group: 
 
     30 years or younger 
     31 to 40 years 
     41 to 50 years 
     51 to 60 years 
     61 years and older 
 
3. Your primary practice site is: 
 
     Hospital based   University-affiliated hospital            Solo, Office-based            Group, office based 
 
     Others, Please Specify: _________________________________________________________ 
   
4. Approximately how many patients with MS do you personally see per week?  _________ patients 
 
5. Have you ever participated in a MS-related clinical trial with a HRQoL component?        Yes             No 
 
6. Please indicate the year in which you received your board certification in neurology: __________ 
    
7. How many years have you been in practice as a neurologist?   
                              
          Currently a resident                                    
          5 years or fewer                    
          6-10 years                                     
          10 years or more                    
              




THANK YOU FOR YOUR INPUT! 
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Performed literature searches, data analysis, survey development and 
submission of written reports 
 
 
WORK   School of Pharmacy Computer Laboratory, ULM  
EXPERIENCE  2001 to 2003 
    Graduate Assistant 
    Responsibilities 
Provided computer-related support to Pharm. D students and managed 
inventory 
 
Chemical, Industrial & Pharmaceutical Laboratories (Cipla) Ltd., 
Mumbai, India  
1999 
    Summer Intern 
    Responsibilities 
Internship experience involved practical training in Manufacturing & Quality 
Control and Quality  Assurance departments 
 
 
PUBLICATIONS Pawar V, Smith MJ (2006). “Asthma-Related Health Care Utilization and 
Costs by African-Americans Enrolled in West Virginia Medicaid”. Respiratory 
Medicine 100 (9): 1579-87 
 
Mangone C, Tessaro I, Parker I, Pawar V (2006). “Knowledge, Barriers and 
Predictors of Colorectal Cancer Screening in an Appalachian Church 
Population”. Preventing Chronic Disease - In Press 
 
Zizzi S, Goodrich D, Wu Y, Parker L, Rye S, Pawar V, Mangone C and 
Tessaro I (2006). “Correlates of Physical Activity in a Community Sample of 
Adults in Appalachia”. Journal of Aging and Physical Activity - In Press 
  
Mody R, Kalsekar I, Kavookjian J, Iyer S, Rajagopalan R and Pawar V 
(2006). “Economic Impact of Cardiovascular Co-morbidity in Patients with 
Type 2 Diabetes”. Journal of Diabetes and Its Complications - In Press 
       
Jones DL, Kriska AM, Irrgang JJ, Lian Y, Pawar V, Crossett LS, Kwoh CK, 
Cauley JA (2006). “Physical Activity as a predictor of Long-term Physical 
Health Status after Total Knee Arthroplasty for Osteoarthritis”. Abstract 
submitted to Osteoarthritis Research Society International 
 
Tessaro I, Coughlin S, Pawar V (2006). “Colorectal Cancer Screening and 
Preventive Practices among Appalachian Men and Women with a Positive 
Family History”. Submitted to CDC for initial review 
 
Pawar V, Miller LA (2006). “Quality of Life in Multiple Sclerosis: Choosing a 
Suitable Measure”. Manuscript in progress 
 
Goodrich D, Tessaro I, Pawar V (2006). “Social Network Support, Church 
Integration & Support and Health Promoting Behaviors”. Manuscript in 
progress 




POSTER Pawar VS, Miller LA (2006). “Comparison of health-related quality of  
PRESENTATIONS  questionnaires in multiple sclerosis: A review”.  International Society of 
Pharmacoeconomics and Outcomes Research (ISPOR) Meeting, 
Philadelphia, May 2006 
  
 Mody R, Kalsekar I, Kavookjian J, Iyer S, Rajagopalan R, Pawar V (2005). 
“Economic Impact of Cardiovascular Co-morbidity in Patients with Type 2 
Diabetes”.  International Society of Pharmacoeconomics and Outcomes 
Research (ISPOR) Meeting, Washington, D.C., May 2005.  Abstract 
published in Value in Health, May 2005 
 
Kavookjian J, Mody R, Iyer S, Rajagopalan R, Kalsekar I, Pawar V (2005). 
“Prevalence of Co-morbid conditions and concomitant medication use among 
Type 2 Diabetes patients in a State Medicaid population”.  International 
Society of Pharmacoeconomics and Outcomes Research (ISPOR) Meeting, 
Washington, D.C., May 2005. Abstract published in Value in Health, May 
2005 
Pawar VS, Smith MJ (2004). “Asthma-Related Health Care Services 
Utilization by African-Americans in a Medicaid Population”.  International 
Society of Pharmacoeconomics and Outcomes Research (ISPOR) Meeting, 
Washington, D.C., May 2004.  Best Poster Finalist Award.  Abstract 
published in Value in Health 2004; 7(3): 313 
 
Pawar VS, Raval DH (2002). “Dietary Fat Intake and the Nutritional Aspects 
of Type 2 Diabetes: A Literature Review”. Presented at the Southern 
Pharmacy Administration Conference, University of Louisiana at Monroe, 
Monroe, LA, 2002 
 
 
RESEARCH  West Virginia Veteran Prostate Cancer Focus Groups: Plan for Examining 
PROJECTS  Public Health Practices (2006) 
         Role: Conducted and transcribed focus groups and analyzed data using  
   QSR*N6 software 
 
A descriptive analysis of colorectal cancer-related health services utilization 
in the West Virginia Medicaid population (2005) 
         Submitted to the WVU Faculty Senate Award (Principal Investigator: Lesley- 
   Ann Miller) 
         Role: Performed data cleaning, management and analysis. Helped in writing  
   the final report 
 
Building the West Virginia Collaborative Health Outcomes Research of 
Therapies and Services (CoHORTS) (2005)  
        Submitted to the Agency for Healthcare Research and Quality “Building  
   Research and Infrastructure program (Principal Investigator: S. Suresh  
   Madhavan) 
         Role: Assisted with research design for the research portion of the proposal 
 
Cost-Effectiveness of Irbesartan in the treatment of ESRD among patients 
with Type 2 Diabetic Nephropathy (2005) 
   Decision Analysis class project, WVU School of Pharmacy  
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Developing a novel approach to rural emergency preparedness and injury 
prevention in a particularly vulnerable population and aim to enhance rural 
hospital emergency preparedness by providing accurate and timely 
information (2004) 
Role: Performed literature reviews and assisted in constructing a survey to 
assess emergency  
   preparedness in a rural population  
 
 
RELEVANT  Pharmacoepidemiology   Claims Data Analysis 
COURSES  Research Design and Data Analysis  Survey Research Methods   
COMPLETED  Pharmacoeconomics   Decision Analysis  
Health Economics    Healthcare Finance 
Introductory and Multivariate Statistics Introductory Econometrics  
Healthcare & Hospital Administration 
Health Behavior and Health Education    
Intro to Statistical Analysis Software (SAS)  
 
 
COMPUTER   Statistical Softwares: SAS ver.9.0, SPSS ver. 11.0 
SKILLS   Decision Analysis: DATA Treeage 
Productivity Programs: Microsoft Office (Word, Excel and PowerPoint) 
Qualitative Data Analysis: QSR*N6  
Database Management Systems: Microsoft Access, FoxPro 
Reference Management Applications: Reference Manager 10.0 
 
 
HONORS AND  President, WVU-ISPOR student chapter (2005 – 2006) 
AFFILIATIONS Member, Rho Chi Honor Society (2004 – Present) 
Secretary, WVU-ISPOR student chapter (2004 – 2005) 
Best Poster Finalist Award, ISPOR 9th Annual International Meeting (2004) 
Member, International Society for Pharmacoeconomics & Outcomes 
Research (ISPOR) (2003 – Present) 
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